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Pulmonary diseases are a major global health burden affecting approximately one billion 
people every year. They result from many types of insults including but not limited to infections, 
such as tuberculosis (TB), and dysregulations of the lung physiology, such as idiopathic 
pulmonary fibrosis. (IPF) The key to producing better therapeutics to treat pulmonary diseases is 
in understanding the role of immune mediators in these diseases. Transforming growth factor-β1 
(TGF-β1) is an immune mediator that has been implicated in the exacerbation of both TB and 
IPF. TGF-β1 is traditionally described as and anti-inflammatory cytokine, thought to restrict the 
immune response. TGF-β1 affects a variety of cellular processes including proliferation, 
cytokine secretion, and even apoptosis. These effects are very cell type specific and often 
concentration dependent. Effective modulation of the immune response through TGF-β1 requires 
understanding which cells are being regulated, what are the specific results of TGF-β1 
regulation, and through what mechanisms TGF-β1 is acting on the cells. To answer these 
questions it is necessary to look across biological scales at TGF-β1 signaling on a molecular 
scale, a cellular scale, and a tissue scale. 
The role of TGF-β1 across multiple biologic scales has not been well characterized in the 
context of pulmonary disease. In this work I took a multi-scale systems biology approach to 
understanding the mechanistic role of TGF-β1 in pulmonary disease across molecular, cellular, 
and tissue scales. I constructed a novel ordinary differential equation (ODE) model of TGF-β1 
receptor ligand signaling in a single fibroblast and from that model, identified the necessity for 
	 xix	
simultaneous TGF-β1 and prostaglandin E2 signaling to maintain homeostatic fibroblast 
response during injury. I then combined this ODE model with a novel in silico agent based 
model (ABM) of fibroblasts and epithelial cells in co-culture in order to evaluate the effects of 
molecular scale signaling dynamics of cellular scale outputs such as cell proliferation, 
differentiation, and survival. With this model I identified a need for differential therapeutic 
treatment of fibroblasts and epithelial cells in order to prevent exacerbation of fibrotic disease.  I 
then introduced TGF-β1 signaling into the existing in silico ABM model of TB induced 
granuloma formation in the lung (GranSim). Using this updated version of GranSim in 
combination with studies performed in non-human primates, I demonstrate the inhibition of 
TGF-β1 in the granuloma increases bacterial killing and promotes lesion sterilization by enabling 
increased effector functions from cytotoxic T cells. I also show that macrophages and cytotoxic 
T cells are differentially regulated in the granuloma by interleukin-10 and TGF-β1 respectively.  
Finally, I combine work on fibrosis and granuloma formation by introducing fibroblasts with an 
ODE model defining TGF-β1 receptor-ligand signaling dynamics into GranSim in order to 
characterize the formation of fibrotic granulomas. In this work I have advanced the 
understanding of TGF-β1 regulation in pulmonary disease and opened doors for further 






 Pulmonary diseases are a major health concern affecting an estimated one billion people 
every year (1). A 2013 report from the Forum of International Respiratory Societies (FIRS) titled 
“Respiratory Disease in the World: Realities of Today—Opportunities for Tomorrow” highlights 
the global burden of this class of diseases (2).  According to the FIRS report 4 million adults die 
prematurely ever year from chronic respiratory infections (2). The burden of these diseases does 
not only fall on adults (2). In children under the age of 5, pulmonary diseases are the most 
common cause of death and are responsible for 9 million deaths annually (3). In the United 
States, lung diseases account for 8.9% of all deaths (4) and an estimated 15% of adults ages 40–
79 live with chronic lung diseases (5). Not only do lung diseases restrict survival and quality of 
life for millions of people, they also incur tremendous financial burden to health care systems 
(2). Respiratory infections cost the United States between 71 and 167 billion dollars annually in 
medical bills and lost wages (6), with asthma costing 50.1 billion dollars in medical expenses 
alone (7). In addition to the previously mentioned diseases, interstitial lung diseases (ILDs) are a 
rising health burden in the United States (8). Advancements in prevention, diagnosis, and 
treatment of pulmonary diseases have the potential to improve hundreds of millions of lives and 
reduce global health costs immensely. In this work I will focus on the study of two 
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prototypical interstitial lung diseases, non-infectious pulmonary fibrosis and infectious 
tuberculosis (TB).  
1.1.1 Pulmonary Fibrosis 
Pulmonary fibrosis is defined by the thickening, stiffening and scarring of the lung tissue 
(9-13). Symptoms of pulmonary fibrosis include coughing, shortness of breath, fatigue, chest 
pain, loss of appetite and weight loss (9, 14, 15). Approximately 50,000 new cases of pulmonary 
fibrosis are diagnosed every year in the United States (15). The United States also sees 
approximately 40,000 deaths annually due to pulmonary fibrosis (15). It can be caused by a 
variety of triggers including infection, antibiotic treatment, occupational and environmental 
exposure, and smoking (9, 16-23). Pulmonary fibrosis can also be described as idiopathic, 
meaning it has no known cause.  
 There are few treatments and no curative therapies available for pulmonary fibrosis (24-
26). The FDA recently approved two drugs, Pirfenidone and Nintedinab, for the treatment of 
pulmonary fibrosis. These drugs slow the progression of the disease, but do not halt or reverse it 
(27-33).  According to a 2014 article by The Bloomberg Report, the cost of treatment with either 
of these drugs is between $94,000 and $96,000 per year (34). Idiopathic pulmonary fibrosis (IPF) 
is a particularly devastating diagnosis, with a prognosis for patients between 2 to 5 years from 
time of diagnosis (14, 35). Understanding the complex immunological regulation that occurs in 
the lung, and specifically that which contributes to the formation of pulmonary fibrosis enables 






 In contrast to IPF, which although devastating, affects a relatively small number of 
people, Tuberculosis (TB) is among the pulmonary diseases that have the greatest impact 
globally. Approximately one third of the world’s population is infected with the bacterium 
Mycobacterium tuberculosis (Mtb), the causative agent of TB (36). TB infection is transmitted 
when an infected individual exhibiting disease symptoms coughs and bacteria are released into 
the air in sputum droplets. An uninfected individual then inhales these droplets, resulting in a 
new exposure that likely will lead to infection, particularly upon repeated exposure (36). Of the 
over 2 billion people that are infected with Mtb, about 10 percent show clinical symptoms of the 
disease (called primary, active TB). There are 9 million new cases and 1.4 million deaths 
annually from TB (36). Although the majority of people infected with Mtb have controlled the 
infection and do not show clinical symptoms (latent TB), there is a 10% chance that these people 
will experience reactivation (progression from latent to active disease) in their lifetimes (37).  
 The most common form of TB is pulmonary TB (38). Inhalation of Mtb stimulates the 
formation of complex immune structures called granulomas, which serve to contain the infection 
and protect surrounding tissue (39, 40). However not all granulomas successfully contain or clear 
the bacteria, which can lead to dissemination of the infection to different sites in the lung (41-
44).  Even for granulomas that do contain the infection, their structure and density can present 
challenges for treatment and clearance of the bacteria (45).  Granulomas are found in infected 
individuals who show symptoms of TB, as well as those that do not. They are found primarily in 
the lungs, but can also be seen in lymph nodes and other tissues (40, 41, 46-48).  An individual 
with active TB has on average 42 granulomas (43), each with a unique composition and 
trajectory. A single person can have granulomas that fall into different categories. Understanding 
	 4	
the complex mechanisms that drive granuloma formation and function provides much needed 
insight into the dynamics surrounding Mtb infection, and enables me to predict potential 
therapeutic targets to better treat TB.  
Pulmonary fibrosis is a dysregulation of the wound healing process in the lungs, which 
can be induced by many different insults. It is often seen in association with Mtb infection. 
Fibrosis can be found surrounding granulomas both in patients that have received antibiotic 
treatment and those that have not (49). Understanding the coordination between these ILDs can 
highlight key mechanisms relevant across pulmonary disease. 
At the foundation of developing new treatments for pulmonary disease is identifying both 
the role of the immune system in disease progression and the unique actions of the immune 
system specific to the lung environment (50-55). The immune system is comprised of cells and 
cytokines (molecules that drive the immune response) that serve a wide variety of functions in 
fighting infection and repairing tissue damage. Cytokines and chemokines (a subclass of 
cytokines specifically involved in cellular recruitment) are key to the recruitment and regulation 
of immune cells, driving granuloma formation (41, 42, 44, 46, 56-60), and pulmonary fibrosis 
(61-84). Transforming growth factor-β1 (TGF-β1) is one such cytokine that has been 
demonstrated to have great importance in lung immunology (61, 62, 64, 66-68, 74, 77, 78, 84-
91). While the importance of TGF-β1 has been identified in many pulmonary diseases, the 
mechanisms of TGF-β1 regulation often remain a mystery. For other diseases the role of TGF-β1 
has yet to be identified.  
 TGF-β1 has been shown to play a central role in the development of pulmonary fibrosis, 
an interstitial lung disease. Exploring the role of TGF-β1 in these two distinct but overlapping 
ILD diseases has enabled me to advance the field of pulmonary immunology, to predict potential 
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therapeutic targets, and to establish a focused trajectory of research to more efficiently explore 
future questions.  
 
1.2 Fundamentals of transforming growth factor-β1 
 TGF-β1 is a member of the transforming growth factor-β superfamily of cytokines (62, 
89, 92).  This is a large family consisting primarily of TGF-βs and bone morphogenic proteins 
(BMPs) (93, 94). TGF-β1 is secreted as homodimer of the bioactive TGF-β1 ligand molecule 
(25kDa) covalently bound to a homodimer of a latency-associated peptide (LAP) (95, 96). This 
complex is called the small latent TGF-β1 complex (42 kDa) (95).  Following secretion, TGF-β1 
can be stored in the ECM as a large latent TGF-β1 complex (290 kDa) which contains the small 
complex and an additional protein known as the latent TGF-β1 binding protein (LTBP1) (97). 
Activation of TGF-β1 occurs through removal of the LAP from the bioactive ligand by 
proteolytic cleavage, mechanical extraction, or changes in pH of the surrounding environment 
(95). Once dissociated from the LAP, the bioactive TGF-β1 molecule (active TGF-β1) is free to 
bind its respective member of the TGF-β1 superfamily of receptors. 
 
1.2.1 TGF-β1 signaling  
 The TGF-β1 superfamily of receptors is made up of two subpopulations (Type I and 
Type II) of transmembrane serine/threonine kinase receptors (93). Active TGF-β1 binds first to 
the TGFβRII (a member of the Type II receptors), which is constitutively active (93). This 
complex then recruits the activin-like kinase 5 (ALK5) receptor (a member of the Type I 
receptors) (98, 99). ALK5 is transphosphorylated by TGFβRII, inducing downstream signaling 
through the canonical SMAD2/3, and non-canonical rho/ROCK signaling cascades (100).   
	 6	
 
Figure 1.1. General actions of TGF-β1 on various cell types. In clockwise order TGF-β1 
inhibits M1 differentiation, promotes M2 differentiation, promotes fibroblast proliferation, 
promotes fibroblast to myofibroblast differentiation and collagen secretion, inhibits cytotoxic T 
cell effector functions, promotes regulatory T cell down regulation of other cells, induces 
epithelial cell apoptosis, inhibits dendritic cell antigen presentation, and inhibits neutrophil 
degranulation.  
 
 TGF-β1 ligand is an autocrine and paracrine signal that is secreted by most cell types 
(101). Similarly, TGF-β1 receptors are expressed on most cells (102) rendering them sensitive to 
the signal. Despite the universality of TGF-β1, it plays very specific and different roles for 
different cell types (Figure 1.1). It is known to induce fibroblast proliferation at low 
concentrations (70, 103, 104), but drive differentiation and secretion of ECM proteins at higher 
concentrations (62, 89, 92, 100, 105). Epithelial cells undergo apoptosis in high concentrations of 
TGF-β1 (67, 106, 107). TGF-β1 has been shown to cause cell cycle inhibition in keratinocytes 
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(108, 109), inhibits secretion of TNF-α by macrophages (110), and plays a variety of roles in T-
cell differentiation and maturation (111-117). The diversity of functions preformed by TGF-β1 is 
enabled in part by its co-regulation with other cytokines. 
 
1.2.2 Pro- and anti-inflammatory cytokine interactions 
Table 1.1 General action of cytokines and mediators of inflammatory processes 
 
ê Denotes anti-inflammatory, é Denotes pro-inflammatory 
 
 
Expression of and signaling by TGF-β1 occurs in the context of a complicated cytokine 
and eicosanoid milieu and, depending on the specific tissue, other cytokines influence cellular 
response and sensitivity to TGF-β1 (85, 118-124). Cytokines are often descried as generally pro- 
or anti-inflammatory though there are many exceptions to these categorizations (Table 1.1). 
TGF-β1 is typically described as anti-inflammatory because the majority of it’s known functions 
in immunity involve suppressing cell activity, regulating effector functions, and inducing 
apoptosis (63, 85, 92, 108, 110, 113, 119-121, 124-142). Outside of immune-related function, 
TGF-β1 has been shown to play an important role in embryonic development, tissue genesis, and 
wound healing (98, 105, 143-156). Other cytokines directly and indirectly affect the role of TGF-
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β1 in these processes. A subset of these cytokines specifically relevant to this work includes anti-
inflammatory cytokine interleukin 10 (IL10) (157, 158), and pro-inflammatory cytokines tumor 
necrosis factor-α (TNFα) (158-165), and interferon-γ (IFNγ).  In addition to cytokines, lipid 
mediators can have a strong effect on the functionality of TGF-β1. One particular pro-
inflammatory lipid mediator relevant to this work is prostaglandin E2 (PGE2) (66, 83, 166-169). 
 Pro-inflammatory cytokines promote cell activation and effector function in order to 
mount an immune response during infection. TNFα is a 17.4kDa pro-inflammatory cytokine 
secreted by activated and infected macrophages, as well as CD4+ and CD8+ T cells during 
infection (170, 171). TNFα secreted by macrophages stimulates the secretion of chemokines 
such as CCL2, CCL5 and CXCL9 at the site of infection. These chemokines signal for the 
recruitment of other immune cells to the site of infection.  TNFα can also induce cellular 
apoptosis, a critical component of sterilizing infection and wound healing. Co-regulation 
between pro-inflammatory TNFα and anti-inflammatory TGF-β1 maintains balance during 
infection. TNFα promotes macrophage expression of TGF-β1 and MMP9. TGF-β1 inhibits 
macrophage expression of TNFα.  IFNγ is another pro-inflammatory cytokine that plays an 
important role during pulmonary disease. IFNγ is primarily secreted by Th1 T cells, and works 
to promote macrophage activation in granulomas.   
 IL10 is an 18kDa regulator of inflammation during infection (172).  It can be secreted by 
a wide variety of cell types, including T cells and macrophages (41, 173-176). IL10 inhibits pro-
inflammatory cytokine secretion, prevents apoptosis and necrosis, and restricts macrophage 
activation (172, 174-180). These functions serve to control the magnitude of the inflammatory 
response and prevent excessive tissue damage in the context of infection. The anti-inflammatory 
effects of IL10 have been correlated with pathogen virulence in Mtb infection because they 
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restrict the hosts ability to induce inflammatory responses (41). IL10 correlates with a decrease 
in scar formation during wound healing (181). Scar formation is increased during wound healing 
in IL10 KO mice (182). IL10 and TGF-β1 have been shown to have regulator effects on each 
other. TGF-β1 can promote IL10 production by macrophages (183) and T cells (184) in some 
cases, but can also inhibit IL10 production by peripheral blood monocytes in other cases (185). 
In the inverse IL10 has been shown to inhibit TGF-β1 synthesis by bone marrow cells (186).  
IL10 and TGF-β1 are both anti-inflammatory cytokines, however their respective roles may 
differ depending on the specific tissue context, and in some cases are not known.  
 Prostaglandin E2 (PGE2) is a lipid mediator that induces diverse cell type specific 
responses including homeostasis, inflammation, and sometimes anti-inflammatory responses. 
Many different cell types including epithelial cells, neutrophils, macrophages, and fibroblasts 
secrete PGE2. PGE2 is influenced by common non-steroidal anti-inflammatory medications 
(NSAIDs). In the context of pulmonary disease relevant to this work, PGE2 induces fibroblast 
quiescence to prevent excessive fibroblast proliferation, collagen secretion and tissue remodeling 
(187, 188). TGF-β1 and PGE2 have inverse regulatory effects on fibroblasts. The combinatorial 
effects of TGF-β1 and these cytokines and mediators on immune cells are likely the key to 
understanding the role of TGF-β1 in pulmonary disease.  
 
1.3 Computational modeling of pulmonary diseases 
 The regulation that occurs between cells, cytokines and the host immune response is 
extremely complex. Because different aspects of the immune response are so intertwined, 
performing reductionist experiments in vitro and in vivo can be challenging and has limitations. 
These types of studies provide pieces of information about the system, but are not conducive to 
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comprehensive systems analysis. Systems biology combines in vitro and in vivo studies with 
computational methods to predict the mechanisms behind experimental results and clinical 
outcomes (Figure 1.2).  
 
Figure 1.2. Systems biology combines many different scientific approaches including in 
vitro, in vivo, in silico, and mathematical models. In silico is a term used to reference models 
generated using computer systems rather than biological systems. In silico alludes to the use of 
silicon in computer chips. 
 
 
 Computational models can be constructed using either math and/or computer 
programming to address different kinds of biological questions (63, 83, 157, 158, 189-198).  In 
silico models are similar to in vitro models in that they take a reductionist approach focusing on 
first order interactions including the most important aspects of a system and reducing other 
noise. In silico models can also resemble in vivo models that are able to capture complex 
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dynamics over extended time and space. In silico models are calibrated and validated using 
biological data, which can be derived either in vitro or in vivo. The origin of the data used for 
calibration determines which system the model best reflects.  
 An important feature of mathematical and computational models is that they can be 
manipulated in ways that biological models cannot. Data can be collected from in silico models 
more easily and more often than either in vitro or in vivo models. They can be used in high 
volume to perform thousands of simulated experiments in less time, and requiring less labor than 
biological models. The outputs collected from mathematical and computational models can be 
statistically analyzed to indicate specific mechanisms driving different model outcomes. Model 
outputs that do not reflect biological observations can indicate a key component of the system 
that is erroneous or absent, further informing both models and experiments.  
 
Figure 1.3. Computational models provide outputs at many different biological scales. 
These outputs can be compared to results provided by different experimental methods including 
but not limited to flow cytometry, live cell imaging, ELISA assays, and histology. 
 
  
Ordinary differential equation (ODE) models are mathematical models that track changes 
in concentration over time. ODE models are continuous, deterministic, and do not account for 
space or spatial heterogeneity (199). ODE models are relatively quick to run and work well for 
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processes that occur on short time steps and in homogeneous environments, such as receptor 
ligand signaling events. ODE models can also be useful for studying long processes that occur 
over years, like epidemiological models. Because they are continuous, non-spatial, and 
deterministic, ODEs are not an optimal tool for studying discrete or stochastic events (Figure 
1.4).  
 
Figure 1.4. Diagram outlining differences between continuous and discrete models. 
Ordinary differential equation models are classified as continuous. Agent based models are 
classified as discrete. 
 
 
 For this work, I also use agent-based models (ABMs) to capture discrete, stochastic, and 
spatial events occurring at the cellular scale. ABMs are a class of in silico models that capture 
system level dynamics as a result of the adaptive behavior of individual agents. These models 
assign probabilistic actions and traits to individual agents within a system using rules rather than 
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equations and track these actions over time and space (200). Agents within the model are tracked 
in a discrete manner and outputs of ABMs can be temporal as well as spatial (Figure 1.4). The 
behaviors of discrete agents can be probabilistic, and therefore agent-based models are stochastic 
in nature.  
 In silico models can capture the dynamics of biological events at different scales 
including molecular, cellular, tissue, and organismal (Figure 1.3). In this work molecular scale 
dynamics, such as receptor/ligand binding of TGF-β1, are modeled using ordinary differential 
equations (ODEs) (83, 157, 158, 169, 201, 202). There are many ODE models of pulmonary 
disease including those studying IPF (169, 203-207), cystic fibrosis (208), and tuberculosis (160, 
165, 209-214). These models focus on specific aspects of pulmonary disease at a single 
biological scale. In addition to the in silico studies of pulmonary disease that utilize ODE 
models, there are a wealth of studies using ABMs. These models examine the development of 
such diseases as chronic obstructive pulmonary disease (63, 215), acute inflammation (216), 
fungal infection (217), and tuberculosis (158, 160, 164, 165, 218-220). These ABMs focus 
primarily on cellular behavior and intercellular signaling. Still other ABMs study the 
transmission of pulmonary diseases within populations (221-224). In this work I build off prior 
studies that examine the behavior of immune cells in the lung following Mtb infection (157-162, 
164, 165, 190, 192, 193, 201, 209, 210, 212, 220, 225-228).  
 In addition to capturing events at individual scales, models can also capture events at 
multiple biological scales simultaneously. Multi-scale modeling takes a systems approach to 
studying biological questions. In this work, I use multi-scale hybrid modeling, (i.e. combining 
molecular scale ODEs and cellular scale ABMs), to capture complex tissue scale dynamics. 
Output from the ODE model at the molecular scale is a feed forward input into the ABM at the 
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cellular and tissue scales. Cytokines secreted from cells in the ABM determine concentrations 
that feed into the ODE models. Therefore, extracellular cytokine levels and intracellular cytokine 
signaling events link the cellular and molecular scale models creating hybrid multi-scale models 
for the study of pulmonary disease. Analyses of these complex multi-scale models is 
approachable and we have developed techniques to explore them including USA (229) and 
tuneable resolution (230).  
 
1.4 Fundamentals of pulmonary fibrosis studies  
Pulmonary fibrosis is thought to be the result of dysregulation of the wound healing 
process (22, 143, 148, 231). Normal wound healing occurs in four stages: (I) coagulation and 
hemostasis, (II) inflammation, (III) proliferation, and (IV) remodeling (148). The first and 
second stages of wound healing are characterized by platelet aggregation at the site of exposed 
ECM, secretion of large amounts of cytokines, and recruitment of cells to the site of the injury 
(232, 233). During the third stage of the wound healing process, fibroblasts proliferate into the 
wound gap (152). Fibroblasts are an essential part of tissue regeneration and wound healing (150, 
156). In healthy tissue fibroblasts persist in a quiescent state (105) under continual PGE2 
signaling from epithelial cells (66, 122, 188, 234). Upon injury, the architecture of the tissue is 
disrupted stimulating the wound healing process to begin and eventually inducing the 
proliferation of fibroblasts (105) (Figure 1.5).  
	 15	
 
Figure 1.5. Mechanism of wound healing in the lungs. During proliferative phase of the 
wound healing response, (1) fibroblasts proliferate into the site of the wound. (2) They secrete 
cytokines including TGF-β1, (3) which induces their own differentiation. (4) Fibroblasts 
differentiate into myofibroblasts , which preform two key functions during the remodeling phase 
of the wound healing response. (5) Myofibroblasts secreted ECM proteins, which produce a 
substrate for re epithelialization. (6) They also synthesize αSMA, which enables them to contract 
and remodel injured tissue (148, 156). 
 
 
Fibroblasts secrete TGF-β1 and other growth factors leading to fibroblast-to-
myofibroblast differentiation (235-237), and the fourth stage of wound healing (66, 100, 105, 
234). During this stage fibroblasts differentiate into myofibroblasts (105). Myofibroblast 
differentiation is characterized by secretion of ECM proteins (143, 152, 156) and synthesis of α-
smooth muscle actin (αSMA). ECM proteins are cross-linked to provide a substrate for re-
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epithelialization of the wounded area (152).  αSMA is a cytoskeletal protein that gives 
myofibroblasts a contractile phenotype (105, 189, 238), enabling them to remodel tissue and 
close the wound gap (148-150, 156, 239, 240). 
 In conjunction with fibroblasts and myofibroblasts, epithelial cells play an important role 
in normal pulmonary wound healing (241). Epithelial cells are a substantial component of lung 
tissue, covering the bronchi, airways, and alveoli. They provide a surface for gas exchange and 
create a barrier against infection (242-244). Wounds break the epithelial layer causing damage to 
the cells (18, 66, 245). Regeneration of the epithelium is needed to restore proper function of the 
lung tissue. During normal wound healing epithelial cells proliferate onto the ECM secreted by 
myofibroblasts, restoring the integrity of the epithelial barrier (152).   
 Fibrosis occurs when the normal wound healing processes become dysregulated, 
specifically during the third and fourth stages. Excessive proliferation and differentiation of 
fibroblasts destroys the tissue architecture resulting in inhibited inspiration and expiration. This 
tissue is characterized as being stiff and scarred, and is not suitable for gas exchange (12, 246). 
Excessive remodeling leads to even further degradation of the tissue by destroying the alveoli. 
Although the specific cause of dysregulation is often unknown, TGF-β1 is implicated in driving 
excessive fibroblast proliferation and differentiation. TGF-β1 is also toxic to epithelial cells in 
high concentrations (84, 88). Epithelial cell damage is associated with the induction of 
pulmonary fibrosis (187, 241, 245, 247, 248). Stimulation of myofibroblast driven tissue 
remodeling by TGF-β1 may further exacerbate epithelial damage by reducing the available 
surface area for re epithelialization (231, 249). The loss of epithelial cells in the tissue further 
relieves inhibition of fibroblasts and myofibroblasts by PGE2, and contributes to a snowball 
effect of tissue remodeling and fibrosis. 
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 Previous studies of wound healing and fibrosis have been preformed in vitro, in vivo, and 
in silico. Scratch assays are one in vitro model used to study wound healing, specifically cell 
migration during wound healing (250). In a scratch assay, cells (usually epithelial cells and/or 
fibroblasts) are plated onto a petri dish and a scratch is made through the cells, destroying cells in 
the middle of the plate. Photos of the plate are taken to track migration of cells and they fill the 
gap (251-253).  Another assay used for studying wound healing in vitro is the transwell assay. 
Transwell assays place cells on one side of a membrane and chemokines on the other (66). 
Migration of cells though the membrane can be measured.  
 There are two common in vivo models of pulmonary fibrosis in mice. Bleomycin is used 
to induce pulmonary fibrosis (16, 18, 167, 248, 254-256) and is typically administered either 
intratracheally or intravenously (254). Bleomycin induces pulmonary injury, which is visible 
within one week and treatment, and features of fibrosis, which are visible two weeks after 
treatment (254). Another in vivo model of pulmonary fibrosis is the fluorescein isothiocyanate 
(FITC) induced model. FITC is introduced inratracheally into the lung and has a green 
fluorescence color that can be visualized to see the initiation of injury (257, 258).  
 Previous studies by other groups include computational models of wound healing of the 
epidermis (145, 146, 259-270), cornea (271-274), pressure ulcers (275, 276), and other systems. 
There are also a number of in silico models of extracellular matrix formation, and organization 
(273, 277, 278). There are also a wide array of models of fibrosis including ODE models, agent 
based models, and biomechanical models (63, 83, 169, 203, 279-283). However models that 
focus specifically on pulmonary fibrosis are fewer (63, 203).  Current computational models of 
pulmonary fibrosis focus on cellular scale interactions (63, 203). These models include 
representations of cytokines but do not focus on molecular scale interactions (63, 203). These 
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models also do not focus on epithelial cell survival (241, 284). In this work we construct a multi-
scale model combining molecular and cellular scale events to study the effects of fibroblasts 
directly on epithelial cells.  
 
1.5 Fundamentals of tuberculosis studies 
 Pulmonary TB is the result of infection by inhalation of Mtb. Once in the lung, Mtb is 
phagocytosed by an alveolar macrophage at the initial site of infection. The bacteria are able to 
avoid phago-lysosomal fusion, and can survive within the macrophage (41, 44, 46, 60, 285, 286). 
Bacterial replication can ultimately lead to rupture of the infected macrophage, releasing bacteria 
into the surrounding tissue. These, now extracellular, bacteria are available for phagocytosis by 
other nearby macrophages leading to propagation of the infection in the local area. Infected 
macrophages secrete cytokines, which recruit monocytes and neutrophils from the blood to the 
site of infection (41). As cells accumulate at the site of infection they contribute to the early 
stages of granuloma formation. Two to three weeks following the initial infection, dendritic cells 
will carry antigen from the site of infection to nearby draining lymph nodes to initiate the 
adaptive immune response (60, 286). Once primed, T cells are recruited to the site of infection 
where they perform a variety of effector functions including cytotoxic killing of infected cells 
and macrophage activation (41, 287). Together, the cells at the site of infection contribute to the 
formation of granulomas. 
	 19	
 
Figure 1.6 Schematic of TB progression and relevant immune response. The process begins 
in the top left corner where Mtb are inhaled into the lungs and phagocytosed by macrophages 
resulting in intracellular infection. As a result macrophages secrete cytokines, which recruit 
dendritic cells to the site of infection. Dendritic cells acquire antigen and travel from the lung to 
the lymph node where they present antigen to naïve T cells. Stimulated T cells then travel back 
to the site of infection in the lung and contribute to granuloma formation. Macrophages at the 
site of infection are activated to kill bacteria by effector T cells. Some macrophages become 
infected and if they cannot kill the infecting bacteria, will rupture releasing the bacteria and 
contributing to the spread of infection. 
 
 Granulomas are highly organized cellular structures that function in coordination with the 
immune system to isolate bacteria and infected cells from the surrounding tissue and provide an 
environment for clearance of the infection. The structure of granulomas also works to the 
advantage of the pathogen, making it challenging for uninfected cells and drugs to access and 
effectively kill bacteria (192, 288). The spatial organization of granulomas can vary but 
generally follows the following pattern from inside out: a caseous center of bacteria, dead cells, 
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and infected cells; a ring of resting and infected macrophages; a ring of lymphocytes and resting 
macrophages (57). Due to their complexity, granulomas can be classified based on cellular 
composition, number of bacteria present, and overall size and shape. Cellular classifications of 
granulomas include but are not limited to caseus (having a necrotic center of bacteria and dead 
cells) (Figure 1.7 A), suppurative (made up primarily of neutrophils) (Figure 1.7 B), solid 
cellular (having no caseum in the center) (Figure 1.7 C), and fibrotic (having collagen and ECM 
proteins throughout the granuloma and especially on the periphery) (Figure 1.7, D) (46, 57, 285).  
Granulomas classified by number of live bacteria present (CFU) are referred to as contained 
(having a CFU that is stable, i.e. neither increasing nor decreasing over time), disseminating 
(having an increasing CFU) and sterilized (having achieved a CFU of zero). 
 
Figure 1.7 Histology of Mtb induced pulmonary granulomas from NHPs. A) Caseus necrotic 
granuloma. B) Suppurative necrotic granuloma. C) Solid cellular granuloma. D) 




 Granuloma CFU’s are determined largely by the immune response to infection. The host 
immune system has several mechanisms for killing bacteria utilizing macrophage and T cells 
specific mechanisms (289). Macrophages phagocytose extracellular bacteria and perform 
phagolysosomal fusion to kill the bacteria (46), or target them with reactive oxygen species (46). 
These processes are typically unsuccessful resulting in infection of the macrophage itself (289). 
Macrophages that have been activated by the second signal IFNγ (through the STAT1 pathway, 
the signal being bacteria through the NFkB pathway) are better killers of intracellular bacteria. 
Another first signal can be TNF which also signals through NFkB. Infected macrophages can be 
killed by T cells through Fas/Fas-ligand mediated apoptosis (290). Infected macrophages are also 
killed by cytotoxic T cell induced apoptosis through the secretion of perforin, granzymes, and 
granulysin (289). Collectively, these mechanisms contribute to killing of bacteria within 
granulomas. 
Due to the complex nature of granuloma formation, the best models for studying 
pulmonary tuberculosis are NHPs (37, 42, 43, 46, 49, 56, 57, 59, 60, 163, 170, 285, 291-295). 
NHP studies are very expensive because large animals must be housed in a biological safety 
level three facility and experiments take weeks, months, or years to preform. Limited biological 
samples and reagents can make some experiments very difficult to do in vivo. Rabbits are also 
used to study the formation of granulomas (192, 193, 285, 296-304). Rabbits face similar reagent 
limitations to NHPs. In some cases mice are also used to study pulmonary tuberculosis infection 
despite being a poor model of granuloma formation (170, 305).  
 Computational models of tuberculosis infection include ordinary differential equation, 
partial differential equation, and agent-based models. Differential equation models of TB have 
been used to study the role of cytokines in granuloma formation and function (162, 164, 212, 
	 22	
219). They have also been used to study the pharmacokinetics of drugs during TB treatment 
(297, 306-309). Agent based models of tuberculosis infection have been used to study the 
immune response to TB and granuloma formation (220, 227). Agent based models and 
differential equation models have been combined to form hybrid multi-scale models, which are 
used to examine the cross-regulation between events at the cellular, molecular, and tissue scales 
(158-161). In this work we combine a cellular scale agent based model of TB granuloma 
formation with molecular signaling dynamics of TGF-β1 to study the role of TGF-β1 in 
granuloma formation and function (83, 169). 
 
1.6 Dissertation overview 
 The goal of this work is to answer questions regarding the role of TGF-β1 in ILDs such 
as fibrosis and TB. To address these questions I have developed computational models 
describing the role of TGF-β1 in fibrotic responses and infection. Using a multi-scale systems 
biology approach I have predicted mechanisms responsible for dysregulated fibroblast behavior 
and proposed potential therapeutic targets. In particular my thesis is designed to determine what 
molecular scale mechanisms are responsible for driving cellular and tissue scale fibrotic 
phenotypes. I focused on the role of TGF-β1 dynamics in fibroblast activation as well as the 




Figure 1.8. Hybrid multi-scale modeling. This is a conceptual illustration of how different 
types of models are combined to create a single hybrid multi-scale model of granuloma 
formation in the lungs. At the molecular scale is an ODE model of TGF-β1 receptor ligand 
signaling dynamics within a single fibroblast (169). Cytokine secretion by cells and diffusion 
within the environment also occurs at the molecular scale. At the cellular scale is an agent-based 
model of the immune response in in the lung (158, 160, 220). This model is made up of 
individual cellular agents including macrophages, T cells, and fibroblasts, which respond based 
on probabilistic rules to stimuli and cytokines within their local environment. At the tissue scale 
is emergent behavior determined but the collective behaviors of individual agents within the 
model. This emergent behavior can be characterized and compared to biological phenomena. 
Each model scale is linked to the other scales through cytokine concentrations and/or agent 
behaviors. Molecules secreted and diffused at the molecular scale dictate the behavior of cells at 
the cellular scale (arrow 1). The actions of cells at the cellular scale dictate the emergent 
behavior at the tissue scale (arrow 2). The emergent behavior of the tissue scale defines local 
environments, which in turn influence cytokine concentrations at the molecular scale (arrow 3).  
 
 
 In my thesis I created a hybrid multi-scale model with a focus at the molecular level on 
the role of TGF-β1 receptor ligand signaling dynamics and downstream signaling events in 
fibroblast activation, and at the cellular level on fibroblast and epithelial cell co-regulation, as 
well as the role of TGF-β1 in the context of lung tissue and TB infection with readouts at the 
tissue scale. This model combines molecular scale, cellular scale, and tissue scale dynamics from 
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existing and novel models (Figure 1.8). I used this model to evaluate real-time molecular events 
and derive mechanisms driving pathogenic fibroblast behavior across the tissue, cellular and 
molecular scales. I am conducting my research according to the following specific aims 
paralleling in silico and in vitro approaches:  
 
1.6.1 Aim 1: Predict host factors that regulate fibroblast activation and αSMA synthesis at 
the molecular scale.  
Many previous studies identify an important role for TGF-β1 in fibroblast activation (70, 
189, 310, 311), however there are still many question regarding the dynamics of fibroblast 
regulation that remain unanswered. The temporal dynamics of TGF-β1 and PGE2 regulation of 
fibroblast activation have not been characterized. In this work we utilize relevant in vitro 
experiments and ODEs to identify specific characteristics of fibroblast activation and examine 
the behavior fibroblasts in the context of TGF-β1 and PGE2 signaling. I develop a molecular 
scale mathematical model of specific TGF-β1 receptor ligand signaling dynamics to capture 
molecular scale events of TGF-β1 regulation of a single fibroblast (169). In vitro experiments 
measure fibroblast production of collagen and αSMA in response to TGF-β1 stimulation at 
different doses and over time. With these combined techniques I identify the time course 
dynamics of fibroblast response to TGF-β1 signaling and predict cellular conditions that result in 
healthy wound healing, fibrosis, and anti-fibrotic lack of wound healing. I also preform time 
course simulations of fibroblast response to different dosing regiments of TGF-β1 and PGE2 and 
use uncertainty and sensitivity analysis to predict the mechanisms driving model outcomes.  
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1.6.2 Aim 2: Identify mechanisms driving fibroblast behavior and epithelial cell survival in 
a co-culture environment.  
TGF-β1 and PGE2 co-regulation of a single fibroblast alludes to mechanisms that may be 
relevant in a more complex tissue environment. The development of fibrosis involves both the 
dysregulation of fibroblasts and the disruption of epithelial cells. Therefore in order to identify 
key mechanisms driving fibroblast dysregulation during fibrosis, it is necessary to evaluate 
fibroblast behavior in a complex co-culture environment. In this work we capture the interactions 
between fibroblasts and epithelial cells in co-culture at a cellular level, integrate molecular scale 
dynamics, and validate against in vitro experimental results (83). In addition, we also perform 
co-culture experiments with fibroblasts and epithelial cells in different treatment conditions and 
measure collagen 1 and αSMA synthesis, as well as fibroblast proliferation and epithelial cell 
death. I construct a cellular scale in silico agent-based model of fibroblast and epithelial cell 
agents in co-culture, and integrate the molecular scale ordinary differential equation model in the 
fibroblast agents.  
I perform time course simulations of the co-culture model under different initial 
conditions and apply uncertainty and sensitivity analysis to predict the mechanism driving model 
outcomes. With this model I can characterize the time course dynamics of fibrotic dysregulation 
in co-culture and predict the outcome of different initial tissue on fibroblast activation and 





1.6.3 Aim 3: Identify a key role for TGF-β1 in regulating granuloma formation and 
function during pulmonary Mtb infection.  
The action of TGF-β1 is relevant to many pulmonary pathologies, in addition to fibrosis. 
It has been predicted to play a role in TB, although the details and magnitude of this role in a 
complex immunological environment such as a granuloma have not yet been characterized.  
Previous work has examined the roles of both pro- and anti-inflammatory cytokines in the 
context of a granuloma using our hybrid multi-scale model of immune responses in the lung 
GranSim (157-159, 164, 209). In order to identify a mechanistic role of TGF-β1 in the 
progression of TB granuloma development and in granuloma sterilization, I introduce TGF-β1 
dynamics into GranSim. I use uncertainty and sensitivity analysis to predict key mechanisms in 
driving outcome. We pair these in silico studies with in vitro studies from NHPs infected with 
Mtb and compare cytokine receptors present on different cell types in the granuloma to validate 
or refute predicted roles of TGF-β1 in the granuloma. 
 
1.6.4 Aim 4: Predict mechanisms driving regulation and development of fibrosis across 
biological scales in the complex tissue environment of the lung and predict potential 
therapeutic targets for different types of pulmonary fibrosis.   
In some cases, the development of pulmonary fibrosis is associated with pulmonary TB. 
Collaborators have characterized the development of fibrosis in association with TB (49). They 
have identified the occurrence of fibrosis in NHPs that have been treated with antibiotics and 
those that have not. The appearance of fibrosis differs somewhat between these groups. External 
fibrosis surrounds the granuloma and is associated with untreated granulomas, while central fibro 
calcific granulomas are associated with anti-biotic treatment. Because TGF-β1 plays an 
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important role in the development of both of these pathologies, we suspect that it may be central 
to the fibrosis developed during infection. To examine mechanisms of fibrosis formation in the 
context of TB, we combine cellular agents maintaining their molecular dynamics from the co-
culture model into the granuloma lung model, GranSim. Uncertainty and sensitivity analysis can 
predict key mechanisms driving different fibrotic outcomes in granulomas. With this model we 
can identify regulators of fibrotic development in the context of a TB granuloma and compare 




Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation 
 
2.1 Introduction 
 Fibroblasts are necessary for tissue regeneration and wound healing (150, 156). 
Fibroblasts exist in tissue in a quiescent state (105) until disruption of the tissue structure triggers 
differentiation into myofibroblasts (105).  This differentiation is characterized by secretion of 
extracellular matrix (ECM) proteins and production of α-smooth muscle actin (αSMA), a 
cytoskeletal protein that enables contraction and tissue remodeling (150, 156). Previous work has 
identified several critical functions performed by myofibroblasts including ECM protein 
secretion (148, 149, 239) and remodeling of damaged tissue. Dysregulation of  fibroblast to 
myofibroblast differentiation can result in severe pathology that can compromise function of 
affected tissue; however, excessive ECM secretion can lead to detrimental tissue remodeling and 
fibrosis (22). Fibrosis, the stiffening and scarring of tissue, can result in poor clinical outcomes 
depending on the extent of the affected tissue, and patients with fibrosis often have poor 
prognoses (312). Idiopathic pulmonary fibrosis (IPF), for example, results in decreased 
inspiration and expiration capacity and has an average prognosis of 2-4 years (30, 33, 35, 313, 
314).  There are currently two treatments available for pulmonary fibrosis in the United States, 
both of which provide only a moderate extension of prognosis (about 6 months) (30, 33, 35, 313, 
314). There are no available treatments that halt or reverse fibrosis. We aim to understand why 
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fibroblast differentiation becomes dysregulated and which signaling mechanisms drive this 
outcome in order to develop new therapeutics for this and other fibrotic diseases.  
The cytokine transforming growth factor-β1 (TGF-β1) has been shown to play a critical 
role in fibrosis-associated pathologies. TGF-β1 is a major contributing factor to pulmonary 
complications and fibrosis following bone marrow transplant (20, 87). TGF-β1 sustains 
myofibroblast function and can exacerbate IPF (78, 241). It has been clearly established that 
TGF-β1 is key in driving development of fibrosis; however, there are still open questions as to 
the mechanisms involved in TGF-β1-induced dysregulation of fibroblast differentiation and 
myofibroblast function. To identify which factors contribute to fibrotic dysregulation and predict 
how best to inhibit this process, we construct a mathematical model describing the contribution 
of molecular mechanisms driving fibroblast to myofibroblast differentiation. 
 TGF-β1 is a growth factor and member of the transforming growth factor-β superfamily 
of cytokines known to drive differentiation of fibroblasts as well as secretion of ECM proteins 
(62, 89, 92). TGF-β1 is secreted in a latent form as a homodimer of TGF-β1 bound to a 
homodimer of the latency associated peptide (LAP) referred to as the small latent TGF-β1 
complex (42 kDa) (95). It is stored in the ECM as a large latent TGF-β1 complex (290 kDa) 
which includes the small complex and an additional protein referred to as the latent TGF-β1 
binding protein (LTBP1) (97). Release of TGF-β1 from the LAP produces an active TGF-β1 
molecule. Latent TGF-β1 can be activated by proteolytic cleavage, mechanical extraction, and 
changes in pH of the surrounding environment (95). TGF-β1 is bound in its active form by a 
specific membrane receptor complex of ALK5 (TGF-β1 receptor 1) and TGFβ1RII (TGF-β1 
receptor II) (98, 99). The effect of TGF-β1 on cells is tissue-and-cell specific. For example, 
TGF-β1 can induce differentiation of fibroblasts through downstream canonical SMAD2/3, and 
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non-canonical rho/ROCK signaling cascades (100). In keratinocytes TGF-β1 causes cell cycle 
inhibition (108, 109) and it has been shown to play several opposing roles in T-cell 
differentiation and maturation (111-117).  Because of the cell specificity associated with TGF-β1 
signaling, we focus on identifying fibroblast-specific mechanisms of action. 
Several mathematical models have been developed to complement experimental 
approaches in exploring TGF-β1 receptor-ligand signaling dynamics in other cell types (206, 
207, 315). Vilar et al. showed that the ratio of constitutive degradation of  TGF-β1 receptors to 
degradation induced by ligand binding dictates whether cellular responses to TGF-β1 are 
transient or permanently elevated for keratinocytes and pancreatic cancer cell lines (207). Zi et 
al. identified that the duration of a cellular response to TGF-β1 is dependent on whether the 
receptor-ligand complex is internalized into a clatherin-coated or clatherin-independent 
endosomal compartment. In keratinocytes, if the predominant form of endocytosis is clatherin-
independent, the response will be transient. However, if the predominate form of endocytosis is 
clatherin-dependent, the response will be prolonged (205). Recently, Vizan et al. demonstrated 
that keratinocytes experience a refractory state following a TGF-β1 signaling event, where cells 
are temporarily insensitive to further TGF-β1 stimulation. They showed that the duration of this 
refractory period is dependent on the rate of receptor turnover and the ratio of ligand-induced to 
constitutive receptor degradation for keratinocyte s (315). Together, these models emphasize the 
importance of endocytosis and constitutive vs. ligand-induced receptor degradation in 
determining the cellular response to TGF-β1 signaling.  
Fibroblast responses to TGF-β1 differ from keratinocyte and pancreatic cell responses. 
As a result there are mechanisms specific to fibroblasts that were not considered in these prior 
mathematical models. Fibroblast responses to TGF-β1 are highly dependent on the simultaneous 
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presence of adhesion signaling (100). Adhesion signaling through integrin binding is necessary 
for TGF-β1 induced fibroblast to myofibroblast differentiation to occur (100). Previous work has 
demonstrated that fibroblasts plated onto plastic surfaces, such as a tissue culture plate, respond 
to TGF-β1 to induce differentiation (measured by synthesis of a-SMA). In contrast, when 
fibroblasts are suspended in liquid culture they show no response to treatment with TGF-β1 
(100). These data indicate that fibroblasts require adhesion in order to respond to TGF-β1 
stimulation (100). The stiffness of the substrate adhered to is influential in the strength of the 
fibroblast response to TGF-β1; the stiffer the substrate the greater the adhesion signaling, and 
stronger the response (238, 316-321). Another important factor in the regulation of TGF-β1 
signaling in fibroblasts is a negative regulator present in the system, namely prostaglandin E2 
(PGE2). PGE2 indirectly inhibits TGF-β1 signaling by inhibition of FAK in the adhesion 
signaling cascade (168) rather than acting directly on TGF-β1 by limiting SMAD 
phosphorylation (168). No other forms of cross talk between PGE2 and the canonical TGF -β1 
signaling cascade have been demonstrated. PGE2 has been shown to inhibit adhesion signaling, 
and in turn inhibit fibroblast responses to TGF-β1 (122, 168, 234, 322). Fibroblasts are exposed 
in vivo to PGE2 secreted by epithelial cells, and it has been proposed that this constitutive 
signaling induces fibroblast quiescence, maintaining homeostasis of the tissue environment (187, 
188). High levels of PGE2 have been linked to increased fibroblast apoptosis (323). Previous 
work has shown that fibroblasts can lose sensitivity to PGE2 in vitro by down-regulating EP2 
receptor synthesis (324). This is a phenomenon that is also seen during fibrotic responses in the 
lung (167).   PGE2 can mediate functions of multiple cells via binding to four unique receptors 
(325). Because it is a strong inhibitor of adhesion signaling, however, understanding the 
mechanistic relationships between TGF-β1, adhesion signaling, and PGE2 allows us to identify 
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environmental conditions favorable to healthy wound resolution as well as signaling mechanisms 
that are key to establishing those conditions.   
Thus, to gain further insight into the role of TGF-β1 in regulation of fibroblast 
differentiation into a myofibroblast, we take a systems biology approach to identify the influence 
of molecular-scale mechanisms of TGFβ signaling on regulation of this transition. We use a 
combination of in vitro experimentation, mathematical modeling, and statistical analyses to 
identify key mechanisms driving fibroblast differentiation and dysregulation. We developed a 
nonlinear ordinary differential equation model that tracks the temporal concentrations of key 
species (Table 2.1) in receptor/ligand binding, trafficking and signaling cascades to evaluate how 















Table 2.1 Model variables 
Symbol Definition Units 
TGF-β1 Receptor Ligand Variables 
𝑻𝑮𝑭𝜷𝟏𝒍𝒂𝒕 Latent TGF-β1 
𝑚𝑜𝑙𝑒𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 
𝑻𝑮𝑭𝜷𝟏𝒂𝒄𝒕 Activated TGF-β1 
𝑚𝑜𝑙𝑒𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 
𝑹𝒔𝒖𝒓𝒇 Free receptor on the cell surface 
#
𝑐𝑒𝑙𝑙 













PGE2 Input Variables 
𝑷𝑮𝑬𝟐𝑺𝒐𝒍 Soluble Prostaglandin E2 
𝑚𝑜𝑙𝑒𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 
𝑷𝑮𝑬𝟐𝒊𝒏𝒕 Internalized Prostaglandin E2 
#
𝑐𝑒𝑙𝑙 
α-Smooth Muscle Actin Output Variables 
𝑷𝑹𝑫𝑺 Post-receptor simplified downstream signaling events 
#
𝑐𝑒𝑙𝑙 




We build and test the model with data derived from fibroblast differentiation 
experimental studies performed herein, and we analyze the model to predict which mechanisms 




Figure. 2.1. Processes relevant to fibroblast differentiation. Latent TGF-β1 can be activated 
and then is able to bind surface receptors. Receptor/ligand complexes are internalized, initiating 
a downstream signaling cascade which, in combination with adhesion signaling, induces the 
synthesis of α-smooth muscle actin. PGE2 can inhibit the adhesion signaling, preventing 
completion of the signal cascade and protein synthesis. Our model tracks latent TGF-β1, active 
TGF-β1, free surface receptors, free cytoplasmic receptors, bound surface receptors, bound 
cytoplasmic receptors, the number of bound receptor internalization events, extracellular PGE2, 
intracellular PGE2, and α-smooth muscle actin synthesis. We have simplified the adhesion, 
SMAD, and PGE2 signaling pathways. 
 
2.2 Results 
2.2.1 PGE2 is necessary to Explain In Vitro Data of αSMA Synthesis  
 We first evaluated the level of αSMA synthesized in the presence of TGF-β1. We 
compared fold changes in concentration of αSMA at 4, 12, 24, or 48 hours in the presence of an 
initial concentration of 1ng/ml of TGF-β1 to 4 hours untreated.  Data show no increase at 4 hours 
post treatment over the untreated and an approximately 2.5 fold increase in αSMA at 12 hours 




Figure. 2.2 αSMA time course studies and simulations. (A) αSMA measured in 3T12 
fibroblasts at either 4 hours untreated or 4, 12, 24, or 48 hours treated with 1ng/ml of activated 
TGF-β1 using Western blot and densitometry analysis. N=2/condition. (B) Simulation of αSMA 
production.  Solid line with filled squares representing the experimental data described in part a) 
and gray triangle representing 4 hour untreated sample using 3T12 fibroblast cell line and 1ng/ml 
of activated exogenous TGF-β1, dotted curve representing simulation results following treatment 
with 1ng/ml of activated exogenous TGF-β1, and PGE2 inhibition, and dot-dashed line 
representing simulation control with no TGF-β1 treatment. We have previously published similar 
kinetics using 2 ng/ml TGFβ suggesting that TGF-β1 is in excess in this system (168). 
 
These results mirror our earlier findings when stimulating fibroblasts with 2 ng/ml TGFβ, 
indicating that TGFβ is not limiting.  We also simulated fibroblasts with our mathematical model 
under the same experimental conditions (untreated or 1ng/ml of TGF-β1) and measured the 
αSMA concentration at 4, 12, 24, 48 hours. We parameterized the model using values derived 
from previously published data or estimated using uncertainty analysis (Table 2.2), and then 







Table 2.2 Model Parameters 
Symbol Parameter Value Range Unit Source 
General Parameters 
vol Volume of media 2 N/A mL N/A 
cells Total number of cells 5.0e5 N/A # N/A 
TGF-β1 Receptor Ligand Parameters 
𝒌𝒔𝒚𝒏
𝑻𝑮𝑭𝜷𝟏𝒍𝒂𝒕 Latent TGF-β1 Synthesis 5e-15 
1.0e-17 – 
1.0e-10 moles/min*volume est. 
𝒌𝒅𝒆𝒈






1.0e3 1/min est. 
𝒌𝒊𝒏𝒅𝒔𝒚𝒏
𝑻𝑮𝑭𝜷𝟏𝒍𝒂𝒕 Latent TGF-β1 Induced Synthesis 0.001 
1.0e-4 – 












4.35e14 N/A 1/min (72) 
𝒌𝒅𝒆𝒈
𝑻𝑮𝑭𝜷𝟏𝒂𝒄𝒕 Active TGF-β1 Degradation 0.577 N/A 1/min (326) 
𝒌𝒔𝒚𝒏𝑹  
TGF-β1 Receptor 
Synthesis 4.0 N/A #/(min)*cell (327) 
𝒌𝒊𝒏𝒕𝑹  
TGF-β1 Receptor 
Internalization 0.333 N/A 1/(min) (207) 
𝒌𝒓𝒆𝒄𝑹  
TGF-β1 Receptor 





0.333 N/A 1/(min) (207) 
𝒌𝒅𝒆𝒈𝑹  
TGF-β1 Receptor 












Table 2.2 Model Parameters cont. 
PGE2 Parameters 
𝒌𝒔𝒚𝒏𝒕𝒉𝑷𝑮𝑬𝟐  PGE2 Synthesis 2.1*104 N/A #/min * cell (328) 
𝒌𝒊𝒏𝒕𝑷𝑮𝑬𝟐 
PGE2 Receptor Ligand 
Binding Rate 0.0096 
1.0e-3 – 
1.0e2 1/min est. 
𝒌𝒅𝒆𝒈𝑷𝑮𝑬𝟐 PGE2 Degradation 0.001 N/A 1/min (329) 





1e-1 1/min est. 
𝒄𝒂𝒄𝒕𝑨𝒅𝒉𝒆𝒔𝒊𝒐𝒏 
Adhesion Signal 
Strength 1 0 or 1 N/A est. 
𝒄𝑺𝒕𝒊𝒇𝒇𝑴𝒂𝒕𝒓𝒊𝒙 
Matrix Stiffness 
Effect 100 0 - 1000 N/A est. 
𝒌𝑰𝒏𝒉𝒊𝒃𝒊𝒕𝑷𝑮𝑬𝟐  
Strength of PGE2 
Inhibition 1.0e-5 
1e-7 – 
1e-3 1/min est. 
𝜶𝟏 
Non-zero so 
denominator ≠0 1 0<n≤1 #/cell est. 
𝒌𝒅𝒆𝒈𝜶𝑺𝑴𝑨 αSMA Degradation 0.0001 
1e-5 – 
1e0 1/min est. 
 
Our simulations show an approximately 2 fold increase in αSMA by 4 hours post 
treatment and a 6-fold increase by 12 hours post treatment which was maintained at 48 hours 
(Data not shown). These levels are much higher than the experimental data, indicating a lack of 
negative regulation in the system. We predicted that the absence of negative regulation is 
responsible for the discrepancy in experimental and simulation results. We introduced negative 
regulation by PGE2 into our model and simulated fibroblasts (untreated or 2ng/ml of TGF-β1) 
and measured the αSMA concentration at 4, 12, 24, 48 hours in the presence of of 100μM PGE2 
and found no increase in αSMA at 4 hours post treatment over the untreated and an 
approximately 2.5 fold increase at 12 hours post treatment which is maintained at 48 hours post 
treatment. Simulation results closely match the experimental data consistent with the idea that a 
negative regulator is necessary to explain in vitro data regarding fibroblast differentiation 
(Figure. 2.2B). 
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In order to test our hypothesis that PGE2 signaling was needed for our model to 
recapitulate experimental data, we performed the experiment described above with fibroblasts in 
the absence of PGE2 signaling by treating them simultaneously with 2ng/ml of TGF-β1 and 
indomethacin (an inhibitor of PGE2) (Figure 2.3A). We found that in the absence of PGE2 
signaling the concentration of αSMA in fibroblasts was significantly increased (p-value < 0.05).  
 
 
Figure. 2.3 αSMA studies and simulations with and without PGE2 signaling. (A) αSMA 
measured in 3T12 fibroblasts at 24 hours untreated, treated with 2ng/ml of TGF-β1, or treated 
with 2ng/ml of TGF-β1 and 10µM of indomethacin using Western blot and densitometry 
analysis. N=2/condition. (B) Simulation of αSMA production.  Dashed curve represents 
simulation results in the absence of PGE2 inhibition. Dotted curve represents simulation results 
in the presence of PGE2 inhibition, and solid line represents simulation control with no TGF-β1 
treatment. Experimental data for αSMA at 24 hours following treatment with 2ng/ml of TGF-β1 
and 10µM of indomethacin, 2ng/ml of TGF-β1, or serum free media (SFM) are represented by 
open square open diamond and open circle respectively. N=2 
 
2.2.2 Transient TGF-β1 Signaling in the Presence of PGE2 
Previously published work identifies PGE2 as an important regulator of TGF-β1 signaling 
(168)  and we show above that including PGE2 gives simulation that are consistent with 
experimental data of TGF-β1 induced αSMA synthesis. In order to better understand the 
dynamics of PGE2 inhibition of fibroblast differentiation, we characterized the fibroblast 
response to TGF-β1 in the presence of a fixed concentration of PGE2 using our in silico model. 
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During this simulation we identified two phenomena that we refer to as response and refraction. 
Response describes periods of increasing αSMA concentrations in the fibroblast. Refraction 
refers to periods of declining concentrations of αSMA indicating that fibroblasts are not able to 
respond to TGF-β1 and that αSMA is degrading in the cell. We define the magnitude and 
duration of a response as the maximal concentration of αSMA achieved following treatment and 
the time it takes for this concentration to return to pre-stimulatory levels, respectively. In the 
transient TGF-β1 signaling simulations we fixed the concentration of PGE2 and simulated 




Figure. 2.4 In silico TGF-β1-induced α SMA synthesis in the presence of constant 
concentration of PGE2. The x-axis represents time in hours, and the y-axis represents the 
concentration of α SMA in units/cell. a α SMA synthesis in a constant concentration (1 nmol) of 
PGE2 and dosing with 0.5 ng/ml TGF-β1 (dotted) 1 ng/ml TGF-β1 (solid), and 2 ng/ml (dashed) 
at 4 and 28 h. b α SMA synthesis in a constant concentration (1 nmol) of PGE2 and dosing with 
1 ng/ml TGF-β1 at 4 and 28 h. Dashed line simulation receives an additional dose of PGE2 at 
440 min  
 
Prior to TGF-β1 treatment the cells are in a refractory state with no change in 
concentration of αSMA (Figure. 2.4A). Following treatment with TGF-β1, an induction of 
αSMA synthesis occurs but is transient and αSMA levels eventually return to a refractory state 
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indicating that the signal has dissipated. We observed that the magnitude of a signal response 
increases as the TGF-β1 dose is increased; however, the duration of this response does not 
change. Having observed a dose dependent signal response to TGF-β1 in the presence of a 
constant concentration of PGE2 we wanted to see if this response could be abrogated. We next 
repeated the simulation but in addition to periodic doses of TGF-β1 we added an additional dose 
of exogenous PGE2 during the response phase (Figure. 2.4B). We observe that the addition of 
exogenous PGE2 following TGF-β1 treatment does reduce the magnitude of the signal. However, 
this reduction is transient and restricted to the current dose response. It does not affect the ability 
of the cell to respond fully to a later dose of TGF-β1.  This suggests that intermittent treatment of 
differentiated cells with negative regulators is only temporarily effective at suppressing αSMA 
synthesis. 
 
2.2.3 PGE2 Induced TGF-β1 Signaling Refractory State 
We showed above that PGE2 can reduce the magnitude of response to a single dose of 
TGF-β1. We tested how PGE2 affects fibroblast responses to a constant concentration of TGF-β1 
in order to evaluate effects of PGE2 dosing on fibroblasts in the context of excessive TGF-β1 
synthesis.   We examined αSMA concentration in conjunction with constant TGF-β1 
concentrations and periodic PGE2 dosing.  We predicted that dosing with PGE2 induces a 
refractory period where a cell is unresponsive to TGF-β1 (Figure. 2.5A). This refractory period 




Figure. 2.5 In silico PGE2 -induced refraction in TGF-β1-induced α SMA synthesis. The x-
axis represents time in hours (A–C). The y-axis represents the concentration of α SMA for panels 
(A) and (C). The y-axis represents the concentration of active TGF-β1 for panel (B). A α SMA 
synthesis in the presence of a constant dose (1ng/ml) of TGF-β1. Dashed curve represents dosing 
with 10nmol PGE2, solid curve represents dosing with 100 nmol PGE2 , and dotted curve 
represents dosing with 5 μmol of PGE2 . B Concentration of TGF-β1 over time corresponding to 
output in panel (C). C All were dosed with 100 nmol of PGE2 at 0 and 4 h. Filled curve 
simulation was also treated with and additional dose of 1ng/ml of TGF-β1 at 100min during the 
refractory period. Dotted curve simulation was treated with an additional dose of 1ng/ml of TGF-
β1 at 220 min during the response period  
 
We varied the size of the dose of PGE2 and examined how that affects the dynamics of 
the TGF-β1 signal response. We found that higher doses of PGE2 induced a longer refractory 
period and a decreased magnitude of signal response following the refractory period (Figure. 
2.5A). As we observed (Figure. 2.5), additional treatment with exogenous PGE2 during the 
response phase could reduce the magnitude of the fibroblast response to TGF-β1. We tested the 
inverse of the phenomenon to see whether a fibroblast could be rescued from refraction by 
adding exogenous TGF-β1 during the refractory period. We simulated treatment of our in silico 
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cells with PGE2 and gave an additional dose of exogenous TGF-β1 (Figure. 2.5B) during the 
refractory period. We observed that additional TGF-β1 could not rescue cells from refraction 
(Figure. 2.5B). We also treated cells with additional exogenous TGF-β1 during the response 
phase to test whether we could induce a stronger signal response, however we predict that 
treatment does not alter the magnitude or duration of the signal response in these cells (Figure. 
2.5C). This suggests that consistent exposure to negative regulators such as PGE2 reduces the 
cells’ sensitivity to fluctuations in concentration of positive differentiation signals such as TGF-
β1. 
 
2.2.4 Identifying States of Controlled Myofibroblast Function 
We predicted that constitutive levels of PGE2 result in predominantly quiescent 
fibroblasts (decreasing concentration of αSMA) with transient responsiveness to periodic dosing 
with TGF-β1, and that constitutive levels of TGF-β1 result in increasing fibroblast 
differentiation (based on increasing concentrations of αSMA) with transient refraction following 
periodic PGE2 dosing (Figures. 2.3 and 2.4).  Based on these studies, we know that PGE2 and 
TGF-β1 influence the state of fibroblast differentiation. The question remains as to whether 
fibroblasts can achieve a steady state in terms of the concentration of αSMA. We simulated 
treating cells with constant concentrations of both PGE2 and TGF-β1 and observed that under 
these conditions, αSMA concentration achieved a steady state that was maintained (Figure. 2.6). 
The magnitude of this steady state is determined by the ratio of TGF-β1 to PGE2 (Figure. 2.7).  
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Figure. 2.6. Three Examples of PGE2 and TGF-β1 induced steady state fibroblast αSMA 





Figure. 2.7. Predicted response outcomes across different TGF-β1 to PGE2 ratios. We 
compare αSMA concentrations of a fibroblast under different ratios of TGF-β1 to PGE2 for 24 
hours in the model (1)-(10). The x-axis represents the concentration of TGF-β1, the y-axis 
represents the concentration of PGE2. The color gradient represents the level of αSMA produced 
in response to these levels of TGF-β1 to PGE2. Blue corresponds to low concentrations of αSMA 
likely leading to fibrosis and red corresponds to high concentration of αSMA likely leading to 
apoptosis (22, 323). Plotted are the steady state concentrations of αSMA at 24 hours for these 
TGF-β1 to PGE2 levels. A balance of these mediators leads to the best outcome: moderate levels 




2.2.5 Identifying Key Molecular Mechanisms Regulating Fibroblast Differentiation  
 To identify molecular mechanisms critical to the dynamics of fibroblast differentiation, 
we performed uncertainty and sensitivity analyses (see Methods).  When all model parameters 
are varied over wide ranges (Table 2.3) and PRCCs are calculated, we can identify mechanisms 
that are significantly correlated with α-smooth muscle actin concentration over time (Table 2.3). 
Because ECM stiffness (𝒌𝑺𝒕𝒊𝒇𝒇𝑴𝒂𝒕𝒓𝒊𝒙) strongly influences αSMA synthesis (316, 317), we also 
performed our analysis holding this parameter constant to reflect the biological scenario where 
we are not able to vary the stiffness of the ECM. In this scenario we can examine the roles of 
other mechanisms/parameters not influenced by the effects of stiffness (Table 2.4). Several key 
mechanisms identified by the model analysis to be driving fibroblast activation are:  PGE2 
induced inhibition, TGF-β1 receptor recycling rate, and active TGF-β1 degradation rate, 
indicating the importance of both positive and negative regulators of fibroblast differentiation. 
Further study of PGE2 induced inhibition is necessary to characterize specific therapeutic 
strategies that take advantage of existing negative regulatory pathways. Therapeutic treatments 
that inhibit receptor recycling or restrict the availability of active TGF-β1 could aid in inducing a 
shift in the environment by down-regulating positive feedback in the TGF-β1 signaling cascade. 
























4 -0.63 -0.23 -0.17 -0.10 0.20 0.65 0.98 0.99 
12 -0.63 -0.49 -0.28 -0.16 0.18 0.65 0.98 0.99 
24 -0.63 -0.61 -0.53 -0.15 0.18 0.64 0.98 0.99 
48 -0.79 -0.64 -0.60 -0.13 0.17 0.63 0.97 0.99 
*Parameters with positive values are positively correlated to αSMA synthesis and negative 
values are negatively correlated to synthesis. 
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4 -0.95 -0.61 -0.54 -0.21 0.50 0.95 
12 -0.93 -0.86 -0.62 -0.49 0.44 0.93 
24 -0.91 -0.90 -0.85 -0.43 0.39 0.91 




 Fibroblasts and myofibroblasts play a key role in promoting wound healing. They restore 
critical extracellular matrix and remodel architecture of damaged tissue (148-150, 156, 239). 
Their actions are tightly regulated to prevent disruption of healthy tissues but dysregulation can 
occur resulting in fibrotic diseases that are detrimental to functionality of surrounding tissues. 
One such disease, IPF, leads to poor prognosis for patients with very limited treatment options 
and lung transplant is currently the only long term solution. Identifying key mechanisms driving 
fibroblast to myofibroblast differentiation and dysregulation enables us to predict targets for 
therapeutic treatment of fibrotic diseases.   
 We developed a mathematical model that captures the dynamics of TGF-β1 induced 
fibroblast differentiation under isolated conditions and characterized by the synthesis of αSMA. 
We utilized previously published (72, 327, 329) and our own in vitro data generated herein 
together with uncertainty and sensitivity analyses to build and test our model. The model details 
receptor/ligand binding and trafficking of TGF-β1, PGE inhibition, and αSMA synthesis. Our 
model includes a simple representation of adhesion dependent signaling, which has been shown 
to be necessary for TGF-β1 induced fibroblast differentiation, and for PGE2 signaling, a major 
inhibitor of TGF-β1 induced fibroblast differentiation. 
	 47	
Prior models of TGF-β1 receptor ligand signaling have been developed based on 
keratinocytes and pancreatic cancer cell lines (206, 207, 315). In these cell types TGF-β1 is a 
negative regulator of cell growth, and proliferation. These models are able to describe how 
temporal loss of sensitivity to TGF-β1 plays a key role in keratinocyte and pancreatic cancer cell 
regulation (330). They demonstrate that desensitization is highly dependent on the ratio of 
constitutive and ligand induced receptor degradation rates. In our model we examine the 
regulatory mechanisms of fibroblast differentiation with TGF-β1 as our focus. TGF-β1 has been 
shown to induce fibroblast differentiation in the presence of adhesion signaling. As a result we 
see a completely opposite cellular response to TGF-β1 signaling in fibroblasts compared to 
previously modeled cell types. Dysregulation of fibroblasts during wound healing is 
characterized by excessive differentiation, characteristic of a positive response to TGF-β1. For 
this reason, a new model of TGF-β1 signaling specifically for fibroblasts is necessary to identify 
key molecular factors that result in dysregulation. 
Our results suggest that experimental outputs were only able to be recapitulated in the 
presence of PGE2 inhibition emphasizing that inhibition of TGF-β1 signaling is important for 
regulation of fibroblast behavior, and in the absence of inhibition factors like PGE2 we observe 
excessive production of αSMA, a marker for myofibroblast function.   
We characterized fibroblast responses to different environmental conditions in order to 
isolate conditions that are favorable for controlled wound healing. These conditions may be 
artificially created in instances of fibroblast dysregulation in order to limit damaging effects of 
fibrosis. We predicted conditions resulting in quiescence (no αSMA), increasing differentiation 
(increasing concentrations of αSMA), and steady state differentiation (constant concentrations of 
αSMA). We simulated how fibroblasts respond to periodic dosing of TGFβ1 in the presence of a 
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constant concentration of PGE2, in order to understand the ability of cells to perform wound 
healing activities in the presence of continual negative regulation. We found that under these 
conditions, fibroblasts were able to respond modestly to dosing with TGF-β1 but quickly 
returned to a quiescent state when the signal was resolved. Cells are not able to maintain a 
constant concentration of αSMA, with only periodic stimulation from TGF-β1.  The magnitude 
of the response, but not the duration, is dependent on the magnitude of the dose of TGF-β1 
administered. We found that while the magnitude of the response in the presence of constant 
PGE2 was dependent on the TGF-β1 dose, the concentration of PGE2 dictated the duration of that 
response.  Higher levels of negative regulators such as PGE2 present at the site of a wound may 
inversely correlate with the extent of damage present and thus inversely correlate with the 
amount of time required for repair mechanisms to take place. It is also possible that rather than 
shortening the duration of the repair, PGE2 and other potential negative regulators of TGF-β1 
may decrease the amount of time each individual fibroblast responds to TGF-β1 signaling 
reducing the overall amount of fibroblast differentiation occurring during a repair event. 
Additional treatment with PGE2 during the response phase of fibroblasts to TGF-β1 was able to 
induce a short refractory period and temporarily decrease the strength of the signal response to 
TGF-β1 following the additional PGE2 treatment. This finding suggests that the cells are not 
refractory to PGE2 signaling in the presence of TGF-β1, and that PGE2 plays an important role in 
regulating TGF-β1 signaling. These results imply that fibroblasts are able to produce a limited 
amount of αSMA in response to TGF-β1 and potentially perform modest wound healing 
activities in the presence of constant negative regulators, but they are not able to maintain a 
prolonged state of continuous αSMA synthesis. An environment with sustained concentrations of 
negative regulatory signals like PGE2 could be permissive to wound healing but also preventative 
	 49	
of fibroblast dysregulation. It is also possible that under these conditions TGF-β1 levels are 
insufficient for wound healing. Steady state secretion of PGE2 by alveolar epithelial cells has 
been demonstrated, and is suspected of keeping fibroblasts quiescent in the absence of injury 
(187, 188).  
We also tested how fibroblasts respond to periodic dosing with PGE2 in constant 
concentrations of TGF-β1 (Figure. 2.5), to evaluate the efficacy of inhibitory factors in the 
presence of substantial stimulation. We found that in the absence of PGE2 the fibroblasts were 
continuously responsive to the presence of TGF-β1, presenting steadily increasing 
concentrations of αSMA. Following treatment with PGE2 the cells were refractory to further 
stimulation of TGF-β1 for a limited period of time and the duration of the refractory state was 
dependent on the dose of PGE2 administered. We tested whether cells could be relieved of 
refraction early if dosed with additional TGF-β1 during that time in order to determine if 
treatment with PGE2 could sustain inhibition of the cellular differentiation in the presence of 
rapidly changing levels of TGF-β1. We found that treatment with additional TGF-β1 could not 
rescue fibroblasts from the refractory period suggesting that PGE2 can block TGF-β1 signaling 
even during a flux in TGF-β1 concentration. These findings illustrate the ability of negative 
regulators such as PGE2 to inhibit fibroblast differentiation during response phase and in the 
presence of constant TGF-β1. This regulation, however, is transient resolving as soon as the 
inhibitor is degraded. Periodic dosing with PGE2 cannot sustain a long term steady state of 
αSMA production. These results suggest that if PGE2 levels are insufficient or inconsistent 
during a wound healing response, myofibroblasts may not maintain a steady state level of αSMA 
production, but rather experience constant stimulation to TGF-β1 except for short transient 
periods of time when PGE2 levels are high enough to induce temporary quiescence. Our model 
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therefore predicts that therapeutic treatments with fluctuating concentrations of negative 
regulators may be insufficient to restrict fibroblast differentiation for extended periods of time. It 
calls instead for treatment strategies that provide prolonged alterations to the environmental 
concentrations of positive and negative regulators. Our predictions remain to be tested 
experimentally, not only in vitro but in vivo as well. 
Having identified environmental conditions that result in constant induction and 
quiescence of fibroblasts, we predict that constitutive concentration of both TGF-β1 and PGE2 
will result in steady state levels of fibroblast differentiation. Our model allows us to compare the 
contribution of each of these molecular factors to the overall outcome of fibroblast 
differentiation characterized by αSMA synthesis, and predict patterns of signal availability that 
are currently untestable in vitro. We tested how fibroblasts respond to simultaneous constant 
levels of PGE2 and TGF-β1 (Figure. 2.6), and found that in the presence of both molecules 
fibroblasts maintained a steady concentration of αSMA. This result indicates that a continuous 
presence of both molecules is necessary for sustained and controlled fibroblast response. This 
suggests that periodic inhibition of TGF-β1 is insufficient to prevent fibroblast dysregulation. 
Periodic dosing with TGF-β1 may or may not induce levels of fibroblast αSMA sufficient for 
successful wound healing, depending on the size and severity of the wound as well as the 
number of fibroblasts available to respond. Further characterization of the functionality of these 
environmental conditions in restricting and reversing the effects of fibroblast dysregulation will 
require a multi-cellular scale model capturing events at molecular, cellular and tissue scale, 
which we are currently building. 
 Sensitivity analysis indicates that the parameters responsible for controlling strength of 
PGE2 induced inhibition (𝒌𝑰𝒏𝒉𝒊𝒃𝒊𝒕𝑷𝑮𝑬𝟐 , α1) are the most significant factors for regulating fibroblast 
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differentiation. In addition to the strength of PGE2 induced inhibition, rates of active TGF-β1 
degradation and receptor recycling were also found to be very important. These parameters 
contribute to either the actual concentration of TGF-β1 and PGE2 in the media or to the level of 
concentration at which the receptor ligand interaction becomes saturated. These findings indicate 
that PGE2 and TGF-β1 receptor ligand signaling dynamics simultaneously contribute to 
fibroblast regulation and together dictate the differentiation of the cell. Because PGE2 inhibition 
was found to be one of the most important parameters in regulating fibroblast differentiation, but 
fibroblasts lose sensitivity to PGE2 over time (167), our findings call for therapeutics that mimic 
the effects of PGE2 through inhibition of adhesion signaling. Therapeutics that provide constant 
inhibition of adhesion signaling are needed to establish favorable environmental conditions for 
regulated wound healing.  Inhibition of TGF-β1 receptor recycling (𝒌𝒓𝒆𝒄𝑹 ) and decreased 
availability of active TGF-β1 (𝑻𝑮𝑭𝜷𝟏𝒂𝒄𝒕) may increase the efficacy of PGE2 mimics in 
establishing favorable environmental conditions.  
The findings of our model indicate that restricting positive differentiation signals like 
TGF-β1, alone cannot account for the regulation of fibroblast differentiation. We identify a need 
for balanced environmental conditions for fibroblasts with consistent levels of positive and 
negative regulators (Figure. 2.7). Extremely high ratios of TGF-β1 to PGE2 produce outcomes of 
excessive αSMA synthesis which we hypothesize correlate to fibrosis. Extremely low ratios of 
TGF-β1 to PGE2 result in very minimal fibroblast differentiation which may be insufficient for 
effective wound healing.  In order to better understand this system and identify specific targets 
for therapeutic treatment, there is great need to explore more detailed dynamics of PGE2 




2.4.1 In Vitro Studies of TGF-β1 induced αSMA Synthesis  
 3T12 mouse fibroblast cell line obtained from American Type Culture Collection 
(ATCC; CCL-164). Approximately 7.5x105cells/400k cells/ well are plated onto 6 well plates 
and either left untreated, treated with 1-2ng/ml of activated TGF-β1, or treated simultaneously 
with 2ng/ml of activated TGF-β1 and 10 μM indomethacin. Untreated cells were harvested at 4 
hours post treatment. Treated cells were harvested at 4, 12, 24 or 48 hours post treatment. Cells 
were lysed in radioimmunoprecipitation assay buffer with protease inhibitor cocktail (Sigma) for 
15 min at 4°C and centrifuged. Total protein concentrations in the supernatants were determined 
by the Bicinchoninic acid assay (Pierce). Equal amounts of protein from each sample were 
separated on a 4–20% gradient SDS-polyacrylamide gel and transferred to a PVDF membrane 
(Amersham/GE Healthcare, Pittsburgh, PA). PVDF membrane was then probed with a 
monoclonal anti-body (Clone 1A4; Dako, Carpinteria, CA) for 1 hour to detect αSMA protein. 
This process was repeated to detect GAPDH (Santa Cruz).  
 
2.4.2 Mathematical model  
2.4.2.1 TGF-β1 Receptor Ligand Dynamics 
To construct a model of fibroblast differentiation that captures molecular mechanisms 
necessary to fibroblast dysregulation, we first describe TGF-β1 receptor/ligand binding and 
trafficking kinetics using mass action kinetics (331), building on studies in a variety of human 
and mouse cell lines and primary cells(206, 207, 315). We account for the TGF-β1 receptors 
ALK5 and TGF-β1RII as a single receptor complex. Because we are exclusively studying TGF-
β1 and no other members of the TGF-β family, we disregard competition for subunits in 
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establishing receptor complexes and assume that all stable receptor complexes include the ALK5 
and TGF-β1RII. Modeling these receptors together as a single receptor unit is relevant because 
both receptors are required for induction of downstream signaling cascades. Because receptor 
subunits have different parameter values, we use the rate limiting value for each parameter to 
describe the dynamics of the receptor complex. About 10% of the TGF-β1 receptors are present 
on cell surfaces in the absence of stimulation; the remaining 90% are sequestered intracellularly 
(327). 
Equations 1-6 track rates of change over time for concentrations of six TGF-β1 signal 
cascade species. These species include the following: latent TGF-β1 𝑇𝐺𝐹𝛽1!"# , active 
unbound TGF-β1 𝑇𝐺𝐹𝛽1!"# , unbound receptors on the fibroblast surface 𝑅!"#$ , unbound 
receptors in cytoplasm 𝑅!"# , bound receptor/TGF-β1 complexes on the fibroblast surface 
𝑇𝑅𝐶!"#$ , and bound receptor/TGF-β1 complexes in cytoplasm 𝑇𝑅𝐶!"#  (Table 2.1, Figure. 
2.1). The rates of change in concentration of these species are dictated by parameter values (see 
Table 2.2 and below).  
The rate of change in concentration of latent TGF-β1 is captured by: 
𝑑







𝑁𝑎𝑣 ∗ 𝑉𝑜𝑙 ∗ 𝐶𝑒𝑙𝑙𝑠 
 (1) 
 
 The first term on the right hand side (RHS) of the equation is 𝑘!"#
!"#$!!"# , the constitutive TGF-
β1 synthesis by fibroblasts, and is estimated by uncertainty analysis (described below) (229). 
The next term in the RHS of the equation represents the loss of latent TGF-β1 to degradation 
(𝑘!"#
!"#$!!"# ) and activation (𝑘!"#
!"#$!!"#).The final term on the RHS of the equation is a positive 
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feedback term for additional latent TGF-β1 synthesis in the presence of TGF-β1 signaling. The 
rate constant 𝑘!"#$%"
!"#$!!"#is also estimated by uncertainty analysis. 𝑁𝑎𝑣 represents Avogadro’s 
number and 𝑉𝑜𝑙 represents the volume of the experimental environment.  𝐶𝑒𝑙𝑙𝑠 represents the 
number of fibroblasts in a given simulation. 




!"#$!!"# ∗ 𝑇𝐺𝐹𝛽1!"# − 𝑘!"
!"#$! ∗ 𝑇𝐺𝐹𝛽1!"# ∗ 𝑅!"#$ ∗ 𝑐𝑒𝑙𝑙𝑠
+
1
𝑁𝑎𝑣 ∗ 𝑣𝑜𝑙 ∗ 𝑘!"##
!"# ∗ 𝑇𝑅𝐶!"#$ ∗ 𝑐𝑒𝑙𝑙𝑠 − 𝑘!"#
!"#$!!"# ∗ [𝑇𝐺𝐹𝛽1!"#] 
(2) 
 
 The first term on the RHS of the equation represents the rate of activation of latent TGF-β1 
(from Equation 1). The second term in the equation is the rate of active TGF-β1 binding to the 
receptor. The next term in the equation is the dissociation rate of active TGF-β1 from cell 
surface receptors. The final term in this equation represents the rate of degradation of active 
TGF-β1.  
Equation 3 represents the rate of change over time of the concentration of unbound surface 
receptor complexes. 
𝑑
𝑑𝑡 𝑅!"#$ = 𝑘!"#
! − 𝑁𝑎𝑣 ∗ 𝑣𝑜𝑙 ∗ 𝑘!"
!"#$! ∗ 𝑇𝐺𝐹𝛽1!"# ∗ 𝑅!"#$ + 𝑘!"##!"# ∗ 𝑇𝑅𝐶! !"
− 𝑘!"#! ∗ 𝑅!"#$ + 𝑘!"#! ∗ ( 𝑅!"# + 𝑇𝑅𝐶!"# ) 
(3) 
 
 (𝑘!"#! ) represents the constitutive rate of receptor synthesis. The second and third terms on the 
RHS of the equation represent the rates of active TGF-β1 binding to and dissociation from 
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receptors on the surface of the cell (from Equation 2). The fourth term is the rate of 
internalization of unbound receptors into the cytoplasm and is proportional to the concentration 
of unbound surface receptors ( 𝑅 !"# ). The last term in the equation is the rate of receptor 
recycling from the cytoplasm to the surface of the cell (327).  
Equation 4 represents the rate of change over time in the concentration of internalized unbound 
receptors. 
𝑑
𝑑𝑡 𝑅!"# = 𝑘!"#
! ∗ 𝑅!"#$ − (𝑘!"#! + 𝑘!"#! ) ∗ 𝑅!"#  (4) 
 
The first term on the RHS of the equation represents the rate of receptor internalization as 
described for Equation 3. The second term in the equation is the loss of internal unbound 
receptors to recycling and degradation. The rate constant 𝑘!"#! represents receptor degradation 
and is defined to satisfy the experimental data as described for 𝑘!"#!  above.  
Equation 5 represents the rate of change over time in concentration of bound surface receptors. 
𝑑
𝑑𝑡 𝑇𝑅𝐶!"#$ = 𝑁𝑎𝑣 ∗ 𝑣𝑜𝑙 ∗ 𝑘!"
!"#$! ∗ 𝑇𝐺𝐹𝛽1!"# ∗ 𝑅!"#$ − 𝑘!"##!"# ∗ 𝑇𝑅𝐶!"#$ − 
(𝑘!"#!"# ∗ 𝑇𝑅𝐶!"#$ ) 
(5) 
 
 The first and second terms on the RHS of the equation represent the rate of TGF-β1 binding to 
unbound surface receptors and the dissociation of active TGF-β1 from surface receptor ligand 
complexes (from Equation 2). The last term in the equation represents the rate of internalization 
of bound receptor ligand complexes. 
Equation 6 represents the rate of change over time in the number of internalized bound receptor 
ligand complexes per cell. 
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𝑑
𝑑𝑡 𝑇𝑅𝐶!"# = 𝑘!"#
!"# ∗ 𝑇𝑅𝐶!"#$  − (𝑘!"#! + 𝑘!"#! + 𝑘!"#! ) ∗ 𝑇𝑅𝐶!"#  (6) 
 
The first term on the RHS of the equation represents the rate of internalization of surface 
receptor ligand complexes (from Equation 5). The second term in the equation represents the loss 
of internalized receptor ligand complexes to recycling, ligand independent degradation, and 
ligand induced degradation and is proportional to the number of internalized receptor ligand 
complexes ( 𝑇𝑅𝐶!"# ).  
 
2.4.2.2 PGE2 Dynamics  
Equations 7 and 8 track the concentration of extracellular PGE2 as well as the 
intracellular concentration of PGE2 (Table 2.1, Figure. 2.1). Recent studies have shown that 
PGE2 is an effective inhibitor of TGF-β1 induced fibroblast differentiation (168). PGE2 can be 
synthesized and bound by fibroblasts making it a component of fibroblast autocrine signaling. 
Thus, to fully understand factors involved in fibroblast regulation and differentiation we include 
equations for soluble and internalized PGE2 that allow for tracking of inhibition of TGF-β1 
induced differentiation.  
𝑑
𝑑𝑡 𝑃𝐺𝐸2!"# = 𝑘!"#$!
!"#! −  𝑘!"#!"#! ∗ 𝑃𝐺𝐸2!"# − (𝑘!"#!"#! ∗ 𝑃𝐺𝐸2!"# ) (7) 
 
𝑃𝐺𝐸2!"#  represents the concentration of soluble PGE2. The first term on the RHS of the 
equation represents the constitutive rate of PGE2 synthesis by the fibroblast. The second term in 
the equation represents the rate of PGE2 being internalized in to the cell. The final term in the 





𝑑𝑡 𝑃𝐺𝐸2!"# = 𝑘!"#
!"#! ∗ 𝑃𝐺𝐸2!"# ∗ 𝑁𝑎𝑣 ∗ 𝑣𝑜𝑙 ∗  
1
𝑐𝑒𝑙𝑙𝑠 − 𝑘!"#$%&
!"#! ∗ 𝑃𝐺𝐸2!"#  (8) 
 
𝑃𝐺𝐸2!"#  represents the concentration of internalized PGE2. The first term on the RHS of the 
equation represents the rate of PGE2 being internalized in to the cell (from Equation 7). The 
second term in the equation is the rate of degradation of internalized PGE2.  
 
2.4.2.3 αSMA Synthesis  
We track αSMA concentration, a known indicator of fibroblast differentiation (105). 
αSMA serves to increase the contractile strength of fibroblasts a phenotype that is associated 
with their differentiated state (189). This phenotype is important for wound contraction and 
tissue remodeling. TGF-β1 receptor binding and internalization induces a signaling cascade 
through either the canonical SMAD2/3 pathway or the non-canonical Rho/ROCK pathway (332). 
Because experimental data detailing the rates of SMAD2/3 and Rho/ROCK signaling cascades 
are limited in fibroblasts, we focused on the receptor/ligand dynamics of the TGF-β1 signaling 
cascade and simplified, i.e. we replaced the entire signaling cascade with a term that tracks the 
effect of the kinase signaling cascade (see more below), the downstream phosphorylation 
cascades into a single event. We can still learn much about the system using this approach, and 
our analyses point to which elements can be elaborated later for further study. 
 We have two equations in our model that enable us to track the synthesis of αSMA. 
Equation 9 tracks the number of receptor ligand internalization events over time 𝑷𝑹𝑫𝑺 . 
Because we do not explicitly measure all the kinase signaling cascades down stream of receptor 
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ligand complex internalization, we use this equation as a surrogate for those events. This 
equation contains a loss term which is the degradation of signaling complexes. These complexes 
serve as a simplification of the complex biological signal cascade far downstream of the initial 
internalization event. We use this equation to bridge the temporal gap between receptor ligand 
events which occur very fast (on a timescale of minutes) and the protein synthesis events that 
occur much slower (on a timescale of hours), without the need to explicitly model every signal in 
the cascade. It is one way to coarse grain (simplify) these intracellular signaling events.  Course 
graining the kinase signaling cascades, for which many parameter values are not known, allows 
us to reduce ambiguity from many unknown parameter values and processes.  However, as key 
factors are identified, our model can point to features that can be fine-grained in future studies to 
further elucidate key signaling mechanisms driving fibroblast differentiation. 
 
𝑑
𝑑𝑡 𝑃𝑅𝐷𝑆 = (𝑘!"#
!"# ∗ 𝑇𝑅𝐶!"#$ − (𝑘!"#!"#$ ∗ 𝑃𝑅𝐷𝑆 ) 
(9) 
 
 The first term on the RHS of the equation represents the rate of internalization of receptor 
complexes (from Equation 5). The second term represents the rate of degradation of the signal.  
Equation 10 captures the rate of change over time for the concentration of αSMA per cell 
𝑎𝑆𝑀𝐴 .  
𝑑
𝑑𝑡 𝑎𝑆𝑀𝐴 = 𝑃𝑅𝐷𝑆 ∗ 𝑐!"#
!"!!"#$% ∗ 𝑐!"#$$!"#$%& ∗  
𝑘!"!!"!#!"#!






The first term on the RHS of the equation represents the rate of αSMA synthesis and is 
proportional to the number of receptor ligand complex internalization events ( 𝑃𝑅𝐷𝑆 ) which 
promote αSMA synthesis and inversely proportional to the concentration of internalized PGE2 
( 𝑃𝐺𝐸2!"# ) which antagonizes αSMA synthesis. The rate constant 𝑐!"#$$!"#$%& represents the 
stiffness of the matrix to which the cell is adhering which positively correlates to adhesion 
signaling (238, 317, 333, 334).  𝑘!"!!"!#!"#!  represents the rate of PGE2 inhibition of adhesion 
signaling. This term dictates how well PGE2 is able to antagonize the induction of αSMA 
synthesis by TGF-β1.  𝛼! represents a small, non-zero number, to bound the denominator away 
from zero. The final term in the equation represents the rate of degradation of αSMA.  
 
2.4.3 Parameter Derivation and Estimation 
 We use uncertainty analysis (below) to estimate parameters in our model. When a 
parameter value is available from the literature, it is used directly, and others are obtained during 
model calibration (Figure. 2.2, also see ranges in Table 2.2).  For the parameters that were 
available in literature, we computed their values as follows. The rate constants for latent TGF-β1 
degradation (𝑘!"#
!"#$!!"#) and active TGF-β1 degradation(𝑘!"#
!"#$!!"#) are derived from the  half-life 
of latent and active TGF-β1 in rat plasma (9.2 ± 1.4 min and 2.7 ± 0.4 min respectively) and 
published by Wakefield et al.(326) assuming first order kinetics. The rate constants for TGF-β1 
binding and dissociation from the receptor  𝑘!"
!"#$! and 𝑘!"##!"#  are estimated based on the 
equilibrium dissociation constant of TGF-β1 (𝐾! = 23𝑝𝑚) published by Kalter et al. (72). The 
rate 𝑘!"#!  is fit to satisfy the experimental data suggesting that approximately 90 of the total 
TGF-β1 receptors reside in the cytoplasm of the cell with the remaining 10% localizing to the 
surface under steady conditions (335), given that there are approximately 10,550 ± 1400 
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receptors per cell (72). Rate constants for receptor recycling (𝑘!"#! ), constitutive receptor 
degradation (𝑘!"#! ), and ligand induced receptor degradation (𝑘!"#! ) are derived from Vilar et al. 
(207). The rate  𝑘!"#$!!"#! is derived from Lin et al. (328).(329) assuming first order kinetics.   
The parameter 𝑘!"#!"!!"#$% represents a switch for the presence or absence of adhesion 
signaling and has a value of either 0 or 1. 𝑘!"!!"!#!"#!  represents the magnitude of PGE2 inhibition of 
adhesion signaling and is estimated by uncertainty analysis. 𝛼! represents a small non-zero 
number. In the absence of PGE2, 𝛼! is given the same numerical value as  𝑘!"!!"!#!"#!  , these terms 
reduce to 1 resulting in no inhibition by PGE2 and avoid dividing by zero.  
For the remaining parameters, quantitative values for these rate constants were not 
available in literature and would be difficult to measure in vitro (  𝑘!"#
!"#$!!"#, 𝑘!"#!"#!, 𝑘!"#$%&!"#! ,  
𝑘!"#!"#$%&', and 𝑘!!"!"#$ ) so we estimate their values using uncertainty analysis and model 
calibration techniques.  
 
2.4.4 Uncertainty Analysis 
We use uncertainty analysis to quantify how variations in parameter values leads to 
variations in model outputs. Uncertainty analysis allows us to examine outcomes based on a 
wide value range for each unknown parameter value individually and simultaneously. We vary 
numerous parameters in the model over a wide range (Table 2) and compare how these 
variations affect model outputs. Latin hypercube sampling (LHS) is a method for varying 
multiple parameters simultaneously and then sampling the parameter space (229). When used for 
parameter estimation, uncertainty analysis allows model calibration to available data and 
identification of values for unknown parameters that allow for this when varied simultaneously.  
.  
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2.4.5 Sensitivity Analysis 
We use sensitivity analyses to identify which model parameters have a significant effect 
on model output and the extent of this effect. Sensitivity analysis identifies which parameters 
have a significant effect and the extent of the effect. Partial rank correlation coefficients 
(PRCCs) are used to quantify the effects of varying each parameter on the model output and 
therefore discerning which parameters have the strongest influence on a given output, or in other 
words the sensitivity of an output to a given parameter. PRCC values range from -1 to +1. A 
value of -1 signifies a perfect negative correlation between the parameter and the output whereas 
a value of +1 signifies a perfect positive correlation between the parameter and the output. The 
closer a PRCC value is to 0 the weaker the correlation, whether positive or negative. PRCC 
values are differentiated with a student t-test of significance. However since PRCC quantifies 
non-linear correlations, even small PRCC values can be significant. In this work we use the LHS 
algorithm to generate 1000 unique parameter sets. This number of simulations gives high 
accuracy when identifying PRCC values (229). PRCC values are considered significant and with 
a p-value of 0.01.   
 
2.4.6 Model Solution, Calibration and Validation 
We solve Equations (1)-(10) with parameters as listed in Tables 1 and 2 using MATLAB 
ODE15s solver.  While the equations are given in units/time, we simulate both calibration and 
validation studies using quantities in terms of fold change. This is how experimental data for 
these studies are measured and it allows us to compare directly with data. We also compare the 
relative outputs in responses to treatment as fold change compared to untreated simulations. 
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Initial conditions are chosen to calibrate the model based on previously identified values 
specific for fibroblasts to achieve a steady state (327), or selected to replicate experimental 
conditions (Figure. 2.2). Kalter et al. observed that fibroblasts have approximately 10,550 ± 1400 
TGF-β1 receptors per cell, and approximately 90% of those receptors are in the cytoplasm at 
steady state  (72). Based on this observation and rates derived in Vilar et al. for receptor 
recycling and synthesis we select parameter values using uncertainty analysis  that allow us to 
achieve these steady states. Variables for which the steady state is unknown are given initial 
values of 0 (Table 2). Using our model and the set of identified baseline parameter values that 
reflect differentiation of fibroblasts (Table 2), we validate our model by comparing output to 
additional experimental data derived in our lab and not used in the calibration of the model 
(Figure. 2.3). First, we simulate exposing our model fibroblasts to an initial concentration of 
0.6nM of TGF-β1 and compare the concentration of αSMA at 4, 12, 24 and 48 hours as well as a 
4 hour untreated control to in vitro experimental data described below (Figure. 2.2). Second, we 
simulate how output from different model constructions compares to experimental data 
published previously by our group. For example, we introduce into the model PGE2 inhibition of 
adhesion signaling and compare to simulation experimental results in the presence and absence 
of PGE2 (Figure. 2.2) (168). Time course in vitro experiments were performed on mouse 3T12 
transformed fibroblasts Additional in vitro experiments were performed using primary mouse 
lung fibroblasts to effectively capture the sensitivity of lung fibroblasts to PGE2. Comparative 
simulations were done using different initial concentrations of TGF-β1 to reflect differences in 
effective concentration of and sensitivity to TGF-β1 between these two cell types. The difference 
in magnitude of αSMA synthesis in response to TGF-β1 treatment between in vitro experiments 
(Figure. 2.2) is likely due to differences between transformed cells and primary cells. 
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2.4.7 Calculating the Balance between TGF-β1 and PGE2 levels  
 We use LHS sampling as described above to generate 1000 simulations of our model 
with different TGF-β1 and PGE2 concentrations and then compare the concentration of αSMA at 
48 hours. From this simulated data we generated a heat map of the concentration of αSMA with 
respect to TGF-β1 and PGE2 using the meshgrid, TriSCatteredInterp, and contour functions in 





Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial 
Cells is Necessary for Treatment of Pulmonary Fibrosis  
3.1 Introduction 
Pulmonary fibrosis is a pathologic feature associated with many interstitial lung diseases 
(24). A wide range of lung insults can result in development of fibrosis, including antibiotic 
treatment, infection, and environmental exposures (16, 23, 336, 337). In cases described as 
idiopathic pulmonary fibrosis (IPF), no explicit cause of fibrosis can be identified (8). Disease 
presentation includes stiffening and scarring of lungs, decreased flexibility of tissues, and 
diminished gas exchange (12, 13, 17, 312, 313, 338). Patients suffering from pulmonary fibrosis 
have difficulty breathing, reduced quality of life, and ultimately a poor prognosis (10, 13, 246, 
312, 330, 338-341). 
Although mechanisms leading to pulmonary fibrosis are not well-characterized, it is 
believed that pulmonary fibrosis occurs as the result of dysregulation during the wound healing 
process (22, 143, 148, 231). Wound healing occurs in four stages: (I) coagulation and 
hemostasis, (II) inflammation, (III) proliferation, and (IV) remodeling (12). During the third 
stage of wound healing, fibroblasts proliferate into the wound gap (152).  They secrete cytokines, 
including transforming growth factor-β (TGF-β), which act in both an autocrine and paracrine 
manner to induce further proliferation and/or eventual differentiation of fibroblasts into 
myofibroblasts (66, 100, 105, 234). Myofibroblasts play an important role in the fourth stage of 
	 65	
the wound healing process, the remodeling stage. They secrete extracellular matrix 
(ECM) proteins including collagen and fibronectin (143, 152, 156) that are cross-linked to 
provide a substrate for re-epithelialization of wounded tissue (152). Myofibroblasts also express 
α-smooth muscle actin (α-SMA), a protein that integrates into actin filaments giving cells a 
contractile phenotype (105, 189, 238). Through integrin binding, myofibroblasts are able to 
adhere to surrounding tissue and contract, collapsing the wound gap (100, 240). Dysregulation of 
this process, through unknown mechanisms, results in excessive ECM protein secretion and 
tissue remodeling. These actions result in the formation of stiff, scarred tissue that is inflexible 
and unproductive for gas exchange (12, 246). 
In addition to fibroblasts and myofibroblasts, epithelial cells are a critical component of 
effective pulmonary wound healing (241).  Epithelial cell damage is congruent with pulmonary 
fibrosis (187, 241, 245, 247, 248). Epithelial cells are an essential component of properly 
functioning lung tissue. They line the bronchi, airways, and alveoli of the lungs providing a 
surface for gas exchange and a barrier for infectious agents (242-244). During pulmonary injury, 
epithelial cells are damaged and repair is needed in order to restore functionality to the wounded 
tissue (18, 66, 245). During fibrosis, excessive secretion of pro-fibrotic cytokines such as TGF-β 
(associated with deregulation of the third stage of wound healing) produces an environment that 
is toxic to epithelial cells (84, 88). Furthermore, excessive tissue remodeling (deregulation 
occurring during the fourth stage of wound healing) can induce further epithelial cell damage, 
loss of epithelial protective factors and tissue contraction reducing the surface area available for 
re-epithelialization (231, 249).   
At the apex of cell-cell interactions during pulmonary wound healing are two key classes 
of cytokines: pro-fibrotic mediators and anti-fibrotic mediators. TGF-β1, the most well 
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characterized pro-fibrotic mediator in pulmonary fibrosis, is a cytokine secreted by a wide range 
of cell types including fibroblasts, with effects that are cell type and tissue specific (100, 108, 
109, 111-114, 116, 117). TGF-β1 is an autocrine and paracrine signal that can induce fibroblast 
proliferation and/or differentiation into myofibroblasts (Figure 3.1) (235-237). Growth factors 
are necessary for fibroblast proliferation and TGF-β1 is representative of these growth factors. 
Fibroblasts cultured in vitro in serum free media are unable to proliferate well. In some studies, 
TGF-β1 is sufficient to stimulate proliferation in vitro (70, 103, 104). TGF-β1 is also able to 
induce fibroblast to myofibroblast differentiation, which can be measured by the presence of 
αSMA in cultured cells (Figure 3.1) (89, 100, 105). Once differentiated into myofibroblasts, 
these αSMA positive cells have not been found to proliferate (342). High concentrations of TGF-
β1 have been shown to induce alveolar epithelial cell apoptosis (Figure 3.1) (67, 106, 107) and 
are therefore detrimental to epithelial cell survival during wound healing. In contrast, TGF-β1 
may prevent apoptosis of fibroblasts and this differential response of these cell types to TGF-β1 
has been called the “apoptosis paradox” (343). In opposition to TGF-β1, PGE2 is a well 
characterized anti-fibrotic lipid mediator with a wide range of influence that is cell and tissue 
type specific. In pulmonary tissues, PGE2 is predominantly secreted by epithelial cells as an 
inducer of fibroblast quiescence (187, 188). It also serves as a negative regulator of TGF-β1, 
inhibiting fibroblast proliferation and differentiation, myofibroblast ECM secretion, and TGF-β1 
induced epithelial cell apoptosis (Figure 3.1) (66, 122, 188, 234, 322). PGE2 inhibits FAK 
mediated adhesion signaling, indirectly inhibiting TGF-β1 signaling cascades (168). We consider 
PGE2 is representative of mediators that inhibit fibroblast activation. It is well established that 
epithelial cells, fibroblasts, and myofibroblasts all play important roles in lung function and 
pulmonary wound healing (22, 88, 148, 150, 241). Their interactions and co-regulation are 
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paramount to understanding the mechanisms underlying dysregulation of the wound healing 
process and the development of fibrosis (Figure 3.1). Recent work published by the Sime 
laboratory at the University of Rochester shows that alveolar epithelial cells from healthy lungs 
are able to inhibit TGF-β1-induced fibroblast differentiation and secretion of ECM proteins in a 
PGE2 dependent manner in vitro (66). Recent systems biology and modeling approaches by our 
group further demonstrate the importance of PGE2 in regulating the activation of fibroblasts 
(344). Using computational analyses, we predicted that modulation of fibroblast differentiation 
by targeting pro-fibrotic signaling cascades alone is insufficient for prolonged regulation of the 
fibroblast  (344). As observed in other systems, it is likely that a balance of both positive and 
negative regulators (e.g. TGF-β1 and PGE2 respectively) is necessary for achieving homeostasis 
and avoiding excessive fibroblast activation (158, 344). PGE2 is also shown to protect epithelial 
cells from toxicity of pro-fibrotic mediators like TGF-β1 (345). Together TGF-β1 and PGE2 
serve as examples of positive and negative regulators to preserve balance in the responses of 
epithelial cells, fibroblasts, and myofibroblasts to tissue damage (Figure 3.1).  
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Figure 3.1: Diagram of the co-regulatory relationship between fibroblasts, myofibroblasts, 
and epithelial cells through TGF-β1 and PGE2 signaling occurring in lung tissue. Dashed 
arrows indicate secretion of a molecule. The thickness of the arrow indicates relative 
contribution of the cell type to the mediator concentration. Solid lines indicate an action of the 
cytokine on a given cell type. Arrows indicate a positive effect on the cell while dashed lines 
indicate a negative effect. ECM is the extracellular matrix.  
 
Treatments for pulmonary fibrosis are limited. Until recently the only therapeutic 
treatments available for pulmonary fibrosis were treatments for the causative agents themselves. 
Cases of fibrosis with unknown cause could not be treated. Lung transplantation was considered 
the only available intervention. In October of 2015, two drugs were approved by the United 
States Food and Drug Administration (FDA) for the treatment of IPF (25). One of the drugs is 
nintedanib, a tyrosine kinase inhibitor that blocks ATP binding to the receptors of several pro-
fibrotic growth factors including, but not limited to, vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), and platelet derived growth factor (PDGF) (27, 28, 32, 314, 346). 
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The second drug is pirfenidone, which is reported to have anti-inflammatory, anti-fibrotic, and 
anti-oxidant properties (25). While the specific mechanisms of action of pirfenidone are 
unknown, pirfenidone can reduce TGF-β1 signaling and inhibit fibroblast differentiation in vitro 
and in vivo in a rat model (30, 33, 346). Regardless, neither of these available therapies is 
curative. Both treatments slowed but did not halt or reverse the progress of IPF marked by a 
reduction in the decline of patients forced vital capacity (FVC) (28, 30, 31, 267, 347). 
The current therapeutic strategies for treating pulmonary fibrosis can reduce the rate of 
decline in patient lung function. Both therapies approved for use by the FDA target the dynamics 
of fibroblasts, namely inhibiting proliferation, differentiation, and TGF-β1 production. However, 
neither nintedanib nor pirfenidone have been demonstrated to promote the survival or 
regeneration of epithelial cells in a fibrotic lung. There is evidence that pirfenidone may even 
inhibit retinal epithelial cells (250).  
Here we construct an in silico model that captures the co-regulation of fibroblasts and 
epithelial cells in vitro. There is substantial support for constructing agent-based models of in 
vitro co-culture systems in the literature. These models are used to study a wide range of 
processes including but not limited to wound healing (191, 195, 196, 273), tissue patterning 
(348), and tumor progression (198, 349, 350). The construction of this model is based on 
previous work in our lab building a 3D model of granuloma formation in the lung.  
With this model we seek to identify which mechanisms of co-regulation determine 
fibroblast and epithelial cell outcomes during wound healing. By capturing a wide range of 
possible outcomes we are able to predict which mechanisms would be good potential therapeutic 
targets for preventing and reversing fibrosis.  We hypothesize that a two-hit approach targeting 
specific mechanisms to both inhibit fibroblast dysregulation and simultaneously promote 
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epithelial cell survival is necessary to halt or reverse damage associated with pulmonary fibrosis. 
In order to construct the model and test this hypothesis, we take a systems biology approach that 
combines in vitro experiments with in silico simulations of a co-culture system.  We use a multi-
scale, hybrid agent-based model to identify mechanisms that simultaneously and independently 
drive fibroblast dysregulation and epithelial cell death. We take a reductionist approach to 
fibrosis, looking solely at the cells that are experiencing damage (epithelial cells) or inflicting 
damage (fibroblasts and myofibroblasts) and model representative pro- and anti-fibrotic 
mediators rather than a more complex tissue environment. This co-culture environment enables 
us to focus our search for mechanisms driving outcomes for these cells while limiting potentially 
confounding factors in our system. It also allows us to look specifically at co-regulation of 
fibroblasts and epithelial cells and concurrently compare the effects of intervention strategies. 
Our model enables us to predict whether a two-hit synergistic therapeutic strategy for pulmonary 




3.2.1 TGF-β1 and PGE2 Modulate Fibroblast Proliferation In Vitro in a Dose Dependent 
Manner 
 Previous work has demonstrated the roles of TGF-β1 and PGE2 in fibroblast to 
myofibroblast differentiation (66, 100, 234, 344). We sought to determine the capacity for TGF-
β1 and PGE2 to influence IMR-90 fibroblast proliferation in vitro. We first compared levels of 
radioactive thymidine incorporation after 48 hours in IMR-90 cultures with complete media 
(CM) or CM and the addition of 0.1 – 4.0 ng/ml acid activated TGF-β1 (Figure 3.2A). Data 
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show no increase in proliferation and no decrease in proliferation in fibroblasts treated with 
0.1ng, 0.5ng, or 1.0ng of acid activated TGF-β1. A significant decrease in proliferation in 2.0ng 
or 4.0ng of TGF-β1 indicates decreased proliferation under these conditions (Figure 3.2A). We 
next compared levels of radioactive thymidine incorporation after 48 hours of culture in CM 
media alone, or CM and  0.1 - 100nM of exogenous PGE2 (Figure 3.2B). Data show increased 
proliferation of fibroblasts in 0.1nM PGE2. Fibroblasts cultured in CM with 1.0nM PGE2 showed 
no change in proliferation. Data also show that 10nM or 100nM concentrations of PGE2 induced 
a significant decrease in proliferation (Figure 3.2B).  
 
 
Figure 3.2: Estimating fibroblast proliferation thresholds modulated by TGFβ and PGE2. 
A) IMR90 fibroblasts were cultured in complete media (CM) and treated with different 
concentrations of TGFβ1 for 48 hours in the presence of radioactive thymidine. Proliferation was 
measured in counts per minute (cpm). Sidak’s multiple comparison test was used to determine 
significance(351). B) IMR90 fibroblasts were culture in CM and treated with different 
concentrations of PGE2 for 48 hours in the presence of radioactive thymidine. Proliferation was 
measured in cpm. Sidak’s multiple comparison test was used to determine significance(351). The 
significance line without the end irons indicates p>0.05 for all comparisons under the line.  




3.2.2 TGF-β1 Mediates Fibroblast Differentiation and Epithelial Cell Death In Vitro in a 
Dose Dependent Manner that is Captured by the Multi-scale Model 
 TGF-β1 has been demonstrated to induce fibroblast differentiation (66, 100, 105, 168, 
234). αSMA expression is a marker of fibroblast differentiation (352). We sought to determine 
the ability of TGF-β1 to induce fibroblast differentiation by determining how an initial dose of 
TGF-β1 affects the proportion of differentiated fibroblasts at 24 hours.  We cultured fibroblasts 
in serum free media (SFM) alone, or SFM plus initial concentration of 0.1ng/ml, 0.5ng/ml, 
1.0ng/ml, 2.0ng/ml, and 4.0 ng/ml exogenous acid-activated TGF-β1 for 24 hours and counted 
the number of αSMA positive cells compared to the total number of cells present in high 
powered microscope fields (Figure 3.3A, 3B). Data show a positive dose response between the 
concentration of initial active TGF-β1 and the proportion of activated fibroblasts at 24 hours.  
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Figure 3.3 Comparison between data and computational model fit for fibroblast 
differentiation at 24 h in response to TGF-β1 treatment. IMR90 fibroblasts were cultured in 
serum free media (SFM) alone or with an additional 0.1, 0.5, 1.0, 2.0, 4.0 ng/ml acid activated 
TGF-β1. The proportion of differentiated cells at 24 h was determined by staining with anti-
αSMA and DAPI. A) Representative image of fibroblasts cultured in SFM alone at 100x 
magnification. (B) Representative image of fibroblasts cultured in 4.0 ng/ml TGF-β1 at 100x 
magnification. (C) Representative images of fibroblasts cultured in SFM alone at 400x 
magnification. (D) Representative images of fibroblasts cultured in 4.0 ng/ml TGF-β1 at 400x 
magnification. (E) Open gray triangles indicate experimental results. Solid black squares indicate 
simulation output. The proportion of either experimental or simulated fibroblasts having 
undergone differentiation at 24 h is compared to the initial concentration of active TGF-β1 in the 
tissue culture or simulation. The simulation data closely matches the experimental data.  
	 74	
 
 To capture this fibroblast dynamic in our computational model, we used Eqn. 1 to express 
the relationship between αSMA synthesis and fibroblast differentiation. We performed 1500 
simulations each with 5000 fibroblasts and an initial concentration of 0.0-5.0 ng/ml exogenous 
acid-activated TGF-β1.  After a simulated time of 24 hours, we calculated the percent of αSMA 
positive cells in the total cell population (Figure 3.3C). Our model captures the biology of 
fibroblast differentiation by recapitulating the dose response observed in the experimental 
dataset.  
We sought to identify the correlation between TGF-β1 and epithelial cell death by 
determining how an initial dose of TGF-β1 affects the percentage of caspase positive epithelial 
cells at 24 hours. TGF-β1 has been demonstrated to induce epithelial cell apoptosis (353, 
354)and caspase activation is a marker of apoptosis (355). We cultured type II alveolar epithelial 
cells in SFM or SFM plus an initial concentration of 0.5ng/ml, 1.0ng/ml, 2.0ng/ml, and 4.0 ng/ml 
exogenous acid-activated TGF-β1. At 24 hours, we calculated the percentage of caspase positive 
cells in high-powered microscope fields (Figure 3.4A). Data show a positive dose response 
between the concentration of initial active TGF-β1 and the proportion of apoptotic epithelial 
cells at 24 hours.  
 To capture epithelial cell dynamics in our computational model, we used Eqn. 2 to 
express the relationship between TGF-β1 and epithelial cell apoptosis. We performed 1500 
simulations each with 5000 epithelial cells and an initial concentration of 0.0-4.0 ng/ml 
exogenous acid-activated TGF-β1.  After a simulated time of 24 hours, we calculated the percent 
of the total population of dead epithelial cells. Our model captures the biology of epithelial cell 
apoptosis by recapitulating the dose response observed in the experimental dataset (Figure 3.4B). 
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Figure 3.4 Comparison between data and computational model fit for epithelial cell 
survival at 24 h in response to TGF-β1 treatment. Type II alveolar epithelial cells were 
cultured in SFM alone or with an additional 0.5, 1.0, 2.0, 4.0 ng/ml acid activated TGF-β1. The 
number of caspase 3 positive cells was evaluated at 24 h by fluorescent staining. (A) 
Representative image of cell cultures treated with 0.0, 0.5, 1.0, 2.0, or 4.0 ng/ml of TGF-β1 at 
200x magnification. These images show an increase in caspase 3 activation of the epithelial cells 
in the presence of increasing concentrations of TGF-β1. (B) Open gray triangles indicate 
experimental results. Solid black squares indicate simulation output. We compare the proportion 
of experimental or simulated epithelial cells having undergone apoptosis at 24 h to the initial 
concentration of active TGF-β1 in the cell culture or computer simulated model. The simulation 




3.2.3 Multi-scale Model Captures a Wide Range of Possible Fibroblast, Myofibroblast, and 
Epithelial Cell Outcomes in a Virtual Co-culture Environment 
We next tested whether our computational model can capture the range of possible 
biological co-culture outcomes observed experimentally.  We explored outcomes for a range of 
physiologically plausible parameter values derived from literature, our work, or estimated using 
uncertainty analysis (Tables S1-S4); varying parameter values allows us to manipulate the 
relative importance of particular mechanisms in the model.  Multi-scale model outcomes fell 
primarily into four categories that we classify as: healthy tissue outcome, rapid epithelial cell 
death with fibroblast proliferation and differentiation, gradual epithelial cell death with 
fibroblast proliferation, and early epithelial cell death with excessive fibroblast proliferation and 
differentiation. Representative simulations at the end of seven days illustrate model outcomes 
(Figure 3.4B). We have selected four outcomes that are representative of common trends 
identified in our LHS. Outcomes falling into each category share some parameter trends. These 
trends are described in the figure legend with specific values given for the simulation shown (see 
Appendix Tables S1-4 for full parameter ranges). Our first outcome category, a healthy tissue 
outcome, shows that under idealized conditions epithelial cells survive and fibroblasts remain 
quiescent (Figure 3.5A). By the end of seven days fibroblasts had not proliferated and the 
epithelial cells survived. Our second outcome category, rapid epithelial cell death with fibroblast 
proliferation and differentiation, shows that under some conditions epithelial cells undergo rapid 
apoptosis (Figure 3.5B); approximately 50% of the epithelial cells died in the first 24 hours. 
Fibroblast proliferation occurs during the first 24 hours. Fibroblast to myofibroblast 
differentiation begins very early in the simulation. By 24 hours all fibroblasts have differentiated 
restricting proliferation and resulting in fewer cells overall. In the third outcome category, 
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gradual epithelial cell death with fibroblast proliferation, fibroblasts undergo a large amount of 
proliferation more than doubling in the first 48 hours of the simulation (Figure 3.5C). In this 
simulation epithelial cells experience gradual cell death, and by 168 hours nearly half of the 
epithelial cells have died. Our fourth outcome category, excessive fibroblast proliferation and 
differentiation, shows nearly complete epithelial cell death by 168 hours (Figure 3.5D). In this 
simulation fibroblasts proliferate rapidly doubling by 48 hours. At this time some fibroblasts 
begin to undergo differentiation while others continue to proliferate. After 168 hours all of the 










Figure 3.5 Four distinct classes of multi-scale model simulation outcomes varying 
parameter values. (A) Healthy tissue outcome. Complete epithelial cell survival can be 
achieved by baseline parameter values in the model. (B) Rapid epithelial cell death with 
fibroblast proliferation and differentiation. Parameter combinations leading to rapid epithelial 
cell death and early fibroblast differentiation include high TGF-β1 synthesis (kTGFβ1lat = 1.07 
× 10−16). (C) Gradual epithelial syn cell death with fibroblast proliferation. Parameter 
combinations leading to gradual epithelial cell death include low PGE2 synthesis (VePGE2 = 
3.16 × 10−27) and low TGF-β1 proliferation threshold (minprolifTGFβ1 = 1.15 × 10−25). (D) 
Excessive fibroblast proliferation and differentiation. Parameter combinations leading to 
excessive fibroblast proliferation include high TGF-β1 synthesis (kTGFβ1lat = 9.86 × 10−19), 
high myofibroblast TGF-β1 binding (k = 0.001, and decreased PGE synthesis syn onM 2 
VePGE2 = 1.69 × 10−29). For complete parameter ranges please see Supplementary Material 
Tables S1–S4. For full length time-lapse simulations please see http:// 
malthus.micro.med.umich.edu/lab/movies/Co- culture/.  
 
3.2.4 Analysis of the Multi-Scale Model Reveals Key Mechanisms Driving Fibroblast 
Proliferation, Differentiation, and Epithelial Cell Survival in a Co-culture Environment  
A wide range of possible multi-scale model simulation outcomes for fibroblast 
proliferation, differentiation, and epithelial cell survival can be achieved by manipulating 
mechanisms of fibroblast and epithelial cell co-regulation (Figure 3.5). To determine which 
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mechanisms and to what extent they are responsible for driving these different outcomes, we 
performed sensitivity analysis on the outputs from 1500 simulations of our multi-scale model at 
day 7 as described in Methods. The analysis predicts mechanisms dictating fibroblast 
proliferation without differentiation (determined by fibroblast number) (Table 1A). Of the 
mechanisms found to drive fibroblast proliferation, PGE2 synthesis had the strongest influence (p 
< .01). The analysis predicts which mechanisms dictate myofibroblast differentiation 
(determined by number of myofibroblasts) (Table 1B). Of these mechanisms, TGF-β1 synthesis 
and PGE2 inhibition of TGF-β1-induced differentiation had the strongest effect on myofibroblast 
number (p< .01). PRCC analysis predicts that the strongest mechanisms driving epithelial cell 
survival (determined by epithelial cell number) (Table 1C) are predominantly different from 
mechanisms driving fibroblast proliferation (Table 1A) and differentiation (Table 1B). Of the 
mechanisms found to drive epithelial cell survival; TGF-β1 synthesis and TGF-β1 activation had 
the strongest effect on epithelial cell number (p < .01). These mechanisms may be strong 
candidates for therapeutic intervention. 
 
3.2.5 Multi-target Intervention Strategies Promote Healthy Tissue Repair Better than 
Single Target Strategies  
 From our sensitivity analysis, we established a list of the primary mechanisms driving 
fibroblast, myofibroblast, and epithelial cell outcomes (Table 1). Some of these mechanisms 
reiterate previous understandings about fibrosis, and others provide new insight. Current 
therapies for pulmonary fibrosis target TGF-β1 signaling in order to prevent fibroblast 
dysregulation (30, 33, 346). Our analysis identifies that inhibiting TGF-β1 receptor/ligand 
complex internalization, the first step in TGF-β1 signaling, results in an overall decrease in 
	 80	
myofibroblast number (Table 1B). In vitro studies show that high levels of PGE2 inhibit 
fibroblast proliferation (Figure 2). Our sensitivity analysis further emphasizes this relationship by 
highlighting the strong negative correlation between fibroblast number and epithelial cell 
synthesis of PGE2 (Table 1A).  
 
Table 3.1: Primary mechanisms driving fibroblast, myofibroblast, and epithelial cell numbers.  
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To predict the success of potential therapeutic strategies, we simulated therapeutic 
interventions by either promoting or inhibiting the mechanisms identified by our sensitivity 
analysis as the most significant for driving fibroblast proliferation, fibroblast differentiation, and 
epithelial cell survival. We simulated these therapeutic strategies in the three outcome categories 
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identified as rapid epithelial cell death with fibroblast differentiation, gradual epithelial cell death 
with fibroblast proliferation and differentiation, and excessive fibroblast proliferation and 
differentiation (Figure 3.6). We first tested single intervention strategies intended to either inhibit 
fibroblast proliferation or differentiation, or to promote epithelial cell survival for each outcome 
category. We then took a two-hit approach and combined treatment strategies that inhibit 
fibroblast proliferation or differentiation together with strategies that promote epithelial cell 
survival. Thus, for each case we tested two interventions independently (Figure 3.6 top) and then 
in combination (Figure 3.6 bottom).  
 
Figure 3.6 Virtual individual and combined treatment outcomes for three case studies 
(compare to B,C,D from Figure 3.5). Green line represents epithelial cells, red line represents 
fibroblasts and yellow line represents myofibroblasts. (A) Rapid epithelial cell death and 
recovery. The top panel depicts untreated simulation (solid line) decreased TGF-β1 synthesis 
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(dashed line) or increased PGE2 synthesis (dotted line) in isolation. Decreased TGF-β1 synthesis 
preserves epithelial cell number but does not inhibit fibroblast proliferation. Increased PGE2 
synthesis inhibits excessive fibroblast proliferation but does not rescue epithelial cell number. 
The bottom panel depicts untreated simulation (solid line) and decreased TGF-β1 synthesis in 
combination with increased PGE2 synthesis (dot-dashed line). Combined treatment restricts 
fibroblast proliferation and preserves epithelial cell survival. (B) Gradual Epithelial cell death 
and recovery. The top panel depicts untreated simulation (solid line) decreased TGF-β1 
synthesis (dashed line) or increased PGE2 synthesis (dotted line) in isolation. Decreased TGF-β1 
synthesis preserves epithelial cell number but does not inhibit fibroblast proliferation. Increased 
PGE2 synthesis inhibits excessive fibroblast proliferation but results in more rapid decline in 
epithelial cell number. The bottom panel depicts untreated simulation (solid line) and decreased 
TGF-β1 synthesis in combination with increased PGE2 synthesis (dot-dashed line). Combined 
treatment restricts fibroblast proliferation and preserves epithelial cell survival. (C) Excessive 
fibroblast proliferation and recovery. The top panel depicts untreated simulation (solid line) 
decreased TGF-β1 synthesis (dashed line) or decreased TGF-β1 activation (dotted line) in 
isolation. Decreased TGF-β1 synthesis increases but does not preserve epithelial cell number and 
does not inhibit fibroblast proliferation. Decreased TGF–β1 activation does not inhibit excessive 
fibroblast proliferation or rescue epithelial cell number The bottom panel depicts untreated 
simulation (solid line) and decreased TGF-β1 synthesis in combination with or decreased TGF-
β1 activation (dot-dashed line). Combined treatment restricts fibroblast proliferation and 
preserves epithelial cell survival.  
 
For the outcome category rapid epithelial cell death with fibroblast differentiation (Figure 
3.6A), we virtually reduced fibroblast synthesis of TGF-β1 or we increased epithelial cell 
synthesis of PGE2. Decreasing TGF-β1 synthesis alone inhibits fibroblast to myofibroblast 
differentiation and rescues the epithelial cells at 168 hours but due to the presence of low levels 
of TGF-β1 fibroblast proliferation is not inhibited. Increased synthesis of PGE2 inhibited 
fibroblast proliferation but did not decrease the rate of epithelial cell death (Figure 3.6A top). 
Simultaneously decreasing TGF-β1 synthesis together and increasing PGE2 synthesis inhibited 
fibroblast to myofibroblast differentiation and also restored epithelial cell survival by day 7 
(Figure 3.6A bottom).  
For the outcome category, gradual epithelial cell death with fibroblast proliferation 
(Figure 3.6B), we virtually reduced fibroblast synthesis of TGF-β1 or we increased the rate of 
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PGE2 synthesis by epithelial cells. Reducing TGF-β1 synthesis alone rescues the epithelial cells 
at 168 hours but it does not inhibit fibroblast proliferation. Increasing PGE2 synthesis inhibited 
fibroblast to myofibroblast differentiation and fibroblast proliferation. Increased PGE2 synthesis 
improved epithelial cell survival by day 7 but not to the same level as decreasing TGF-β1 
synthesis (Figure 3.6B top). Combining these effects both inhibited fibroblast proliferation and 
differentiation while fully restoring epithelial cell survival by day 7 (Figure 3.6B bottom).  
Finally, for the outcome category, excessive fibroblast proliferation and differentiation, 
we virtually reduced TGF-β1 synthesis or reduced TGF-β1 activation. Reducing TGF-β1 
synthesis alone inhibited fibroblast to myofibroblast differentiation and made a dramatic 
improvement in epithelial cell survival at day 7, but did not inhibit fibroblast proliferation. 
Decreasing TGF-β1 activation had almost no effect on epithelial cell survival, strongly inhibited 
fibroblast differentiation, but showed no ability to inhibit fibroblast proliferation (Figure 3.6C 
top). However, combining these effects restored epithelial cell survival by day 7 while inhibiting 
fibroblast proliferation and differentiation (Figure 3.6C bottom). A conclusion from the model 
different mechanisms must be targeted simultaneously to affect outcomes of epithelial cell 
survival, fibroblast proliferation, and myofibroblast differentiation. 
 
3.3 Discussion 
 Pulmonary fibrosis results from dysregulation of the wound healing process in the lungs. 
Epithelial cells, fibroblasts, and myofibroblasts each play key roles in tissue regeneration after 
injury. The actions of these different cell types are regulated by pro- and anti-fibrotic cytokines 
such as TGF-β1 and PGE2 respectively. During fibrosis, excessive fibroblast 
proliferation/accumulation and differentiation into myofibroblasts paired with epithelial cell 
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death results in thick, stiff, and scarred lung tissue that is not suitable for breathing and gas 
exchange. Our analysis allowed us to Identifying key mechanisms driving 
fibroblast/myofibroblast dysregulation and epithelial cell death.  With this analysis we can 
predict potential therapeutic targets and strategies for the treatment of pulmonary fibrosis. 
 The use of in silico methods in tandem with experimental approaches allows us to 
identify relationships between specific mechanisms contributing to fibroblast and epithelial cell 
co-regulation and their outcomes such as epithelial cell survival and fibroblast proliferation and 
differentiation during fibrosis. Our multi-scale, hybrid agent-based model is a tool that simulates 
a computation platform similar to an in vitro co-culture system. To ensure that our model 
accurately reflects biology we used data from the literature or generated it herein to calibrate it.  
We take a reductionist approach to understanding fibroblast differentiation and epithelial cell 
regulation and do not capture the full complexity of the lung environment. Nevertheless, like an 
in vitro culture system, our model allows us to test specific mechanisms involved in 
fibroblast/epithelial cell co-regulation. With this unique tool we can evaluate all parts of the co-
regulatory system simultaneously at multiple biological scales over time. Within our multi-scale 
model simulations we can vary rates and magnitudes of cellular and chemical interactions across 
a wide range, simulating the effects of thousands of theoretical intervention strategies. The 
information produced by these simulations includes cell number, local and total chemical 
concentrations, numbers of proliferation or apoptosis events within a given time frame, and 
many other details about the simulated cells and environment. Analysis of these simulated 
outputs allows us to determine which potential interventions or combinations of interventions 
promote epithelial cell survival and inhibit dysregulation of fibroblasts and myofibroblasts. 
	 85	
 Our simulations yield four major categories of outcomes characterized by the number of 
cells left in each cell class after seven days.  We describe these common cases as healthy tissue 
outcome, rapid epithelial cell death with fibroblast proliferation and differentiation, gradual 
epithelial cell death with fibroblast proliferation, and excessive fibroblast proliferation and 
differentiation. It should be clear that there is a wide range of outcomes in between these four 
classes, as cell behavior in our model and in reality is not discrete but a continuous range of 
possibilities. Our results hold nonetheless. Through uncertainty and sensitivity analysis, we 
identify mechanisms driving fibroblast, myofibroblast, and epithelial cell outcomes defined by 
cell numbers at 7 days. Although several mechanisms have a significant impact on fibroblast cell 
number, the strongest regulator is PGE2 synthesis by epithelial cells.  For myofibroblasts, TGF-
β1 synthesis and the ratio of TGF-β1 to PGE2 permissive for differentiation are the key 
mechanisms driving cell number. Epithelial cell outcome is most dependent on TGF-β1 
synthesis and TGF-β1 activation. It is important to note that fibroblast, myofibroblast and 
epithelial cell survival outcomes are largely affected by different mechanisms. This implies that 
treatment strategies intended to reduce or reverse tissue damage associated with fibrosis need to 
target multiple mechanisms specific to different cell types.  
 Further exploration of this “two-hit” therapeutic approach emphasizes the efficacy of 
combinatorial treatment strategies over single target strategies. We performed rescue 
experiments on the three previously identified poor model outcome categories. We reduced the 
synthesis of TGF-β1, increased the synthesis of PGE2, and or decreased TGF-β1 activation in 
these cases and found that in each case, a two-hit treatment strategy was more effective than a 
single target approach. In most cases, one intervention targeted epithelial cells and the other 
targeted fibroblasts and/or myofibroblasts. In some cases there were overlapping effects on 
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multiple cell types, but in all cases at minimum two strategies were required for a complete 
rescue effect.  
 As previously described, there are only two therapeutics available for the treatment of 
pulmonary fibrosis in the United States; Nintedanib and Pirfenidone. Neither of these drugs has 
been carefully tested for effects on epithelial cells as well as mesenchymal cells.  Nintedanib 
inhibits fibroblast proliferation by inhibiting the signaling of receptors of multiple pro-fibrotic 
growth factors (346). This therapeutic is a direct regulator of fibroblast and myofibroblast 
outcomes but may not affect epithelial cell survival. Pirfenidone inhibits TGF-β1 signaling (29) 
and fibroblast to myofibroblast differentiation. Because TGF-β1 synthesis is a key mechanism in 
epithelial cell survival, Pirfenidone may promote epithelial cell survival but may not explicitly 
address fibroblast proliferation. Independently these drugs each target one aspect of fibrotic 
dysregulation. Combined they could potentially have a synergistic effect.  While it is interesting 
to speculate on the biologic usefulness of this approach, currently the costs associated 
specifically with of Pirfenidone and Nintedanib would be prohibitive for most patients. However, 
our model predicts that therapeutic strategies addressing multiple aspects of fibrotic disease are 
essential for the effective treatment of pulmonary fibrosis, and previous analyses have suggested 
that single therapeutic strategies are insufficient  (284). We must identify combined therapeutics 
strategies that are not cost prohibitive to improve the prognosis of pulmonary fibrosis patients.  
 Other existing therapeutic strategies that could be considered for a more cost 
effective combined treatments include, but are not limited to, TGF-β1 receptor fusion proteins 
(356), recombinant human IL-1α and/or TNFα, arachidonic acid (357), and IL-13 receptor 
inhibitors (358-360) (Table 2). TGF-β1 receptor fusion proteins have been shown to block TGF-
β1 signaling in cell types such as mammary tumor cells (356). The use these proteins to inhibit 
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TGF-β1 signaling in epithelial cells could directly reduce their sensitivity to TGF-β1 in a fibrotic 
environment. These proteins could potentially limit myofibroblast differentiation, but may be 
insufficient in protecting tissue integrity if fibroblast proliferation were not also managed, further 
calling for a two-hit therapeutic approach. In thinking about inhibition of TGF-β1 signaling as a 
therapeutic, one must be cautious of the fact that TGF-β1 is a potent regulator of autoimmunity 
(361) and global inhibition of TGF-β1 receptor signaling could result in the development of 
profound immune activation and systemic autoimmunity.  Thus, localized delivery to the lung 
and perhaps more targeted approaches to block downstream mediators may show better efficacy 
overall (202). 










TGF-β1 Synthesis ↑ Pirfenidone ↓ 
PGE2 Synthesis ↓ IL-1α, TNFα, AA,  
IL-13 receptor antagonist 
↑ 
PGE2 Binding ↓ CP-533536 ↑ 
PGE2 Sensitivity  ↓ Forskolin ↑ 
Proliferation        ↑ Nintedanib, IL-13 
receptor antagonist  
(QAX 576) 
↓ 
   Epithelial Cells 
Mechanism 
 






TGF-β1 Synthesis  ↓ Pirfenidone ↓ 
TGF-β1 Activation ↓ anti-αVβ6 ↓ 




↑ indicates promotes cell number, ↓ indicates restricts cell number 
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Recombinant human IL-1α and recombinant human TNFα have been shown to stimulate 
PGE2 synthesis by endometrial cells via the up regulation of the rate-limiting cyclooxygenase-2 
(COX-2) enzyme important for conversion of arachindonic acid to PGH2 (357). The addition of 
arachidonic acid (AA) with recombinant TNFα and IL-1α  further increased the synthesis of 
PGE2 by endometrial cells by providing substrate for COX-2 actions (357). PGE2 can bind to 4 
different cell surface receptors, but the cyclic adenosine monophosphate (cAMP)-coupled EP2 
and EP4 receptors are known to regulate the inhibitory effects of PGE2 on fibroblasts. EP2 (234) 
receptor agonists can simulate PGE2 binding (362). By mimicking PGE2 binding, a mechanism 
highlighted by our sensitivity analysis, cAMP analogues could not only limit fibroblast 
activation, but also promote epithelial cell survival. One of the challenges with PGE2-based 
therapeutics are that lipid mediators have short half-lives in vivo, and systemic delivery of PGE2 
could result in hemodynamic complications due to signaling via other EP receptors in multiple 
cell types (325, 363).  For this reason, targeted EP2 agonist approaches may be more selective, 
but still need to be delivered locally to the lung to limit off-target effects.  This process is 
complicated by the loss of EP2 receptor expression and sensitivity in IPF (167, 364).  Thus, 
better therapeutics may come in targeting downstream mediators of PGE2-EP2 actions.   
IL-13 has been show to promote fibroblast proliferation and increase αSMA synthesis, 
ultimately leading to differentiation (358-360). Reduction of IL-13 signaling in fibroblasts 
through receptor inhibitors such as QAX 576 (Novartis) (26) could reduce fibroblast cell 
number, differentiation, and tissue remodeling functions. It has also been hypothesized that IL-
13 may reduce PGE2 production (360). Thus inhibition of IL-13 receptor signaling may have a 
dual effect of decreasing fibroblast proliferation and increasing PGE2 synthesis.  
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In simulated combinations targeting fibroblasts and promoting epithelial cells, these 
therapeutics and others have the potential to provide synergistic improvement in outcomes over 
individual treatment strategies (Table 2). Fibroblasts, myofibroblasts, and epithelial cells have 
distinct regulatory mechanisms during wound healing. The dysregulation of any or all of these 
processes requires a multifaceted approach for the full restoration of tissue integrity. Addressing 
epithelial cell survival in conjunction with solving fibroblast dysregulation using either new or 




3.4.1 In Vitro Studies of Fibroblast Proliferation 
The IMR-90 normal human lung fibroblast cell line was obtained from American Type 
Culture Collection (ATCC; CCL-186). Approximately 5000 cells/ well are plated onto each well 
of a 96 well plate and either left untreated, treated with 0.1-4ng/ml of activated TGF-β1, or 
treated with 0.1-100nM of PGE2. Cells were treated with 10 μCi of radioactive thymidine 
(Fisher) at 32 hours and harvested at 48 hours post treatment. Cells were harvested onto glass 
fiber filters using an automated cell harvester and filters were counted using a beta scintillation 
counter. Proliferation was compared by counts per minute (cpm) between samples using 
ANOVA with a post-hoc Sidak multiple comparisons test.  
 
3.4.2 In Vitro Studies of Fibroblast Differentiation 
Approximately 75,000 IMR-90 cells were plated into 8-well Titer-tek slides and cultured 
in SFM for 16 hours to synchronize cells and restore basal levels of αSMA. After 16 hours the 
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cells were left untreated, or treated with 0.1ng/ml, 0.5ng/ml, 1.0ng/ml, 2.0ng/ml, or 4.0ng/ml of 
TGF-β1 for 24 hours. Cells were then blocked with 1% fetal bovine serum and stained with a 
1:500 fold dilution of anti-αSMA (Sigma F3777) fluorescently-conjugated antibody. The cell 
nuclei were stained with DAPI and coverslips were added using Vectashield (Vector brand) 
H1200. 3-5 fields per well were counted (at least 300 total cells) and the proportion of total cells 
expressing αSMA was determined.  
 
3.4.3 In Vitro Studies of Epithelial Cell Death 
Type II alveolar epithelial cells were isolated from wild type mice per standard protocol 
(365) and then plated on Matrigel (BD Biosciences) in Small Airways Growth Media (SAGM) 
(Lonza) with 5% Fetal Bovine Serum (FBS) (Hyclone) and 10ng/ml KGF (PeproTech). 24 hours 
later cells were trypsinized and replated in serum free SAGM on Matrigel in a 24-well plate. 
70,000 cells were plated in each well. 24 hours later, the cells were treated with TGFb added at 
different concentrations as well as IncuCyte Caspase-3/7 Reagent for Apoptosis (Essen 
BioScience) at 5   mM, according to the manufacturer’s instructions.  This reagent is cleaved by 
activated caspase-3/7 resulting in nuclear fluorescent staining. 24 hours later, cells were analyzed 
under a fluorescent microscope. The percent of fluorescent cells was manually counted for each 
dose of TGF-β1. We had four replicate wells and counted 2-4 fields per each replicate a total of 
8-16 fields for each dose of TGF-β1. 
 
3.4.4 Multi-scale Model Construction 
3.4.4.1 Cellular scale agent-based model. Agent-based models (ABMs) are a class of in 
silico models that demonstrate how system level dynamics can emerge as a result of the adaptive 
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behavior of individuals. They do this by assigning probabilistic actions and traits to individual 
agents within a system, and then tracking these actions over time and space. These models have a 
defined domain where agents can interact with each other and their environment. Agents (cells) 
are tracked in a discrete fashion (i.e. counted) and therefore some agent-based models can 
provide spatial outputs as well as numerical outputs. Because the behaviors of agents can be 
probabilistic, agent-based models are stochastic in nature. Our ABM consists of three cellular 
agent types: fibroblasts, myofibroblasts, and epithelial cells. The environment of our ABM 
simulates an in vitro cell culture plate representing a cubic area of 1.73mm x 1.73mm x 6.20mm, 
or about one tenth the volume of a well in a 96 well plate (Figure 3.7).  We choose to model one 
tenth of the well to reduce the computational burden of the three dimensional (3D) model. Our 
simulated plate is partitioned into a grid with side lengths of 81 compartments (81 x 81) and 
makes up the first layer of our model. There are 6,561 compartments in each layer of the model 
and 282 layers in total. The bottom layer represents the surface of the dish. The 281 layers above 
the dish make up a large media compartment that represents the depth of a plate  
(approximately6.2mm ). There are a total of 1,850,202 compartments in the model with a total 
volume of approximately 19.7 μL. The construction of this model is based on our previous work 
with agent-based models, including unpublished work with 3D models (157-159, 227, 366, 367). 
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Figure 3.7: Schematic representation of both cellular and molecular scale physiological 
interactions in the hybrid multi-scale computational co-culture model showing linking of 
models. Arrows indicate promotional effect while barred lines indicate inhibitory effect. 
Contents within the red circle depict a previously published molecular scale model of TGFβ 
signaling (344) that is operational within all fibroblasts. 
 
Within this framework, agents follow cell-type-specific rules capturing physiological 
interactions tracked at the cellular scale (Figure 3.7). Cellular interactions are guided by rules 
that include movement of fibroblasts on the surface of the plate, cellular contact inhibition; 
myofibroblast cell death, TGF-β1 mediated epithelial cell death, TGF-β1- and PGE2-mediated 
fibroblast proliferation, fibroblast differentiation into myofibroblasts, and myofibroblast 
secretion of ECM. For a full list of cellular model rules, see Appendix. Cells in our simulated 
culture dish, like cells in vitro, are adhesion-dependent, meaning that they adhere to the surface 
of the plate (100). ECM and latent TGF-β1 also adhere to the bottom of the plate (368). The 
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ECM proteins are assumed to be cross-linked, forming a matrix on the bottom of the plate (368). 
Latent TGF-β1 adheres to this matrix. When TGF-β1 is activated, the active molecule is released 
from the matrix and can diffuse through the media.  
 
3.4.4.2 Molecular scale ordinary differential equation model. Figure 3.7 shows a 
schematic of the molecular scale model. We use our ordinary differential equation (ODE) model 
of fibroblast receptor-ligand dynamics described previously (344).  Briefly, non-linear ODEs 
capture not only TGF-β1 synthesis, degradation, activation, receptor binding, and dissociation 
but also receptor dynamics including synthesis, internalization, recycling, and degradation of the 
TGF-β1 receptor complex. The model provides coarse-grained dynamics for SMAD and 
Rho/ROCK signaling as well as for adhesion and PGE2 signaling in fibroblasts. This earlier work 
identified the need for both a positive and negative regulator to achieve homeostatic fibroblast 
activation. For example, periodic signaling from either TGF-β1 (an example positive regulator) 
or PGE2 (an example negative regulator) was insufficient to produce controlled fibroblast 
activation.  
Active TGF-β1 and PGE2 are secreted from cells or released from the ECM into the 
media compartment where they diffuse in 3D (218). Both TGF-β1 and PGE2 can degrade over 
time. Extracellular mediator concentrations influence αSMA synthesis by fibroblasts and 
myofibroblasts, as detailed in the molecular model described below.  Similarly, αSMA from the 




3.4.4.3 Linking molecular and cellular scale models. We capture both molecular and 
cellular actions in a multi-scale hybrid model by linking the cellular scale virtual co-culture 
ABM and molecular scale TGFb dynamics ODE model described above using techniques 
previously described (157-159, 218).  In particular, an output from the molecular level model – 
αSMA – is a feed forward input into the cellular level model, driving fibroblast to myofibroblast 
differentiation. The concentration of TGF-β1 and PGE2, secreted by fibroblasts and epithelial 
cells, are outputs of the cellular scale model and inputs into the molecular scale model of 
fibroblast activation. These mediators dictate αSMA synthesis in the molecular scale model 
completing the connection between the two models and scales. Thus, the cellular and molecular 
scale models are connected by extracellular levels of TGF-β1 and PGE2, and intracellular αSMA 
(Figure 3.7). 
 
3.4.5 Parameter Derivation and Estimation 
 Parameter values are identified from published experimental work, estimated from 
experiments herein, and/or predicted using uncertainty analysis. The rate constants for latent and 
active TGF-β1 degradation were derived from half-lives published by Wakefield et al. (9.2 ± 1.4 
min and 2.7 ± 0.4 min respectively) assuming first order kinetics (326). Additional parameters 
obtained from the literature are as described in Warsinske et al. (344). 
The threshold concentrations of TGF-β1 and PGE2 that allow or inhibit fibroblast 
proliferation in vitro were derived from experiments herein.  Fibroblasts proliferate in 
concentrations of TGF-β1 up to 1ng/ml as compared to fibroblasts cultured in complete media 
(CM) alone (Figure 3.2A). At 2ng/ml and 4ng/ml fibroblast proliferation is significantly reduced 
compared to untreated cells, likely due to myofibroblast differentiation. Fibroblasts proliferate 
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uninhibited in concentrations of PGE2 up to 1nM (Figure 3.2B). At 0.1nM PGE2 fibroblasts 
proliferate significantly more than fibroblasts cultured in CM alone (Figure 3.2B). Fibroblast 
proliferation is significantly inhibited at 10nM and 100nM concentrations of PGE2 (Figure 3.2B). 
Fibroblasts cultured in complete media had a doubling time of approximately 24 hours (data not 
shown).  
 Parameters estimated using uncertainty analysis (described below) include soluble PGE2 
degradation rate constant, fibroblast sensitivity to PGE2, probability of fibroblast movement, 
αSMA synthesis rate, max αSMA, and level of TGF-β1 lethal to epithelial cells.  
 
3.4.6 Cellular-Scale Model Calibration 
The cellular scale ABM is calibrated to reflect in vitro experimental data generated by 
our group (Figures 3.3, 3.4). Fibroblast differentiation is calibrated to fit in vitro studies of 
fibroblast differentiation described above. We assume that the probability that a fibroblast will 
differentiate in a given simulation time step is linearly related to the amount of αSMA 




𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝛼 𝑀𝐴 𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑧𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝛼𝑆𝑀𝐴 𝑎 𝑐𝑒𝑙𝑙 𝑐𝑎𝑛 𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑧𝑒 
where the slope determines the sensitivity of the system to αSMA. This relationship allows us to 
calibrate the slope and max αSMA so that the system reasonably fits experimental data of 
fibroblast differentiation (Figure 3.3). We also assume that the probability that an epithelial cell 
will apoptose in a given time step is proportional to the amount of TGF-β1 it has bound (Figure 
3.4), and that this relationship is captured by a saturation curve: 
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 (EQN 2) 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑎𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠
= 𝑚 ∗
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑇𝐺𝐹𝛽1 𝑏𝑜𝑢𝑛𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑇𝐺𝐹𝛽1 𝑏𝑜𝑢𝑛𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙 + 𝑘 ∗ 𝑎𝑚 𝑢𝑛𝑡 𝑃𝐺𝐸!𝑏𝑜𝑢𝑛𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙 + 𝐶
 
where m determines the sensitivity of the system to TGF-β1, k determines the sensitivity of the 
system to inhibition by PGE2, and C is a non-zero constant. We calibrate m, k, and C so that the 
system reasonably fits experimental data.  
Initial conditions for the cellular scale virtual co-culture ABM are chosen to replicate 
experimental conditions. 5000 epithelial cells and 500 fibroblasts are seeded on the surface of the 
model plate at time 0, creating a simulation environment that has approximately 84% cellular 
confluence. 1500 simulations (virtual experiments) were performed varying all parameter values 
by approximately 2 orders of magnitude except for the initial conditions and diffusivities of 
TGF-β1 and PGE2. 
 
3.4.7 Uncertainty and Sensitivity Analysis 
We use uncertainty analysis to quantify how variation in parameter values leads to 
variation in model output (229). These variations can occur at the molecular and cellular scales 
in the model and can influence outputs spanning these biological scales. When parameters at one 
scale influence outcomes at that scale they are considered to have an intra-model influence. 
Intra-model influences can occur within either the molecular or cellular scale models. When 
mechanisms at one scale effect outcomes at the other scale these parameters are said to have 
inter-model influence. Uncertainty analysis allows us to observe model outcomes based on a 
wide value range for each parameter value. We vary numerous parameters in the model over a 
wide range (two orders of magnitude) and compare how these variations affect model outputs. 
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Sensitivity analyses enable us to identify which model parameters have a significant influence 
and the extent of that influence on a given model output (229, 344). Partial rank correlation 
coefficients (PRCCs) are used to determine the sensitivity of an output to a given parameter. 
PRCC values describe the correlation between the parameter value and the output in a range 
from -1 to +1. PRCC values are differentiated using a student t-test of significance. In this work 
we use the LHS algorithm to generate 500 unique parameter sets, and run each set in triplicate 
(229). PRCC values are considered significant and with a p-value less than 0.01. We evaluate our 
model simulations (defined below) at day 7 because this time-point reflects the full range of 
possible model outcomes.     
 
3.4.8 Multi-Scale Model Simulation 
 Our hybrid multi-scale model links both the molecular and cellular scale models,  
described previously. The combined model, resulting from the linking of the two models (see 
Linking molecular and cellular scale models above) allows us to simulate biological events with 
molecular and cellular scale details over time. Simulations are defined as an iteration of the 
multi-scale model that is run on the computer over a defined period of time. Simulations include 
a set of initial conditions, model rules, equations, and parameter values (see Appendix for 
complete description of parameters and rules).  
  Model simulations can be evaluated by comparing individual outputs or the combined 
overall outcome of the simulation. Initial conditions include the number of each cell type, the 
concentrations of TGF-β1 and PGE2 in the environment, and the number of TGF-β1 receptors 
present on each fibroblast at time 0. In our model we track number of epithelial cells, fibroblasts, 
and myofibroblasts over time and position in the environment. Model outputs consist of not only 
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these numbers in space and time but also concentrations of PGE2 and TGF-β1. A model outcome 
differs from a model output in that it encompasses multiple outputs and evaluates them over the 
entire timespan of the simulation. An example of a model outcome would be “Rapid epithelial 









Mycobacterium tuberculosis is a pathogenic bacterium and causative agent of 
tuberculosis (TB). Approximately one in three people are infected with M. tuberculosis, resulting 
in 1.4 million deaths in 2015, including 140,000 children (369). The only vaccine for TB is a 
live, attenuated M. bovis strain that confers some protection against severe manifestations of 
pediatric TB but does not offer lasting protection. With the development and spread of multi-
drug resistant TB, there is a need for new therapeutics for TB (169). Current therapeutic 
strategies require months of multi-drug treatment and treatment failures can lead to reactivation 
disease, sometimes years after initial infection (37). Developing new therapies to address TB will 
require an improved understanding of host immune responses to M. tuberculosis.  
The most common outcome of infection is formation of dense, organized immunological 
structures called granulomas in lungs (295, 370). Granulomas isolate infected cells from adjacent 
tissue and prevent bacterial dissemination, but can also make it difficult for the immune system 
and drugs to kill all bacteria, leading to a stalemate between the immune system and bacteria 
(192, 288, 371). Granulomas are complex structures that can be classified by their cellular 
composition, the number of bacteria present, and overall shape (372). Three categories that can 
be used to describe granulomas include contained, indicating the number of live bacteria in a 
	 100	
granuloma has stabilized over time, disseminating, indicating the bacterial load in a 
granuloma is increasing and the infection is not well controlled, and sterilized, indicating all the 
bacteria have been killed (Table 1) (294). Identifying immunological mechanisms that 
differentiate sterilized, contained, and disseminating granulomas could present therapeutic 
targets to improve TB treatment.  
Table 4.1: Categorization of simulated granulomas by bacterial status 
 Description CFU by day 200 Simulation snapshot 
Sterilized All bacteria have been killed 0 
 
Contained 
Number of live 
bacteria has stabilized 
over time 
Less than or equal to 
twice CFU at day 100 
 
Disseminated 
Number of live 
bacteria is increasing, 
infection is not well 
controlled 
Greater than of equal 





There is increasing evidence suggesting that cytokine signaling is responsible for 
establishing granulomas that successfully control M. tuberculosis infection. Pro-inflammatory 
cytokines including TNFα and IFNγ have been investigated for their anti-microbial functions. 
TNFα has been shown to induce macrophage activation (373), recruit immune cells to the site of 
infection by promoting chemokine secretion from macrophages (291), and can induce cellular 
apoptosis (305). Inhibition of TNFα during M. tuberculosis infection leads to unstructured 
granulomas and increased bacterial burden (158, 165, 374). Similarly, IFNγ is also responsible 
for macrophage activation during infection (59, 60). A balance of pro- and anti- inflammatory 
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cytokines is required for establishing granulomas that successfully control M. tuberculosis 
infection (41, 46, 158, 164). 
Anti-inflammatory cytokines including TGF-β1 and IL10 have come under increasing 
scrutiny for their association with severe TB (85, 158, 163, 173, 174). TGF-β1 is highly 
conserved across taxa (375) and can influence many cell types (108, 111, 113, 249) by signaling 
through the TGFβR1/TGFβR2 receptor complex (93). TGF-β1 has a variety of inhibitory effects 
including the ability to downregulate macrophage activation and effector function (129, 135, 
138, 376, 377), decreasing cytokine secretion by macrophages and cytotoxic T cells (110, 378), 
and decreasing proliferation of T cells (134). Moreover, TGF-β1 inhibits effector functions in 
antigen-stimulated cytotoxic T cells in tumors, (125, 379) and TGF-β1-expressing regulatory T 
cells (Tregs) suppress cytotoxic T cell function (380). TGF-β1 may also exacerbate TB by 
downregulating M. tuberculosis-specific pro-inflammatory cytokine secretion and proliferation 
by T cells (110, 134, 381). Systemically, M. tuberculosis infection upregulates TGF-β1 
expression, and peripheral blood monocytes from TB patients display elevated TGF-β1 secretion 
(90, 132, 382). Granulomas from non-human primates (NHPs) show high levels of TGF-β1 (49). 
In vitro studies have demonstrated that TGF-β1 promotes mycobacterial growth within 
mononuclear cells, and addition of exogenous TGF-β1 leads to increased M. tuberculosis 
replication (131, 133). Inhibiting TGF-β1 restricts bacterial growth (131, 133). Despite evidence 
of the effects of TGF-β1, the role of TGF-β1in the granuloma is still unknown.  
IL-10 is another anti-inflammatory cytokine expressed by T cells and macrophages in 
granulomas. It signals through its receptor, IL-10R (175), and can inhibit macrophage 
antimicrobial activities that are critical for protection against TB (173, 179). These actions play 
an important role in early granuloma formation and macrophage regulation (157, 164). In silico 
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deletiion of IL-10 between the time of infection and 45 days post-infection increases granuloma 
sterilization and this effect is attributable to modest increases in macrophage activation (157). 
However, the benefit of IL-10 deletion decreases at later time points and there is an increase in 
potentially pathologic inflammation (157). Moreover, virulent M. tuberculosis strains are 
associated with upregulated IL-10 expression, suggesting the effects of IL-10 may have survival 
benefits for M. tuberculosis (41, 383, 384). The trade off between the cause and effect of  IL10 
and TGF-β1 remains unclear. 
The effects of TGF-β1 on overall granuloma development and function, as well as the 
interplay between IL10 and TGF-β1 in regulating inflammation in granulomas remain unknown 
(54, 158). Both cytokines are elevated in the bronchoalveolar lavage fluid in patients with 
pulmonary TB when compared to patients with other lung diseases and healthy patients (85). 
These findings, and others (69, 85, 90, 120, 131-133, 382, 385-387), emphasize the importance 
of TGF-β1 and IL10 in pulmonary TB, but their interaction and regulation remain 
uncharacterized (46). Previous work indicates TGF-β1 and IL10 may differentially regulate 
lymphoid- and myeloid-derived cells. For example, TGF-β1 regulates lymphoid-derived NK cell 
involvement in T helper type 1 cell development and NK cell maturation (388), but not myeloid-
derived dendritic cell involvement in T helper type 1 cell development (136). In contrast, IL-10 
is a major regulator for myeloid-derived cells including dendritic cells and monocytes (177, 
178).  This dichotomous regulation has not been examined in TB, and could significantly impact 
development of new vaccines and therapeutics.  
 With this study, we identify TGF-β1 as an important regulatory factor impacting 
mycobacterial control in granulomas with effects that are distinct from those of IL10. NHPs and 
rabbits are the best animal models for TB with human-like granulomas, but these animals have 
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practical limitations making their study challenging (57). We take a systems biology approach 
pairing GranSim (157, 159, 164, 192, 193, 219, 220, 389), an in silico hybrid multi-scale agent-
based model that captures tissue, cellular, and molecular scale interactions of cells and cytokines 
in granulomas, with experimental data from NHPs with TB. This unique combination of 
computational and experimental methods represents a novel approach to investigating questions 
that cannot be addressed by traditional experimental systems. We find that TGF-β1 primarily 
regulates the effector function of cytotoxic T cells, and not macrophages, in granulomas. 
Deletion of TGF-β1 leads to improved bacterial clearance and lesion sterilization. The role of 
TGF-β1 in granulomas differs from that of IL10, highlighting a novel differential regulation of 
cytotoxic T cells and macrophages. Understanding regulatory roles of cytokines can further our 
ability to predict therapeutic targets.  
 
4.2 Results 
4.2.1 Deleting anti-inflammatory mediators decreases colony-forming units (CFU) and 
improves granuloma sterilization. 
 We simulated a set of 1337 granulomas using our baseline parameters (see Methods and 
Table S1) to serve as our wild-type (WT) containment set of granulomas. For direct comparison, 
we simulated the same 1337 granulomas three additional times in the absence of IL10, TGF-β1, 
or both IL10 and TGF-β1 to create virtual IL10 knockout (KO), TGF-β1 KO, and double KO 
sets, respectively. Simulation results show that removal of the anti-inflammatory cytokines 
decreases CFU per granuloma over time (Figure. 4.1A) with greatest decreases in the double KO 
set compared to WT followed by TGF-β1 KO and IL10 KO sets, respectively. The effects of 
cytokine removal are visible in the double KO set as early as day 20 post infection (PI), and 
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remain present in all simulation sets from day 30 through day 200 PI. Lesion sterilization 
increased in the absence of one or both anti-inflammatory cytokines (Figure. 4.1B). Consistent 
with previously published computational studies (157), we observed that 60% of the lesions in 
IL10 KO sets experienced sterilizing immunity, while TGF-β1 KO resulted in 85% of lesions 
becoming sterile and knocking out both IL10 and TGF-β1 led to 98% of lesions being sterilized 
(Figure. 4.1B). These simulation results suggest that TGF-β1 plays a stronger role in inhibiting 
bacterial clearance than IL10.  
 
Figure 4.1: Comparison of CFU from simulated granulomas between wild type, IL10 
knockout (KO), TGF-β1 KO, and TGF-β1/IL10 double KO days 50 to 200 post-infection. 
A) Each line represents the mean CFU of all1337 simulated granulomas. B) Table indicates 
percentage of simulated granulomas when CFU = 0 at day 200 PI under the aforementioned 
conditions. 
 
4.2.2 Cytotoxic T cells are responsible for decreased bacterial load in TGF-β1 knockout 
granulomas.   
 We performed a sensitivity analysis on our simulations (see Methods) and identified that 
TGF-β1 has a strong influence on cytotoxic T cell effector function (Table A.2-A.3). Using the 
model, we have the ability to dissect individual activities of cells. Thus, we compared the 
number of bacteria killed by cytotoxic T-cell activity in our knockout containment sets by day 
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200 post infection (PI) (Figure. 4.2A). Granulomas without TGF-β1 killed significantly more 
bacteria by cytotoxic T-cell activity than any other KO set (Figure. 4.2A). The double KO set 
shows significantly better bacterial killing by cytotoxic T cells than the baseline set, while the 
IL10 KO sets kill significantly fewer bacteria by cytotoxic T cells (Figure. 4.2A). We also 
compare sets for the total percent of bacteria killed per granuloma due to activity attributable to 
cytotoxic T-cells by day 200 PI (Figure. 4.2B). The percent in the TGF-β1 KO and double KO 
sets was significantly greater than in the baseline set. There was no significant difference 
between the TGF-β1 KO and double KO sets. The IL10 KO showed no significant increase in 
percent bacterial killing by cytotoxic T-cell activity compared to baseline granulomas. These 
data indicate that in the absence of TGF-β1, cytotoxic T cells kill more bacteria than they do in 
the presence of TGF-β1. 
To confirm that this result could not be attributed to macrophage-directed behaviors, we 
also examined the percent of bacteria killed by macrophage activity and did not find significant 
differences between the knockout containment sets (Figure. 4.2C). When we compared bacteria 
killed by Fas/Fas-ligand activity we found significant reductions in the TGF-β1 KO and double 
KO sets compared to baseline granulomas (Figure. 4.2D). This decrease is attributable to lower 
numbers of infected macrophages over the 200 days PI in the TGF-β1 KO and double KO 
scenarios (Figure. A.1). In addition to killing by macrophages, cytotoxic T cells, and Fas/Fas-
ligand interactions, bacteria can also be killed by starvation in the caseum of the granuloma 
(193). Together these four actions account for all bacterial killing in GranSim (Figure. 4.2E) but 
we found the effect of TGF-β1 on bacterial killing is primarily due to the effects of TGF-β1 on 
cytotoxic T cells (Figure. 4.2). In the absence of cytotoxic T cells we see increased bacterial 
killing by Fas/Fas-ligand activity that is more similar to what we see in baseline granulomas 
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(Figure. 4.2F). In the absence of both TGF-β1 and cytotoxic T cells we also observed slight 









Figure 4.2: Comparison of cumulative bacterial killing by cytotoxic T-cells and 
macrophages between simulated wild type, IL-10 knockout (KO), TGF-β1 knockout, and 
TGF-β1/IL-10 double knockout granulomas over 200 days post-infection. A) CFU per 
granuloma killed by cytotoxic T-cells in 1337 simulated granulomas. B) Percent of dead bacteria 
in simulated granulomas killed by cytotoxic T-cells. C) Percent of dead bacteria killed by 
macrophages in simulated granulomas. D) Percent of dead bacteria killed by Fas/Fas-ligand in 
simulated granulomas. E) Percent of bacterial killing caused by Fas/Fas-ligand signaling, 
cytotoxic effector functions, starvation, and macrophages in the four cytokine-knockout (KO) 
sets. F) Percent of bacterial killing caused by Fas/Fas-ligand signaling, cytotoxic effector 
functions, starvation, and macrophages in the four cytokine KO sets with the additional KO of 
cytotoxic T-cells. **** = p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05, ns = p >0.05 
 
	 108	
The increased bactericidal activity by cytotoxic T cells seen in the absence of TGF-β1 
(Figure. 4.2A) could be due to an increased number of cytotoxic T cells or to increased cytotoxic 
T cell effector functions.  As shown in Figure 4.3A, at day 40 PI we see fewer total cytotoxic T 
cells (both effector and those primed but not effector) in TGF-β1 KO and double KO granulomas 
than baseline and IL10 KO granulomas (Figure. 4.3A). Of the total cytotoxic T cells, 
approximately 6% of those in the baseline and IL10 KO cases are effector, and approximately 
98% of those in the TGF-β1 KO and double KO cases are effector (Figure. 4.3A). The same 
trend occurs at day 200 PI with a mean of approximately 10% effector cytotoxic T cells in the 
baseline and IL10 KO cases and a mean of approximately 98% effector cells in the TGF-β1 KO 
and double KO cases (Figure. 4.3A). These results suggest that increased bacterial killing by 
cytotoxic T cells in the absence of TGF-β1 is due to increased cytotoxic T cell effector functions, 
and not an increase in number of cytotoxic T cells in the granuloma. These results cannot be 
attributed to an overall increase in inflammation. We observed no increase in numbers of 
activated macrophages (Figure. 4.3B) or total TNFα (Figure. 4.3C) in the absence of TGF-β1 
that would indicate increased levels of inflammation.  
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Figure 4.3: Comparison at two time-points post-infection between effector and non-effector 
cytotoxic T-cells, activated macrophages, and total TNFα in wild type, IL10 knockout 
(KO), TGF-β1 knockout, and TGF-β1/IL10 double knockout simulated granulomas.  A) 
Black fill indicates mean cytotoxic T-cells in 1337 simulated granulomas. Grey fill indicates 
mean effector cytotoxic T-cells in 1337 simulated granulomas. B) Total number of activated 
macrophages per granuloma. C) Total number of TNFα molecules per granuloma.  
 
4.2.3 Macrophages and cytotoxic T cells differentially express anti-inflammatory cytokine 
receptors. 
 We next sought to determine if TGF-β1 regulation of cytotoxic T cells as observed in 
simulations is consistent with cells from the NHP granuloma and to compare TGF-β1 and IL10 
receptor expression between macrophages and cytotoxic T cells (Figure. 4.4). Flow cytometry 
shows increased expression of IL10 receptors on macrophages compared to granzyme B positive 
(cytotoxic) and negative (not cytotoxic) T cells. Expression of TGF-β1 receptor on the surface of 
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granzyme B positive T cells is increased compared to granzyme B negative T cells and 
macrophages (Figure. 4.4A). Due to small sample size these trends are not statistically 
significant but support other data (137, 388) suggesting that there is differential regulation of 
TGF-β1 and IL10, and strengthen our prediction that TGF-β1 and IL10 differentially regulate T 
cells and macrophages in granulomas. We also examined localization of IL10R and TGFβR1 in 
serial sections of a formalin-fixed paraffin-embedded NHP granuloma (Figure. 4.4B). We found 
IL10R localization corresponded with macrophage-rich regions of the granuloma and the 
TGFβR2 corresponded with lymphocyte-rich and neutrophil-rich regions (Figure. 4.4B). 
 
Figure 4.4: Flow cytometry and immunohistochemistry examining expression of TGF-β1 
and IL10 receptor for macrophages, granzyme B (GrzB) positive (cytotoxic) T cells, and 
GrzB- (not cytotoxic) T cells. Dots indicate an individual granuloma. Blue dots come from a 
single NHP, red dots come from another NHP.A) Flow cytometry was performed comparing the 
expression of IL10 and TGF-β1 receptor on three cell types. B) Top left: Serial sections of a 
NHP granuloma. Top right: colored for lymphocyte-rich regions in cyan, epithelioid macrophage 
regions in magenta and neutrophil-rich caseous regions are indicated with asterisks. Bottom left: 
Stained for IL-10R (yellow) and DAPI (Blue). Bottom right: stained for TGF-βR1 (yellow) and 
DAPI (blue).  
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4.2.4 Virtual depletion of TGF-β1 at day 200 post-infection decreases CFU and increases 
bacterial clearance. 
 In the simulations examined above, we focused on the early period of granuloma 
formation and function (0-200 days PI).  In order to determine if TGF-β1 regulates fully formed 
granulomas, we simulated the granulomas from our baseline containment set for 400 days 
(Figure. 4.5A), and then simulated the same 1337 granulomas depleting IL10, TGF-β1, or both 
IL10 and TGF-β1 at day 200 PI. These simulations make up a new group of containment sets: 
IL10 depletion, TGF-β1 depletion, and double depletion sets. We observed that depleting IL10, 
TGF-β1, and both IL10 and TGF-β1 decreases the mean CFU per granuloma (Figure. 4.5A). In 
addition to decreased mean CFU per granuloma we observe an increased percent of granulomas 
that are cleared between day 200 and day 400 PI. Simulations predicted that 70% of granulomas 
in our baseline containment set, and 71% in IL10 depletion set would have sterilizing immunity 
by 400 days PI (Figure. 4.5B). These results indicate that IL10 is not playing an important role in 
bacterial clearance late in infection. Removing IL10 from a fully formed contained granuloma 
will not increase the likelihood of bacterial clearance (157). We also predict that 88% of 
granulomas would clear bacteria by day 400 PI after TGF-β1 depletion (Figure. 4.5B). This 
result suggests that removing TGF-β1 improves bacterial clearance in fully formed granulomas 
as effectively as knocking out TGF-β1 at the time of infection (Figure. 4.1B). There was no 
significant difference in the effect on bacterial clearance between TGF-β1 depleted and double 
depleted granulomas, further demonstrating that IL10 is not playing an important role in bacterial 
clearance between day 200 and day 400 PI (Figure. 4.5B).  
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 Taken together, these results suggest that depletion of TGF-β1 in contained granulomas 
decreases CFU per granuloma and increases lesion sterilization. To determine if these results are 
consistent in disseminating granulomas, we simulated a 1500 granuloma baseline dissemination 
set. We also simulated the same 1500 granulomas with IL10, TGF-β1, or both IL-10 and TGF-
β1 depleted at 200 days PI. The mean CFU per granuloma of the baseline dissemination set 
increases continuously from day 50 PI (Figure. 4.5C). Anti-inflammatory cytokine depletion 
decreases the mean CFU per granuloma (Figure. 4.5C). The TGF-β1 and IL10/TGF-β1 
depletions show the greatest decrease in CFU compared to baseline dissemination set (Figure. 
4.5C). In both cases, the mean CFU per granuloma stabilizes indicating that these granulomas 
are no longer disseminating. The IL10 depletion has a decreased mean CFU per granuloma 
relative to baseline, but continues to increase over time (Figure. 4.5C). We also looked at the 
ability of disseminating granulomas to achieve sterilization under these conditions and found at 
400 days PI the baseline dissemination granulomas become sterile 3% of the time, IL10 
depletion leads to sterilization in 5% of granulomas, and the TGF-β1 depletion leads to 
sterilizing immunity in 29% of granulomas, while the double depletion leads to sterilization in 
24% of granulomas (Figure. 4.5D). These results corroborate results seen in the simulated 
knockout containment granulomas (Figure. 4.1) and further emphasize that TGF-β1 signaling 
inhibits granuloma sterilization. 
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Figure 4.5: Mean CFU for cytokine depleted simulated granulomas at day 200 post-
infection. A) Mean CFU of 1337 simulated granulomas from a containment scenario over time. 
B) Table indicates percentage of simulated granulomas in panel A with CFU = 0 at day 400 PI. 
C) Mean CFU of 1337 simulated granulomas from a disseminating scenario over time with 
cytokine depletions at day 200. D) Table indicates percentage of simulated granulomas in panel 
C with CFU = 0 at day 400 PI.  
 
4.3 Discussion 
Vast numbers of people remain infected with M. tuberculosis despite efforts to improve 
diagnosis and treatment of TB.  With increases in antibiotic resistance rates, and no broadly 
effective vaccine, novel therapeutic approaches are desperately needed to curb this pandemic. 
Many of the challenges in TB treatment stem from factors associated with the complex 
environment of granulomas where immune mechanisms may work against the host and favor the 
bacterium. It is becoming increasingly clear that a balance of pro- and anti-inflammatory 
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mechanisms are required for protection, and this may present opportunities for host-directed 
therapies for TB (295).  While this strategy of manipulating the granuloma environment could 
improve bacterial clearance, too much of a change, changing the wrong factor, or a poorly timed 
perturbation in either a pro- or anti-inflammatory direction could be detrimental to the host.  
Combining GranSim-based in silico analyses with experimental macaque-based studies 
enabled us to identify previously unknown relationships between regulatory mechanisms 
contributing to granuloma formation and infection outcomes in TB. This exclusive platform 
allows us to evaluate regulation in granulomas at multiple biological scales simultaneously over 
time. Because of the expedited rate of computational studies, we can simulate thousands of 
independent and stochastic granulomas and examine them in ways that cannot be accomplished 
in vivo. In this study, we identified TGF-β1-regulated mechanisms of granuloma formation, 
function, and bacterial control, including a key role for TGF-β1 regulated cytotoxic T-cell 
responses that led to suppression of effector functions in cytotoxic T cells during infection. Our 
data suggest that depleting TGF-β1 in TB can increase the effector functions of cytotoxic T cells 
without increasing their numbers and improve bacterial clearance without increasing 
inflammation. Thus, therapeutic inhibition of TGF-β1 signaling may improve lesion sterilization 
in TB and represent a new strategy that can be exploited to improve host responses against M. 
tuberculosis. Pirfenidone, a drug that inhibits TGF-β1 signaling, has recently been approved for 
treating pulmonary fibrosis (33) and our results suggest this compound may have potential to 
promote bacterial clearance during TB treatment. Inhibiting TGF-β1 presents clinical challenges 
because of its pleotropic physiologic importance, but our study highlights the importance of 
cytotoxic T cell effector function in bacterial clearance and suggests stimulating cytotoxic T cells 
may also have therapeutic value in treating TB. 
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We also examined whether IL10 and TGF-β1 represent redundant regulatory mechanisms 
at the site of infection and found that these cytokines differentially regulate TB granuloma 
macrophage and T cell responses. Inhibitory effects of IL-10 on macrophages have been 
characterized previously by our group (157, 164) and others (390). Identification of cytotoxic T-
cell regulation by TGF-β1 in this context is novel, but it has been suggested by other works that 
TGF-β1 predominantly regulates lymphoid-derived cells while IL-10 predominantly regulates 
myeloid-derived cells (388, 391). The dichotomous regulation of myeloid and lymphoid cells by 
anti-inflammatory cytokines could help us better understand mycobacterial persistence in TB, 
and has implications that span the spectrum of infectious diseases and immunological disorders. 
Removing TGF-β1 in silico improves bacterial clearance in the granuloma by enabling cytotoxic 
T cell effector functions without increasing potentially pathologic inflammatory responses. TGF-
β1 regulation of cytotoxic T cells differs from IL10, which has been shown to regulate 
macrophage activation. Identifying specific mechanisms of cytokine regulation in  granulomas 
affords better identification of therapeutic targets for TB.  
 
4.4 Materials and Methods: 
4.4.1 Study Design 
 The goal of our study was to assess the role of TGF-β1 in the formation and function of a 
Mycobacterium tuberculosis (Mtb) induced granuloma. We used GranSim, a well-validated 
agent-based model of granuloma formation and function in the lung, along with ex vivo studies 
from NHPs to identify the primary role of TGF-β1 in pulmonary TB infection. We simulated a 
total of 16,500 granulomas: 1337 granulomas for each of the following categories: baseline 
containment, IL10 KO containment, TGF-β1 KO containment, IL10/TGF-β1 double KO 
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containment, IL10 depletion containment, TGF-β1 depletion containment, IL10/TGF-β1 
depletion containment. We simulated 1500 granulomas for each of the following categories: 
baseline dissemination, IL10 depletion dissemination, TGF-β1 depletion dissemination, and 
IL10/TGF-β1 double depletion dissemination. We used multiple granulomas from two 
cynomolgus macaques infected with M. tuberculosis.  
 
4.4.2 Non-human Primate Immunohistochemistry and flow cytometry Studies  
All samples from cynomolgus macaques (Macaca fascicularis) originated from animals 
in ongoing or completed studies, and procedures and husbandry practices were included in 
protocols approved by the University of Pittsburgh’s Institutional Animal Use and Care 
Committee. Flow cytometry was performed on granulomas excised from macaque lung tissue at 
necropsy as previously described (163). Single suspensions were prepared with either a 
Medimachine and Medicon system (BD Biosciences, San Jose, CA) or enzymatically with a 
GentleMACS tissue dissociator (Miltenyi Biotec, San Diego, CA) using the human tumor 
dissociation kit (Miltenyi) with the tubes heated at 37°C for 37 minutes. Cells were stained for 
CD3 (clone SP34-2; BD Bioscience), CD11c (clone S-HCL-3; BD Bioscience), CD163 (clone 
GHI/61; BD Bioscience), TGFβR2 (goat polyclonal; R&D Systems, Minneapolis, MN) and IL-
10R (clone 3F9; Biolegend, San Diego, CA) under BSL3 conditions, fixed and stained for 
granzyme B (clone GB11, BD Biosciences) intracellularly using the Fix-Perm reagents (BD 
Bioscience). Erythrocyte-free whole blood was prepared with PharmLyse RBC lysing buffer 
(BD Bioscience) and similarly stained as gating controls. Cells were acquired on a LSRFortessa 
flow cytometer (BD Bioscience) and data were analyzed with FlowJo (TreeStar Inc, Ashland, 
OR). Cells were gated as indicated in Supplemental Figure A.2 and to be considered for analysis, 
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granulomas needed to have at least 100 CD3+CD11c- (T cells) or CD11c+CD163- (epithelioid 
macrophages (295)) events. For analysis of cell surface receptor abundance, a “relative MFI” 
was calculated by dividing the mean fluorescence intensity (MFI) of the positive population by 
on the negative population’s MFI to account for the differences in each cell population’s 
autofluorescence. 
Immunohistochemistry and confocal microscopy was performed on formalin-fixed 
paraffin-embedded granulomas as previously described (295) Serial 5 mm sections were stained 
with rabbit anti-human TGF-βR1 (Cell Signaling Technologies, Danvers, MA) or IL-10R 
(Millepore, Billerica, MA), labeled with AlexaFluor546-conjugated donkey anti-rabbit 
secondary antibodies (ThermoFisher Scientific, Waltham, MA), and coverslips were mounted 
with DAPI-containing Prolong Gold Mounting medium (Thermo Fisher). Individual overlapping 
microscopic fields were assembled into full-granuloma composites with Photoshop CS6 (Adobe, 
San Jose, CA). For representation in the Figure 4.4, epithelioid macrophage-rich regions were 
identified by their morphologic characteristics (high cytoplasm:nucleus ratio, large lightly-
staining nuclei) and position adjacent to caseum (295)). 
 
4.4.3 In silico Studies 
4.4.3.1 Agent-Based Model   
The simulation studies in this paper are performed using GranSim, a 2D hybrid agent-
based model of M. tuberculosis granuloma formation and function in the lung (157, 159, 162, 
164, 201, 220, 227, 228). GranSim captures molecular, cellular, and tissue scale dynamics of 
granuloma formation. This version of the model accounts for chemical diffusion of chemokines 
and cytokines at the molecular scale (218). At the cellular scale, GranSim accounts for individual 
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cells including four states of macrophages (resting, activated, infected, and chronically infected) 
and three distinct types of T-cells (cytotoxic, regulatory, and IFNγ producing T-cells). 
Interactions between cells are also captured at this scale. At the tissue scale, GranSim accounts 
for chemokine-directed cellular movement. Granuloma formation is an emergent behavior of the 
model. A complete list of model rules can be found at 
http://malthus.micro.med.umich.edu/GranSim. GranSim provides us with a large amount of 
information about TB granulomas. Much of this information is currently impossible to collect in 
vivo. At the molecular scale, GranSim provides chemokine and cytokine concentration gradients 
over the entire simulation space for every time point. At the cellular scale GranSim tracks 
macrophages and T cells along with their respective states and interactions. This information can 
be quantitative, expressed in numbers and concentrations over time, or it can be qualitative in the 
form of spatial snapshots that provide a spatial-temporal perspective. These snapshots can be 
linked to stream a time-lapse movie 
(http://malthus.micro.med.umich.edu/lab/movies/TGFB_GranSim/). A full list of parameters for 
the model is included in the supplementary material (Table A.1). Prior versions of GranSim 
include rules describing the actions of TNFα, IFNγ, and IL10 on macrophages and T-cells (157, 
159, 164, 165, 227-229). In this version of the model, we introduce rules governing the actions 
of TGF-β1 (Figure. 4.6).  
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Figure 4.6: Schematic representation of physiological interactions of TGF-β1 in the hybrid 
multi-scale computational lung model, GranSim. TGF-β1 is secreted in latent form by 
macrophages and regulatory T-cells. Latent TGF-β1 is activated in the presence of macrophages. 
TNFα promotes activation of latent TGF-β1. Active TGF-β1 inhibits T-cell proliferation, 
cytotoxic killing of infected macrophages by cytotoxic T-cells, killing of extracellular bacteria 
by macrophages, and macrophage secretion of TNFα. IFNγ signaling by inflammatory T-cells 
inhibits macrophage secretion of TGF-β1.  These interactions are included as part of the larger 
ABM GranSim. Full rules for GranSim are found at 
http://malthus.micro.med.umich.edu/GranSim. 
 
In the model, TGF-β1 is secreted in latent form by macrophages and regulatory T-cells. 
Secretion of TGF-β1 occurs on the molecular time-step (Table A.1). Latent TGF-β1 activation is 
coarse-grained in our model:  we consider compartments that contain a macrophage to have 
MMP9  (392, 393) (394), which activates latent TGF-β1 in that compartment 
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The fraction of TGF-β1 that is activated is a function of TNFα concentration in the compartment 
where 𝐴𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛!"#$%&'( is the fraction of TGF-β1 activated by the macrophage and 1−
𝐴𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛!"#$%&'( ∗ 𝑇𝑁𝐹𝛼!"#$%&"$#  is the additional amount activated in response to TNFα.  
T-cell proliferation is inhibited by bound active TGF-β1 (𝐵𝑜𝑢𝑛𝑑𝑇𝐺𝐹𝛽1). The 
probability of proliferation is described by the following equation: 
(EQN 2) 




Where 𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"#$$ is the amount of bound active TGF-β1 ( 𝑜𝑢𝑛𝑑𝑇𝐺𝐹𝛽1) that completely 
inhibits proliferation.  
 Active TGF-β1 deregulates cytotoxic T cells, inhibiting their ability to kill infected 
macrophages. The probability of a macrophage killing of extracellular bacteria is reduced up to 
50% by active TGF-β1: 
(EQN 3) 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑚𝑎𝑐𝑟𝑜𝑝ℎ𝑎𝑔𝑒 𝑘𝑖𝑙𝑙𝑠 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎
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Where 𝑀𝑎𝑐𝐾𝑖𝑙𝑙!"#$%&'$ is the baseline probability a macrophage will kill extracellular bacteria 
and 𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"# is the amount of bound active TGF-β1 (𝐵𝑜𝑢𝑛𝑑𝑇𝐺𝐹𝛽1) that fully inhibits 
bacterial killing. 
Macrophage secretion of TNFα is reduced up to 50% by active TGF-β1: 
(EQN 4) 
𝑇𝑁𝐹𝛼 𝑠𝑒𝑐𝑟𝑒𝑡𝑖𝑜𝑛 = 𝑀𝑎𝑐𝑇𝑁𝐹𝛼!"#$! ∗
(𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"# − (0.5 ∗ 𝐵𝑜𝑢𝑛𝑑𝑇𝐺𝐹𝛽1))
𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"#
 
Where 𝑀𝑎𝑐𝑇𝑁𝐹𝛼!"#$! is the baseline TNFα synthesis rate and 𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"# is the amount of 
bound active TGF-β1 (𝐵𝑜𝑢𝑛𝑑𝑇𝐺𝐹𝛽1) that fully inhibits synthesis. 
IFNγ signaling by inflammatory T cells inhibits macrophage secretion of TGF-β1 by 
50% until the macrophage is no longer sensitive to the T-cell signal (Table A.1). These 
interactions are included as part of the larger ABM GranSim. Full rules for GranSim are found at 
http://malthus.micro.med.umich.edu/GranSim. 
 
4.4.3.2 Simulated Granulomas  
For this study we calibrate parameters in GranSim, including TGF-β1 rules, to a NHP 
dataset of granulomas (Figure. 4.7) (42, 163, 294). CFU per granuloma is scaled from 2D to 3D 
for our simulated granuloma for direct comparison with NHP data. Scaling is performed as 
described in prior work (157). This produces our baseline parameters, which satisfy criteria for 
containment (193). Because of the stochastic nature of GranSim, multiple simulations are 
required. In NHPs the median number of granulomas per infected individual is 46 (42). It has 
been shown that each NHP granuloma has a unique trajectory (42). To capture this naturally 
occurring variation, we vary the baseline parameters by 20% and simulate 500 unique 
granulomas each in triplicate (to account for stochastic as well as parametric uncertainty) (229). 
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From these we excluded all disseminating granulomas. The remaining 1337 granulomas make up 
our baseline containment set. At 200 days PI we see about 50% of granulomas sterilize their 
bacterial load. This is consistent with previous studies (157). The granulomas that do not 
sterilize, have a CFU below 2500 at day 200, and have fewer than twice as many CFU at day 200 
than they did at day 100 PI.  An occasional outlier in this set will progress to dissemination. We 
repeat this same process for a parameter set representing dissemination to generate a baseline 







Figure 4.7: Model quantitatively and qualitatively recapitulates non-human primate 
granuloma dataset. A) CFU per granuloma of simulated granulomas scaled to 3D (see methods) 
and granulomas extracted from non-human primates at different time points (42, 43, 56, 294). 
Black lines indicate CFU/granuloma over time for 256 individual representative simulations of 
1500 total simulations. Blue dots indicate CFU/granuloma of granulomas extracted from non-
human primates at different time points (190). B) Simulated granuloma captures spatial 
organization of granulomas from non-human primates. Simulated granuloma showing resting 
macrophages (green), infected macrophages (orange), chronically infected macrophages (red), 
activated macrophages (blue), Cytotoxic T cells (magenta), IFNγ producing T cells (pink), and 
regulatory T cells (cyan) at 100 days PI. C) Snapshot of the same simulated granuloma from 
panel B showing localization of latent TGF-β1. D) Snapshot of the same simulated granuloma 
from panel B showing localization of active TGF-β1. 
 
4.4.3.3 Virtual Deletion Studies 
 For our knockout studies we use our baseline containment granuloma set. We re-simulate 
them in the absence of different cytokines from day 0. We do this by setting the initial values of 
specified cytokines to be zero as well as preventing any production of these cytokines throughout 




















the duration of the simulation. These simulations become our virtual IL10 knockout, TGF-β1 
knockout, and IL10/TGF-β1 double knockout sets (Figure. 4.1).  
 
4.4.3.4 Virtual Depletion Studies 
 For our first set of depletion studies we take our virtual baseline containment set and re-
simulate each granuloma for 200 days. At day 200 PI we block secretion of a cytokine(s), 
causing concentrations in a granuloma to (rapidly) approach zero, and continue to simulate for an 
additional 200 days. These simulations become our IL10 depletion, TGF-β1 depletion, and 
IL10/TGF-β1 double depletion sets for contained granulomas, respectively (Figure. 4.5A-B). We 
also preform depletion studies on our virtual knockout dissemination set. We re-simulate the 
depletion set for 200 days. At day 200 PI we block secretion of different cytokines and continue 
to simulate for an additional 200 days. These simulations in turn become our IL10 depletion, 
TGF-β1 depletion, and IL10/TGF-β1 double depletion sets for disseminating granulomas, 
respectively (Figure. 4.5C-D). 
 
4.4.3.5 Uncertainty and Sensitivity Analysis 
Uncertainty analysis allows us to quantify how variation in parameters values drives 
variation in model output (229). Parameter variation can occur at the molecular and cellular 
scales and can affect outputs at the molecular, cellular and tissue scales. Often variation in 
parameter values at one scale can influence model outcomes at another scale a phenomenon 
referred to as intra-model influence (229). Uncertainty analysis enables us to observe model 
behavior given a wide value range for each parameter. We vary parameters over two orders of 
magnitude and compare how these input variations affect model outputs. In this work we use the 
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Latin hypercube sampling algorithm to sample from the parameter ranges and generate 500 
unique parameter sets (229). We describe this analysis as spanning the full parameter space, and 
simulate each set in triplicate to account for aleatory uncertainty (229). We also preform 
uncertainty analysis where we vary only certain parameters to see how their influence on model 
outcomes compares. Sensitivity analyses allow us to identify which parameters have a significant 
influence on model outcomes and the extent of that influence (229, 344). We use partial rank 
correlation coefficients (PRCCs) to identify the sensitivity of each output to each parameter 
(229). PRCC values range from -1 to +1, indicating the non-linear correlation between a 
parameter and model output. PRCC values are differentiated using Student’s T-test of 
significance. PRCC values are considered significant with a p-value less than 0.01.  
 
4.4.4 Statistical Analysis 
 Student’s T-tests were performed to compare significant difference between means 






Fibrosis in TB 
 
5.1 Introduction 
 Granulomas are highly organized immunological structures that form around infectious 
agents (47, 295, 395). They are the major pathologic feature of pulmonary Mycobacterium 
tuberculosis (Mtb) infection; affecting one in three people worldwide (369). Ten percent of Mtb 
infections will result in active, contagious tuberculosis disease (TB) (369). There is currently no 
curative therapy for TB. Antibiotic treatment can induce a state of latency, which is not 
symptomatic or infectious, but can reactivate if the host immune system becomes weakened (36-
38, 46, 57, 225, 285, 288, 292, 396).  Patients with latent TB have a one in ten chance of 
experiencing reactivation in their lifetimes (369), which is even higher if HIV-1 is present [ref]. 
The dense cellular structure of granulomas can also make therapeutic treatment of Mtb infection 
difficult by restricting access of drugs to live bacteria (192, 202, 225, 309). Mtb induced 
granulomas simultaneously isolate the bacteria from the surrounding unaffected tissue and 
restrict immune clearance of the infection. Understanding the formation and function of Mtb 
induced granulomas is the key to identifying therapeutic treatments that promote access of drugs 
and immune cells to persistent bacteria, while maintaining the integrity of surrounding tissue.  
 Granulomas can be categorized by size, shape, number of colony forming units (CFU), or 
morphology (40, 45, 56, 69, 219, 295, 397, 398). Granulomas are unique with each having its 
own trajectory (43), but there are common morphological classifications.  These include: 
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caseous, having a necrotic core of dead tissue surrounded by a cuff of live cells, dense cellular, 
having no distinguishable core but rather cells throughout, suppurative, having a large amount of 
neutrophil infiltration, and fibrotic, having a cuff of collagen surrounding the exterior of the 
granuloma (43, 163) which eventually calcifies, leading to the final stage known as tubercles 
(Figure 5.1). This last type of granuloma has been poorly studied and the processes of how and 
when fibrosis occurs, as well as how it is regulated, are not known.   
Fibrosis is a dysregulation of the wound healing process and thus fibrotic granulomas are 
considered to be healing (9, 15, 49, 62, 395, 398, 399). They are typically found during latent 
TB.  Different granuloma classes do not necessarily correlate with a specific host disease state, 
and can be found simultaneously within a single individual. Because the development of 
different classes of granuloma cannot be explained on a host level, factors leading to these 
differences must be the result of environmental differences at the lesion scale. Identifying 
specific immunological mechanisms that drive the formation of different granulomas is key to 
understanding granuloma formation and function in a therapeutic context.  
 Within the classification of fibrotic granulomas exist multiple morphologies that are 
associated with antibiotic treatment status of the presenting individual (Figure 5.1). Our 
understanding of fibrotic granuloma morphology is due in large part to work preformed in non-
human primates (NHPs) (49). Non-human primates are a good model for studying pulmonary TB 
because they develop granulomas much like adult humans. NHPs exhibit two primary fibrotic 
granuloma morphologies (400). The first is peripheral fibrosis found in the form of a fibrotic cuff 
surrounding the perimeter of lesions (49, 400). This fibrotic cuff is thought to contribute to lesion 
containment and restrict disease dissemination (49, 400) (Figure 5.1 A, B). The second form of 
fibrotic lesion has a collagenous structure throughout a lesion, and can be referred to as centrally 
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fibrotic (49, 400) (Figure 5.1 E). These lesions look more like scars than contained granulomas 
and are often associated with sterilization of the lesion. Centrally fibrotic lesions occur more 
frequently following antibiotic treatment than prior to treatment (400). Joanne Flynn’s group at 
the University of Pittsburgh has recently characterized the histology of NHP fibrotic lesions (49) 
and additional images were provided to us  (Figure 5.1).  
 
Figure 5.1 Tuberculous granulomas show signs of TGFβ-driven fibrosis. Top panels feature 
granulomas stained for collagen I (red), phosphorylated SMAD-2/3 (green), and CD163 
(blue). Bottom panels feature granulomas stained for TGFβ (red), L-TGFβ (green), and αSMA 
(blue). Magnification ×200.A) Granuloma from animal with active disease. B) Granuloma from 
animals following two months of antibiotic treatment. C, D) Granulomas are from animals with 
active disease.  
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Fibroblasts are responsible for proliferating into wounds where they differentiate into 
myofibroblasts and secrete extra cellular matrix proteins (ECM) during the process of fibrosis 
(88, 143, 146, 148, 155, 156). The ECM secreted by myofibroblasts provides a substrate for re-
epithelialization of the wound. Myofibroblasts also have a contractile phenotype, which enables 
them to close the wound gap and further restore tissue integrity (100, 231, 240, 317, 352, 401). 
Granulomas are different than traditional wounds because they involve a highly dense organized 
structure that serves to wall off an irritant or infection rather than to restore tissue architecture. 
Granulomas have a unique architecture that differs dramatically from surrounding tissue. 
Fibroblasts have been identified by histology studies to be present in granulomas but how they 
arrive there and what purpose they serve is not well understood (49). Certainly the presence of 
fibrosis is an indication of fibroblast activity, but what stimulates them in the context of the 
granuloma is still unknown. 
High levels of TGF-β1 have been associated with many fibrotic processes (62, 64, 148, 
385) and also in fibrotic granulomas (49). TGF-β1 is known to play an important role in driving 
fibroblast proliferation, differentiation, and the development of fibrotic tissue in other contexts, 
however its role in granuloma formation and function has not been fully characterized (49, 64, 
90, 385, 402, 403). TGF-β1 stimulates fibroblast synthesis of α-smooth muscle actin (αSMA) 
and collagen secreted. αSMA is an indicator of fibroblast to myofibroblast differentiation (100, 
105, 169, 231, 352, 401, 404). Myofibroblasts secrete large amounts of collagen, which are 
synonymous with fibrosis and can be seen in fibrotic granulomas (49, 83, 169). TGF-β1 is an 
important and possibly even necessary driver of fibrosis, however, whether it is sufficient for 
inducing fibrotic granuloma formation has not been determined.   
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While TGF-β1 signaling has been shown to promote fibrotic outcomes, IL10 has been 
associated with improved epithelial integrity and inhibition of TGF-β1 synthesis during 
pulmonary fibrosis (61, 79, 181, 405). IL10 acts on fibroblasts to counteract TGF-β1 signaling 
by blocking adhesion signaling, a requirement for efficient transmission of the TGF-β1 signal 
cascade. IL10 is present throughout the granuloma (295). Its role in macrophage activation 
during TB has been explored (157, 158), but its influence on fibroblasts in this context has not 
been characterized. The regulation of fibroblasts by TGF-β1 and IL10 may be the key to 
understanding the formation of fibrotic granulomas.  
In this work we develop next-generation GranSim, a hybrid multi-scale model of 
granuloma formation and function, to include fibroblasts and molecular scale TGF-β1 signaling 
dynamics. We calibrate and validate this model against NHP studies of fibrotic granuloma 
morphology (49). With this model we can recapitulate the formation of fibrotic granulomas, and 
identify key mechanisms driving their formation. This model enables us to explore the role of 
fibroblasts in granulomas and predict mechanisms leading to fibrotic granuloma formation.  
  
5.2 Results 
5.2.1 Fibrosis morphology in granuloma simulation 
  In this section we track  simulated morphological changes of developing fibrotic 
granulomas over time. In these studies we simulate granulomas for 200 days. We take snapshots 
at 5 time points: day 50 post infection (PI), day 100 PI, day 125 PI, day 150 PI, and day 200 PI in 
order to capture the progression of fibrosis in a single granuloma. We examine many model 
outputs including:  total cell localization (Figure 5.2), fibroblast and myofibroblast specific 
localization (Figure 5.3), and collagen localization (Figure 5.4) as granulomas progress. We 
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compare morphology of simulated granulomas to histology sections of fibrotic granulomas from 
Mtb infected NHPs (see Figure 5.1). Collagen in the simulated granulomas recapitulates the 
NHP histology (Figure 5.4). We find that GranSim can simulate the formation of fibrotic 
granulomas that qualitatively match sections from NHP samples (49). Because initial time of 
granuloma formation cannot be identified in NHPs, it is impossible to compare specific time 
points between simulation and histology. 
 
 
Figure 5.2: Simulations of cellular localization and granuloma morphology over time. 
Representative images of a single granuloma over time generated with baseline parameter set 
(Table. 5.1). Cells are represented by different colors as follows: resting macrophages are green, 
activated macrophages are blue, infected macrophages are orange, chronically infected 
macrophages are red, IFNγ producing T-cells are pink, cytotoxic T cells are violet, regulatory T 
cells are cyan, fibroblasts are maroon, and myofibroblasts are gold. Caseum is represented in 
these images as brown compartments. The entire simulation space shown is representative of 




 Over the course of time following infection we observe the formation of a caseus necrotic 
granuloma (Figure 5.2). This granuloma becomes fibrotic which is evidenced by the presence of 
fibroblasts and myfibroblasts surrounding the lesion. The localization of fibroblasts and 
myofibroblasts is comparable to NHP granulomas (Figure 5.1 B, D). In this simulation we 
observe primarily peripheral localization of fibroblasts and myofibroblasts (Figures 5.A B, 5.1, 
5.2) with some penetration into the center of the lesion by day 200 PI (Figures 5.A F, 5.1, 5.2).  
 
Figure 5.3: Localization of fibroblasts and myofibroblasts from a simulated fibrotic 
granuloma over time. In this representative simulation (same simulation as Figure 5.2) 
fibroblasts are represented as maroon, and myofibroblasts are represented as gold. As time 
progresses the number of both fibroblasts and myofibroblasts increases. They surround and 
penetrate the granuloma beginning at about 125 day PI.  
 
 
 Similar to the localization of fibroblasts and myofibroblasts, collagen is also initially 
located on the periphery of the granuloma and is deposited in the center and fibroblast and 
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myofibroblasts penetrate the lesion (Figure 5.4). The peripheral (5.A C) and central (Figure 5.1 
A, E) collagen localization is also reflected in the NHP granulomas.  
 
Figure 5.4. Collagen localization in a simulated fibrotic granuloma over time. Collagen 
concentration is represented in the above images with red representing the highest concentration 
and blue representing no collagen (same simulation as Figure 5.2). Collagen formation is first 
visible at day 100 PI and it continues to spread throughout the duration of the simulation, until 
day 200 PI when it covers the entire simulation space.  
 
 
5.2.2 Cytokine localization in fibrotic granulomas 
We also compared the localization of cytokines between simulated granulomas and NHP 
histology sections. We examine the localization of TNFα (Figure 5.5), IL10 (Figure 5.6), active 
TGF-β1 (Figure 5.7), and latent TGF-β1 (Figure 5.8) in the progressing granulomas. The 
localization of TNFα and IL10 is consistent with previously published simulations of GranSim. 
TNFα stays relatively localized to the granuloma with some pockets that disseminate from the 
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center of the lesion. These pockets of high TNFα concentration are transient and exist in the 
same location only for a short amount of time (Figure 5.5). IL10 also stays somewhat concentric 
to the granuloma. The amount of IL10 in the simulation decreases as the number of fibroblasts 
and myofibroblasts in the simulation increase. IL10 concentration appears to be inversely 
correlated with fibrosis.  
 
Figure 5.5. TNFα localization in a simulated fibrotic granuloma over time. TNFα 
concentration is represented in the above images for a single representative granuloma over time 
with red being the highest concentration and blue being no TNFα (same simulation as Figure 
5.2). TNFα is visible from the time of infection. TNFα stays concentric to the granuloma 





Figure 5.6. IL10 localization in a simulated fibrotic granuloma over time. IL10 
concentration is represented in the above images for a single representative granuloma over time 
with red being the highest concentration and blue being no IL10 (same simulation as Figure 5.2). 
IL10 is visible early in infection and continues be present throughout the infection.  
 
Localization of active and latent TGF-β1 in simulated granulomas qualitatively matches 
NHP granulomas (Figure 5.1) (49). Active TGF-β1 is visible early in infection and continues be 
present throughout the infection (Figure 5.7). Active TGF-β1 is somewhat concentric to the 
granuloma prior to day 125 PI. As the granuloma becomes more fibrotic active TGF-β1 spreads 
and becomes more prevalent. The highest concentrations of active TGF-β1 are found on the 
periphery of the granuloma, consistant with NHP data (Figure 5.1 B, D, F) Late in infection the 
concentration in the center of the granuloma is depleted. Latent TGF-β1 is visible early in 
infection and continues be present throughout the course of infection. As is the case for NHP 
granulomas, latent TGF- β1 is prevalent throughout the granuloma starting at a relatively early 
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time post infections (Figures 5.A, 5.7). Latent TGF-β1 is somewhat concentric to the granuloma 
very early in infection but is rapidly distributed throughout the simulation space. Latent TGF-β1 
is present throughout the simulation space for the majority of the simulation. 
 
 
Figure 5.7. Active TGF-β1 localization in a simulated fibrotic granuloma over time. Active 
TGF-β1 concentration is represented in the above images for a single representative granuloma 




Figure 5.8. Latent TGF-β1 localization in a simulated fibrotic granuloma over time. Latent 
TGF-β1 concentration is represented in the above images for a single representative granuloma 
over time with red being the highest concentration and blue being no latent TGF-β1. Latent 
TGF-β1 is visible early in infection and continues be present throughout the infection.  
 
5.2.3 Relationship between development of fibrotic lesions and high bacterial burden 
 In addition to qualitative assessment of simulated granulomas, we preformed uncertainty 
analysis to identify the spectrum of possible fibrotic outcomes in our simulated granulomas. We 
simulated 500 granulomas 3 times each, our baseline granuloma set, and to examine the full 
spectrum of possible outcomes. With this model we are able to generate a spectrum of fibrotic 
granulomas (Figure 5.9) with differing levels of fibrosis based on the numbers of fibroblasts and 
myofibroblasts present.  Interestingly, not only the levels of fibrotic cells present change, but 
also the timing of onset of fibrosis. We next explore what drives these differences through 
statistical analysis of the model using US/A.  
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Figure 5.9 Fibroblast and myofibroblast numbers in 1500 simulated granulomas over time. 
Each line represents and individual granuloma from the baseline set (Table 5.1). A) Fibroblasts 
per granuloma over 400 days PI. B) Myofibroblasts per granuloma over 400 days PI. Parameter 
values from Table 5.1. 
 
5.2.4 Mechanisms driving fibrotic granuloma formation in silico 
 We applied PRCC sensitivity analysis to our baseline granuloma set (Figure 5.9) to 
identify key mechanisms driving fibrotic outcomes. Fibrotic granulomas are characterized by the 
presence of fibroblasts and myofibroblasts as well as collagen. We found that nine model 
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parameters significantly influence the number of fibroblasts at day 300 PI (Table 5.1). Among 
these parameters the probability that a fibroblast will move had the greatest correlation to 
fibroblast number. This strong correlation suggests that fibroblasts are highly sensitive to local 
environments and that the more they move the more they are able to find profibrotic 
environments. We found seven parameters significantly influenced the number of myofibroblasts 
and collagen in the simulation at day 300 PI. Of these parameters the degradation rate of αSMA 
and fibroblast sensitivity to IL-10 had the strongest influence on myofibroblast number at day 
400 PI (p<0.001 for Fisher’s z test). Collagen is a product of myofibroblasts. We saw that 
















Table 5.1 Significant PRCC values for parameters driving cell number at day 300 PI. p > 0.001 
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5.2.5 Relationship between fibrotic granulomas and bacterial burden 
 As previously described in this chapter, fibrotic granulomas come in two primary forms. 
Some fibrotic granulomas have a cuff of fibrosis surrounding the lesion. Other granulomas have 
are fibrotic throughout. Solid fibrotic granulomas are more commonly seen following antibiotic 
treatment and are associated with sterilization. Fibrotic granulomas that were simulated using 
GranSim most commonly exhibit the peripheral fibrosis, and they  also typically have higher 
bacterial numbers (data not shown). In some cases GranSim produces  fibrotic granulomas that 
have fibrosis throughout the lesion. These granulomas differ, however, from those seen in non-
human primates as they too tend to have very high bacterial numbers (Figure 5.10). As shown in 
Figure 5.10 B, even granulomas with centrally located fibrotic cells tend to have substantial 
caseum and bacterial burden. 
 
Figure 5.10 Snapshot of a simulated granuloma exhibiting central fibrosis at 150 days post 
infection. A) Snapshot of simulated granuloma showing the localization of all cell types. 
Myofibroblasts can be seen in the center of the lesion. Cells are represented by different colors as 
follows: resting macrophages are green, activated macrophages are blue, infected macrophages 
are orange, chronically infected macrophages are red, IFNγ producing T-cells are pink, cytotoxic 
T cells are violet, regulatory T cells are cyan, fibroblasts are maroon, and myofibroblasts are 
gold. B) Snapshot of simulated granuloma displaying only fibroblasts, myofibroblasts, and 




 In this work we have examined the simulated morphology of fibrotic granulomas and 
identified key mechanisms driving these morphologies. We found that both fibroblast and 
myofibroblast cell numbers at day 400 PI positively correlated with the amount TGF-β1 
activated by a macrophage in a given compartment. This result indicates that the prevalence of 
fibroblasts and myofibroblasts in a granuloma is sensitive to the amount of active TGF-β1 
available to them. We saw no significant correlation with the number of fibroblasts or 
myofibroblasts with the total amount of active TGF-β1 in simulated fibrotic granulomas. This 
data is consistent with NHP data showing high concentrations of TGF-β1 throughout both 
fibrotic and non-fibrotic granulomas (49). Together these observations indicated that total TGF-
β1 levels in the granuloma is a necessary but not sufficient condition for inducing fibrotic 
outcomes.  
Concentrations of active TGF-β1 in specific areas of a granuloma may be the key to 
whether or not a cell will proliferate and/or differentiate. The overall availability of active TGF-
β1 in the granuloma does not necessarily influence the number of fibrotic cells, nor does it 
enable us to predict whether a granuloma will become fibrotic, however the concentration of 
active TGF-β1 in the vicinity of fibroblasts may be a driving factor for why some granulomas 
become fibrotic. This scale effect is currently under investigation.  
 In addition to the amount of TGF-β1 activated by a macrophage in a given compartment, 
the probability that a fibroblast will move has a significant and positive correlation to the number 
of fibroblasts in a given granuloma. This result suggests that fibroblast movement promotes 
fibroblast proliferation. One possible explanation for this is that fibroblasts are very sensitive to 
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local cytokine milieu. Movement enables them to sample many different cytokine environments. 
The more a fibroblast is able to move the better chance it has of finding a cytokine environment 
that is permissive to proliferation. TGF-β1 and IL10 concentrations affect the ability of 
fibroblasts to proliferate and this result further emphasizes that local cytokine concentrations, 
and not the overall environment of the granuloma, have a major influence on fibroblast behavior. 
Again, this scale effect is currently being explored.  
 These results provide challenges in determining what drives fibrotic granuloma formation 
because they indicate that lesion scale outputs are not ideal for studying the behavior of 
fibroblasts and myofibroblasts in the context of the granuloma. In order to better evaluate what 
drives formation of fibrotic granulomas future studies will require quantifiable spatial outputs. It 
may be the case that heterogeneity of granuloma environments is key to both whether and where 
fibrosis occurs. One way to better evaluate whether this is occurring would be to quantify the 
number of compartments within the simulation space that have high, medium or low 
concentrations of latent TGF-β1, active TGF-β1, IL10 and the ratios between these cytokines. 
Due to the volatility of localized cytokine concentrations, these outputs will need to be tracked 
over time and will require the use of a computational model like GranSim. 
 As I have alluded to in this chapter, GranSim is more successful at recapitulating the 
morphology of peripheral fibrotic granulomas than central fibrosis. This may be due in part to a 
lack of antibiotic treatment simulated in our system as compared to the NHP, where antibiotics 
were used (224).  They found that solid fibrotic granulomas have been found more commonly 
following antibiotic treatment, which may be necessary for eliminating the surviving bacteria in 
those granulomas. It is also possible that the architecture of GranSim may make if difficult to 
differentiate between fibrotic granuloma types. Lack of epithelial cells and additional tissue 
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mediators may make it difficult to recapitulate all forms of fibrosis, and to differentiate between 
them. 
 In future work we would like to preform computational histology, applying quantitative 
spatial metrics to our two dimensional simulation snapshots. We would like to further explore 
the influence of specific local cytokine environments on the development of fibrotic granulomas.  
Additional mechanisms including the structural properties of collagen and enzymes that remodel 
collagen architecture would improve our ability to characterize fibrotic granulomas.  
5.4 Materials and Methods 
 In this work we take a systems biology approach to understanding the formation of 
fibrotic granulomas and the role of TGF-β1 in this process. We combine in silico studies with in 
vitro and in vivo data to calibrate and validate our hypotheses wherever possible.  
 
5.4.1 Agent based model (GranSim) 
In this work we use GranSim, our 2D hybrid agent-based model of M. tuberculosis 
granuloma formation and function in the lung (157, 159, 162, 164, 201, 220, 227, 228). GranSim 
has been continuously updated and validated against experimental data since 2003. It captures 
the molecular, cellular, and tissue scale dynamics of granuloma formation and function in the 
lung. Gransim includes cellular, molecular, and tissue scale dynamics. At the molecular scale 
this version of GranSim includes diffusion of chemokines and cytokines (218), and fine grained 
fibroblast specific TGF-β1 receptor/ligand signaling dynamics. These mechanisms are described 
by partial differential equations (PDEs) and ordinary differential equations (ODEs) respectively. 
Both the diffusion and TGF-β1 signaling mechanisms have been described previously (83, 169, 
218). At the cellular scale, GranSim accounts for discrete cellular agents whose actions are 
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governed by model rules. A full list of GranSim’s rules can be found at 
http://malthus.micro.med.umich.edu/GranSim. Within this updated version of GranSim there are 
four macrophage states (resting, activated, infected, and chronically infected) and three distinct 
T-cell types (cytotoxic, regulatory, and IFNγ producing T-cells). This model also include two 
states of fibroblasts (activated fibroblast and myofibroblast), which were imported from a 
previously published model (83). The cellular scale captures interaction between these agent 
groups, and chemokine-directed cellular movement.  
Granuloma formation occurs at the tissue scale and is an emergent behavior of the model. 
This means that granuloma formation is the product of individual agents actions and not a 
higher-level architecture. The model produces reams of information about TB granulomas, most 
of which is impossible to acquire from animal studies. Outputs of the model include: chemokine 
and cytokine concentration gradients over the entire simulation space for every time point, 
details of the position and state for all agents within the simulation, and overall morphological 
depictions of the simulation space. This information can be quantitative or qualitative and can be 
directly compared to data from in vitro and in vivo studies. Snapshots of the simulation 
environment can be linked to produce time-lapse movies 
(http://malthus.micro.med.umich.edu/lab/movies/TGFB_GranSim/).  
 
5.4.2 Fibroblast and myofibroblast agents 
 Fibroblasts from the previously described co-culture model (see Chapter 3) (83) were 
incorporated into GranSim as a unique agent class. This class contains both fibroblasts and the 
differentiated myofibroblasts. These cells maintain their molecular scale TGF-β1 signaling 
dynamics (as described in Chapter 3 and below). Additional rules governing fibroblast and 
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myofibroblast behavior have been incorporated into GranSim. Fibroblasts can proliferate in 
GranSim if they have bound a sufficient amount of TGF-β1 in their lifetime (amount of TGF-β1 
required for fibroblast proliferation), have not bound more than a maximum amount of IL10 
(molecules of IL10 that inhibits fibroblast proliferation/differentiation), and are present in a 
sufficient concentration of TNFα (molecules of TNFα necessary for fibroblast 
proliferation/differentiation). Once a fibroblast has proliferated, it cannot attempt proliferation 
again for 24 hours. Fibroblasts have a probability of moving randomly into an available grid 
compartment if one is available in their Moore neighborhood (the eight compartments that share 
and edge with the compartment they occupy) (probability a fibroblast will move). Fibroblasts 
bind and secrete TGF-β1 according to the equations described previously (see Chapter 2)(169). 
In this work fibroblasts do not bind PGE2 because epithelial cells, the primary source of PGE2 in 
the lungs, are not included in this version of GranSim. In place of PGE2, fibroblasts bind and are 
inhibited by IL10, which works through the same mechanism as PGE2, to inhibit fibroblast 
adhesion signaling.  Fibroblasts can differentiate into myofibroblasts if:  they have not 
proliferated in the current time step, have bound a sufficient amount of TGF-β1 in their lifetime 
(amount of TGF-β1 required for myofibroblast differentiation), have not bound more than a 
maximum amount of IL10 (molecules of IL10 that inhibits fibroblast 
proliferation/differentiation), and are present in a sufficient concentration of TNFα (molecules of 
TNFα necessary for fibroblast proliferation/differentiation). Because GranSim models 
granuloma formation and not the surrounding tissue a signal is necessary to inform fibroblasts 
they have arrived at the site of injury/infection. We use TNFα as a proxy for all the cytokines 
that signal tissue damage to a fibroblast. Myofibroblasts maintain TGF-β1 binding and receptor 
ligand signaling but no longer secrete TGF-β1. Myofibroblasts have chemotactic movement 
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within the simulation space (they are sensitive to the pro inflammatory chemokine milieu). They 
also secrete collagen according to the parameter collagen secretion (collagen synthesis rate), and 
synthesize αSMA. Myofibroblasts have a probability of undergoing apoptosis (probability of 
apoptosis) at each time step.  
 
5.4.3 Fibroblast TGF-β1 signaling dynamics 
 Fibroblast TGF-β1 signaling dynamics are described in detail in Chapter 2 (169). 
Because GranSim does not contain PGE2, IL10 is used as an inhibitor of TGF-β1 signaling in 
fibroblasts (79, 185, 186, 406). IL10 acts in the same way as PGE2 by inhibiting the adhesion-
signaling cascade necessary for effective TGF-β1 signal transduction (168, 234).  
 
5.4.4 Hybrid multi-scale model 
In this work we build upon the existing hybrid- multi-scale model GranSim. We 
introduce a new class of cellular scale agents, and molecular scale TGF-β1 receptor-ligand 
signaling within those agents. Model linking techniques have been described in detail in previous 
works (157-159, 218).  In this work we link new cellular and molecular scale attributes into the 
existing model primarily through TGF-β1 and IL10. Fibroblasts secrete latent TGF-β1, which 
exists in the simulation environment, and is activated by macrophages. Active TGF-β1 is bound 
by many cell types (see Chapter 4). Fibroblasts themselves bind active TGF-β1 linking them to 
macrophages and regulatory T cells. Fibroblasts bind IL10, which is also secreted by 
macrophages and regulatory T cells, and works to inhibit TGF-β1 signaling. Fibroblasts are 
sensitive to TNFα secreted by activated macrophages. Cellular and molecular scales within the 
model are linked when cytokines regulated at the molecular scale influence the states and 
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behaviors of agents at the cellular scale. Thus, the cellular and molecular scale aspects of the 
model are connected by extracellular cytokine and agent behaviors (Figures 4-7). 
 
5.4.5 Hybrid multi-scale model simulations 
 In this work we simulated 500 granulomas 3 times each with large parameter value 
ranges (Table 5.1). These 1500 simulations allowed us explore the full parameter space and 
explore all possible outcomes model outcomes including biologically infeasible outcomes. From 
these simulations we identified a baseline parameter set for a fibrotic granuloma with CFU that 
stabilizes over time. This baseline granuloma set is used for uncertainty and sensitivity analysis 
studies. We selected a representative granuloma from our baseline set for comparative histology 
studies. We present simulation snapshot of the representative granuloma at 50, 100, 125, 150, 
and 200 days PI in order to sufficiently capture the onset and progression of fibrosis. Because 
development of fibrosis typically occurs weeks, months and even years following infection, we 
did not show early PI snapshots.   
 
5.4.6 Uncertainty and sensitivity analysis 
Uncertainty and sensitivity analysis can be applied to the information provided by 
GranSim in order to quantify how variation in parameter values contributes to variation in model 
output (229). This analysis can highlight key mechanisms responsible for different model 
outcomes or predict key components of the biological system that are from the model. Because 
GranSim is multi-scale, parameters that contribute specifically to molecular, cellular, or tissue 
scale mechanisms, may affect outputs at other scales. When parameter values at one scale can 
influence model outcomes at another scale it is described as intra-model influence (229). With 
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uncertainty analysis, we can use the Latin hypercube sampling algorithm to sample from large 
parameter ranges, and model behavior given a wide value range for each parameter (229). We 
consider this analysis to span the full parameter space. In this work we simulate each parameter 
set chosen though LHS three times to account for aleatory uncertainty (229). We also preform 
sensitivity analyses, which allow us to identify parameters that have a significant influence on 
individual model outcomes and the extent of their influence on each outcome (229, 344). We use 
partial rank correlation coefficients (PRCCs) to determine how sensitive a given output is to each 
parameter (229). PRCC values range from -1 to +1, indicating the non-linear correlation between 
a parameter and model output. PRCC values are differentiated using Student’s T-test of 
significance. PRCC values are considered significant with a p-value less than 0.01. Fishers Z test 
is applied to determine if PRCC values are significantly different form each other P-value < 
0.001. 
 
Table 5.1.  Parameters used for wide parameter sweep  
Parameter name Value or range Units 
Mtb parameters 
Growth rate intracellular Mtb 1.003 cells 
Growth rate extracellular Mtb 1.001 cells 
Death rate of extracellular Mtb 
in caseum 1.5 cells 
Core model parameters 
Diffusion time step 60 seconds 
Molecular time step 6 seconds 
Diffusion smoother time step 1.2 seconds 
Number of smoother steps 0 n/a 
Number of host cells causing 
caseation 10 n/a 
Time to heal caseation [1642, 2462] days 
Threshold for TNFα induced 
apoptosis [1393, 2089] molecules 
Rate of TNFα induced apoptosis [1.17e-6, 1.76e-6] 1/seconds 
Minimum number of molecules 
allowing chemotaxis [0.514, 0.77] molecules 
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Maximum number of molecules 
allowing chemotaxis [374, 562] molecules 
Diffusivity of TNFα 5.2e-8 cm2/s 
Diffusivity of IL10 5.2e-8 cm2/s 
Diffusivity of active TGF-β1 5.2e-8 cm2/s 
Diffusivity of chemokines 5.2e-8 cm2/s 
Degradation rate of TNFα 0.00158 molecules/molecular time step 
Degradation rate of IL10 0.00048 molecules/molecular time step 
Degradation rate of inactive 
TGF-β1 [9.28e-6, 1.39e-5] 
molecules/molecular time 
step 
Degradation rate of active TGF-




Fraction of grid compartments 
with a macrophage [0.024, 0.036] n/a 
Number of time steps before a 
resting macrophage can move 2 n/a 
Number of time steps before an 
activated macrophage can move 16 n/a 
Number of time steps before an 
infected macrophage can move [112, 168] n/a 
Synthesis rate of TNFα 
(𝑀𝑎𝑐𝑇𝑁𝐹𝛼!"#$!) 
1.5 molecules/diffusion time step 
Synthesis rate of CCL2 6 molecules/diffusion time step 
Synthesis rate of CCL5 6 molecules/diffusion time step 
Synthesis rate of CCL9 12 molecules/diffusion time step 
Synthesis rate of IL10 by an 
activated macrophage 0.3 molecules/diffusion time step 
Synthesis rate of IL10 by and 
infected macrophage 0.02 molecules/diffusion time step 
Synthesis rate of Inactive TGF-
β1 by macrophages [0.0001, 0.01] molecules/diffusion time step 
Number of bacteria a resting 
macrophage can phagocytose 1 n/a 
Probability of resting 
macrophage killing bacteria 
(𝑀𝑎𝑐𝐾𝑖𝑙𝑙!"#$%&'$) 
[0.23, 0.35] n/a 
Threshold for intracellular 
bacteria causing chronically 
infected macrophages 
[8,12] bacteria 
Threshold for intracellular 
bacteria causing macrophage to 
burst 
[13, 20] bacteria 
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Number of bacteria an activated 
macrophage can phagocytose [4, 6] n/a 
Fraction of inactive TGF-β1 
activated by a mac 
(𝐴𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛!"#$%&'() 
[1e-6, 1] n/a 
Amount of TGF-β1 that inhibits 
macrophages 
(𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"#) 
[1e-6, 1] molecules 
Fraction of active TGF-β1 in a 
compartment bound by a mac [1e-6, 1] n/a 
Probability of an activated 
macrophage healing a caseated 
compartment in its Moore 
neighborhood 
[0.0128, 0.0129] n/a 
T cell parameters 
Probability of a T cell moving to 
the same compartment as a 
macrophage 
[0.05, 0.08] n/a 
Probability of a T cell moving to 
the same compartment as a T 
cell 
0.08 n/a 
Synthesis rate of TNFα by 
IFNγ-producing T-cell 0.15 molecules/diffusion time step 
IFNγ-producing T-cell 
probability of inducing Fas/FasL 
mediated apoptosis 
[0.0152, 0.0228] n/a 
Probability of IFNγ-producing 
T-cell to secrete TNFα [0.048, 0.072] n/a 
Probability of IFNγ-producing 
T-cell to secrete TNFα [0.288, 0.432] n/a 
Synthesis rate of TNFα by 
cytotoxic T-cell 0.015 molecules/diffusion time step 
Probability of a cytotoxic T-cell 
killing a macrophage [0.012, 0.18] n/a 
Probability of a cytotoxic T-cell 
killing a macrophage and all 
associated Mtb 
[0.61, 0.91] n/a 
Probability of cytotoxic T-cell to 
secrete TNFα [0.056, 0.084] n/a 
Synthesis rate of IL10 by 
regulatory T-cell 0.739 molecules/diffusion time step 
Synthesis rate of TGF-β1 by 
regulatory T cell [0.0001, 0.01] molecules/diffusion time step 
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Probability a regulatory T cell 
will deactivate an activated 
macrophage 
[0.011, 0.016] n/a 
Amount of TGF-β1 that inhibits 
T cells 
(𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"#$$) 
[0.04, 0.2] molecules 
Fraction of active TGF-β1 in a 
compartment bound by a  
T cell 
[1e-4, 0.2] n/a 
Fibroblast Parameters 
Maximum fibroblast age 28800 agent timesteps 
Initial number of fibroblasts in a 
simulation 50 n/a 
Probability a fibroblast will 
move [0.001, 0.5] n/a 
Synthesis rate of TGF-β1 by a 
fibroblast [0.001, 0.1] molecules/diffusion time step 
Units of αSMA synthesized per 
TGF-β1 binding event 1e-10 n/a 
Time until a fibroblast can 
attempt to proliferate  [24, 48] hours 
Number of molecules of IL10 
that inhibits fibroblast 
proliferation/differentiation 
[1e4, 2e4] molecules 
Amount of TGF-β1 required for 
myofibroblast differentiation [2.0e-7, 8.0e-7] molecules 
Amount of TGF-β1 required for 
fibroblast proliferation [2.0e-7, 8.0e-7] molecules 
Minimum ratio of TGF-β1 to 
IL10 required for myofibroblast 
differentiation 
[1e-11, 1e-9] n/a 
Molecules of TNFα necessary 
for fibroblast 
proliferation/differentiation 
[0.025, 0.5] molecules 
Myofibroblast Parameters 
Collagen synthesis rate [1e-7, 1e-5] molecules/agent time step 
Probability of apoptosis [0.002, 0.2] n/a 
Recruitment Parameters 
Maximum macrophage 
recruitment probability [0.112, 0.168] n/a 
Maximum IFNγ-producing  
T cell recruitment probability [0.112, 0.168] n/a 
Maximum cytotoxic T cell 
recruitment probability [0.079, 0.12] n/a 
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Maximum regulatory T cell 





Conclusions and Future Directions 
 
 The work described herein focuses on the role of TGF-β1 in interstitial lung diseases. 
This work takes a theoretical approach to studying how disease pathology forms and evolves 
within the lung, with a focus on identifying important mechanisms that drive pathology and 
predicting intervention strategies that could halt and/or reverse pathology. By combining 
mathematical and computation methods with traditional experimental methods, I identify system 
level dynamics and expedite the development of new therapeutic treatments for two classes of 
pulmonary disease (83, 169). TGF-β1 is a pleotropic cytokine that is bound and secreted by 
many cell types (86, 93, 98, 101, 151, 361, 386, 407-411). The effects of TGF-β1 are cell- and 
tissue-type specific, however it is primarily thought of as an anti-inflammatory cytokine that 
inhibits cell cycle activation and effector functions (184). It is known to promote fibrosis (61, 77, 
84, 148, 406, 412) over inflammation and inhibit proliferation for many cell types (108, 113, 
119, 134, 140, 151). Throughout this work I explore the role of TGF-β1 in two different lung 
pathologies, idiopathic pulmonary fibrosis and tuberculosis, associated with lung healing and 
tissue integrity.  
 
6.1 Regulating fibroblast activation 
In these studies I first explore the role of TGF-β1 in fibroblast activation (169). 
Fibroblasts are important during the wound healing response and regulation of their activation is 
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critical to prevent pathologic fibrotic outcomes (88, 143, 148, 150, 155, 156, 196, 232, 233, 239, 
259-261, 264, 413, 414). Because of their critical role in wound healing and fibrosis, many 
groups have explored what molecules induce fibroblast activation (76, 151, 316, 317, 342, 353, 
415-421). Some groups have also looked at what molecules inhibit activation, although this area 
is less well studied (168, 234, 311, 323, 422). I build upon prior work identifying TGF-β1 as a 
major driver of fibroblast activation and explore which specific mechanisms within the TGF-β1 
receptor/ligand-signaling cascade were most important for inducing fibroblast activation (169). 
 
6.1.1 Abrogation of TGF-β1 alone is not sufficient for controlled fibroblast activation 
A key and unexpected finding from this study was that a positive feedback loop 
generated by TGF-β1 signaling could not be effectively regulated by reducing or removing TGF-
β1 alone (169). Instead, an independent negative regulator of fibroblast activation, such as PGE2, 
is necessary to restrict the positive feedback cycle and regulate fibroblast activation. Many 
efforts have been made to generate therapeutic targets that restrict TGF-β1 signaling (12, 25, 27-
33, 250, 267, 313, 314, 346, 347) in an attempt to regulate fibroblast activation, but none have 
been very successful. This finding highlights the need to focus on therapeutic targets of 
fibroblast activation that do not act through the TGF-β1 signaling cascade but rather target 
inhibitors that act downstream.  
 
6.1.2 Potential TGF-β1 independent methods of regulating fibroblast activation 
Based on the results I generated from the models, I propose that future studies should 
focus on identifying inhibitors of fibroblast activation that act on signals downstream of the 
TGF-β1 induced SMAD2/3 signaling cascade, or those that act independently of TGF-β1 
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signaling altogether. Numerous pathways have been identified that act downstream of SMAD 
signaling and include but are not limited to PGE2 (168), Wnt family ligands (423), and β-cantenin 
signaling (424). Increased levels of β-cantenin in the cell nucleus have been associated with 
increased fibrotic outcomes in fibroblasts (425). Decreasing the cellular concentration of β-
cantenin can reduce fibrotic outcomes without fully restricting the ability of fibroblasts to 
become activated. In other words, decreased levels of β-cantenin in the nucleus of fibroblasts 
reduce the magnitude of fibroblast activation (426). Wnt signaling is highly linked to β-cantenin 
levels in fibroblasts. Increased expression of some Wnt family receptors, such as SFRP1 and 
FRBZ, has been correlated with reduced nuclear β-cantenin levels in fibroblasts (426). Other 
studies have shown that increased Wnt signaling is positively correlated with nuclear β-cantenin 
levels in fibroblasts (427). Although there is disagreement in the field as to whether increasing or 
decreasing Wnt signaling reduces β-cantenin levels in fibroblasts, this signaling cascade works 
downstream of TGF-β1 signaling and provides an avenue for TGF-β1 independent therapeutic 
targets. 
In addition to targeting Wnt signaling and reducing nuclear β-cantenin levels, two 
methods that inhibit pro-inflammatory signals, another avenue for possible therapeutics could be 
to promote either prevalence of, or cell sensitivity to, existing inhibitors. For example, inhibition 
of fibroblast adhesion signaling through PGE2 is an existing regulator of fibroblast activation that 
could be exploited as a therapeutic (66, 88, 188, 234, 322, 345, 357, 428). One possible way to 
exploit this system is by inducing the expression of the EP2 receptor, which is primarily 
responsible for binding PGE2, and could promote fibroblast regulation by increasing fibroblast 
sensitivity to PGE2 (364). Therapeutic interventions that promote naturally occurring inhibitory 
mechanisms could be effective TGF-β1 independent targets of fibroblast activation.  
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6.2 Fibroblast/epithelial cell co-regulation  
In the second part of this work, I build upon the previously described studies of fibroblast 
activation to explore the co-regulation of fibroblasts and epithelial cells (83). One role of 
epithelial cells in the tissue environment is to secrete cytokines and lipids that inhibit fibroblast 
activation (187, 188). The absence of these signals following tissue damage or epithelial cell 
disruption enables fibroblasts to become activated and initiate wound healing mechanisms. 
Having predicted the need for external negative regulators in order to achieve controlled 
fibroblast activation, we suspect that the interplay between fibroblasts and epithelial cells is 
central to the tradeoff between normal wound healing and fibrotic outcomes. Here we explore 
the mechanisms that regulate fibroblast proliferation, fibroblast to myofibroblast differentiation, 
and epithelial cell survival. We compare good and bad tissue outcomes to determine what 
mechanisms drive fibroblast regulation and epithelial cell survival (83). 
 
6.2.1 Independent regulation of fibroblasts and epithelial cells 
 Through uncertainty and sensitivity analysis (229) we identified key mechanisms driving 
both fibroblast inhibition and epithelial cell survival. A major discovery within this work was 
that the mechanisms driving fibroblast proliferation and differentiation differ from the 
mechanisms driving epithelial cell survival. Attempts to improve fibrotic outcomes by affecting 
single cell specific mechanisms were unsuccessful. Only combined treatments intended to 
simultaneously promote epithelial cell survival while inhibiting fibroblast proliferation improved 
fibrotic outcomes (83). Up to this point all attempted treatments for fibrosis in the clinic have 
focused on inhibiting fibroblast proliferation (284). Thus, we believe that efforts to both inhibit 
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fibroblast proliferation and improve epithelial cell survival are necessary for effectively treating 
fibrosis. 
 
6.2.2 Potential therapeutic strategies to preserve epithelial cell integrity during fibrosis 
 The most often prescribed treatments for fibrosis have focused on inhibiting fibroblast 
proliferation and differentiation (as well as the actions of myofibroblasts following 
differentiation) (26, 284, 346, 419). These treatments focus primarily on inhibiting the actions of 
pro-fibrotic mediators. I suggested, based on studies described herein, that negative regulators of 
fibrosis are the key mechanisms in regulating fibroblast activation (see Table 3.1). Inhibiting 
pro-fibrotic mediators is not sufficient for regulating fibroblast activation. On the other hand, 
inhibiting pro-fibrotic mediators (primarily growth factors) is important for promoting epithelial 
cell survival. These strategies alone will not work well in late stage fibrosis when substantial 
epithelial cell damage has resulted in few to no surviving epithelial cells, but may have some 
advantageous effects in promoting epithelial cell survival during early pathology. In the previous 
section I describe several strategies for increasing fibroblast sensitivity to existing negative 
regulators, and/or targeting fibrotic regulators downstream of growth factor signaling. These 
methods leading to fibroblast regulation could be combined with existing therapeutics for 
inhibiting growth factor signaling and promoting epithelial cell survival, to target both cell types 
necessary for healthy tissue outcomes. I propose that a novel two-hit approach, inhibiting 
fibroblast proliferation and promoting epithelial cell survival, to treating fibrosis will provide 




6.3 The role of TGF-β1 in granuloma formation and function 
 In the third section of my work I explore the role of TGF-β1 in granuloma formation and 
function. TGF-β1 has the capacity to act on many cell types within the granuloma, however in 
this work I focus on the impact of TGF-β1 signaling on T cells and macrophages. Previous 
studies have examined the role of another anti-inflammatory cytokine, IL10, in a similar context 
(85, 158, 163, 164, 173, 174). Recently, in vivo histological studies have been performed looking 
at the localization of TGF-β1 in the granuloma (49), but due to the nature of granulomas, it has 
been impossible to study mechanistic action of TGF-β1 within a relevant system, like primate 
granulomas. In this work I identify a role for TGF-β1 in regulating cytotoxic T cells, and not 
macrophage anti-microbial functions.  
 
6.3.1 Potential host directed therapies for chronic inflammatory diseases utilizing 
differential regulation of lymphoid and myeloid derived cell types by TGF-β1 and IL10 
 Previous studies have alluded to a dichotomous regulation of lymphoid and myeloid 
derived cell types by TGF-β1 and IL10 respectively (136, 137, 388, 391). These studies have 
focused on NK and dendritic cells. In this work we find the same dichotomous regulation to 
occur between cytotoxic T cells and macrophages in the context of Mtb induced granuloma. This 
discovery, if applied to a broader immunological context has implications for host directed 
treatment of many different diseases. 
 Diseases that could be improved by cell specific host directed therapies include age-
related chronic inflammatory diseases (429, 430). Aging is a co-morbidity for many chronic 
diseases, in part, because of waning immunity that occurs during aging. People with advanced 
age are described as having immunoscenescence, and are less effective at fighting off pathogens 
	 160	
and establishing memory responses (430). Despite the presumed non-responsiveness of the 
advanced immune system, immunoscenescence is also characterized by an overall inflammatory 
state (430). This increase in overall inflammation may be due to hormonal changes, increased 
cell death, or dysregulated cytokine signaling. Whatever the source, heightened inflammation is 
associated with many kidney diseases, dementia, and is a major source of discomfort for the 
elderly. Understanding the interplay between different anti-inflammatory cytokines could lead to 
improved treatment of chronic inflammation without putting patients at increased risk of 
infection.  
 In the context of TB we find that depleting TGF-β1 has a much greater effect on 
improving bacterial clearance by stimulating cytotoxic T cell effector functions than depleting 
IL-10, which is a major suppressor of macrophage activation. In contrast, we find that depleting 
IL-10 results in a state of increased inflammation compared to depleting TGF-β1. Macrophage 
secretion of pro-inflammatory cytokines is highly associated with chronic inflammation in the 
context of advanced age. Macrophages, a myeloid derived cell type, are highly sensitive to 
suppression by IL-10. On the other hand cytotoxic T cells, a lymphoid derived cell type, are not 
significantly impaired in the presence of IL10.  Increasing IL-10 signaling while suppressing 
TGF-β1 signaling in elderly patients could reduce chronic myeloid derived inflammation without 
impairing anti-microbial responses. Further exploration in the dichotomous regulation of 
immune cells by anti-inflammatory molecules will optimal cytokines profiles and potential 





6.3.2 Potential host directed cell therapies for TB using cytotoxic T cells 
 In this work we identified a role for TGF-β1 in suppressing cytotoxic T cell effector 
function in the context of the TB granuloma. Deletion of TGF-β1 increased bacterial killing by 
cytotoxic effector functions and improved granuloma sterilization. From this study we can 
conclude that inhibiting TGF-β1 within the granuloma specifically could improve TB outcome. 
Several challenges arise with exploiting this strategy for therapy. TGF-β1 has been proposed as a 
target of therapy to treat numerous diseases but therapeutics intended to inhibit TGF-β1 
signaling have been relatively unsuccessful. One reason for their failure is that TGF-β1 plays 
such a critical role in so many aspects of cellular regulation, and inhibitors frequently have 
severe side effects. The dense cellular architecture of granulomas and their localization within 
the lung provides additional challenges for treatment (192).  
Because of the difficulty with specifically and effectively inhibiting TGF-β1, I propose 
that therapeutic strategies should focus on promoting cytotoxic T cell effector functions 
independent or downstream of TGF-β1 signaling within granulomas. Recent work in cancer 
treatment has proposed the use of specifically engineered T cells to recognize tumor-associated 
antigens (431). This therapeutic strategy could be relevant in treating TB as well. Genetically 
engineered cytotoxic T cells that lack sensitivity to TGF-β1, but have artificial shutoff switches 
could be introduced to improve bacterial clearance independent of TGF-β1 concentrations in 
granulomas. These cells would be highly active and antigen specific. If introduced to the lungs, 
these cells would have access to the site of infection. Small molecules that are sensitive kill 
switches could reduce the risk of rogue cells and protect patients from aberrant cytotoxicity. 




6.4 Formation of fibrotic granulomas 
 Fibrosis has been associated with Mtb induced granulomas in humans and NHPs (49, 
303, 395, 398, 399). Histological studies of granulomas show the formation of a fibrotic cuff 
surrounding the densely cellular structure (49). The role of this cuff, although only recently 
explored in detail, is proposed to be containment and isolation of the infectious structure. Some 
granulomas present fibrosis throughout the structure and not just on the periphery suggesting an 
additional role beyond containment for fibrotic mechanisms (49). Granulomas that present 
continuous fibrotic phenotypes are often sterile; leading to a hypothesis that fibrosis is associated 
with lesion healing. This is not a far stretch because fibrosis is associated with wound healing in 
many other tissue contexts. Fibrotic lesions are found in both NHPs that have been treated with 
antibiotics and those that have not [ref]. The continuous fibrotic phenotype is more closely 
associated with antibiotic treatment while the peripheral fibrotic phenotype is more closely 
associated with untreated animals (49). Better characterization and understanding of the 
formation and function of these fibrotic phenotypes could highlight potential therapeutic 
strategies to induce lesion containment of clearance in patients with TB.  
 
6.4.1 Mechanisms driving fibrotic granuloma formation and morphology 
 Fibrotic granulomas have only recently been extensively characterized. In this work we 
build upon that characterization to explore the progression of fibrosis in the context of Mtb 
induced granulomas, and to begin to identify mechanisms responsible for driving different 
fibrotic outcomes. We find that the development of fibrotic granulomas is closely related to local 
cytokine environments in the vicinity of fibroblasts and that likelihood of fibrosis developing 
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cannot be easily correlated to the overall environment of the granuloma. Macrophage activation 
of latent TGF-β1 and the probability of fibroblast movement within the tissue were both 
positively correlated with the number of fibroblasts present in the simulation at day 400 PI. 
Myofibroblast numbers were also primarily sensitive to the amount of latent TGF-β1 activated 
by macrophages in a given compartment. These results emphasize the influence of local cytokine 
environments and heterogeneity of the lesion on overall tissue outcome. The influence of these 
mechanisms could not be identified using homogenous methods and further studies will require 
highly sensitive spatial analysis.  
 
6.4.2 Computational histology studies to further elucidate the significant of fibrosis in the 
context of TB and beyond 
 Our studies of fibrotic granuloma formation are in their infancy and there is still a good 
deal of work to do to fully understand the mechanisms behind fibrotic granuloma formation. To 
date we have introduced fibroblasts and TGF-β1 receptor ligand signaling into GranSim (157-
162, 164, 165, 190, 201, 209, 210, 218, 219). These fibroblasts are capable of proliferating and 
differentiating into myofibroblasts. Myofibroblasts in GranSim can secrete collagen and produce 
αSMA. Collagen secreted in the simulation environment can be directly compared to histology 
studies from NHP granulomas. At this time however it does not serve any structural purpose in 
the simulated granulomas. In future work, I propose introducing collagen restricted cell 
migration where cell movement is slowed and possibly even inhibited by the presence of 
collagen (432). This additional function would serve two purposes. First, it would allow fibrotic 
granulomas to be contained not only by the functions of immune cells, but also by the presence 
of collagen itself, and second, it would prevent migration of resting macrophages from outside 
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the granuloma into fibrotic granulomas (49, 385). Effects of these changes would be non-linear 
and cannot be explicitly predicted without running the simulations. 
 In addition to updating collagen associated cell behavior in the granuloma, I also propose 
studies that introduce epithelial cells to the simulation environment. The current simulation 
environment of GranSim is a homogenous space where cytokines can diffuse and cells can move 
about. Epithelial cells are a major component of the lung architecture and are present of the site 
of granuloma formation (88, 244). Though they are not predicted to play a large role in 
granuloma formation; previous studies suggest that they do play a role in progression of 
pulmonary fibrosis. Epithelial cells signaling could be a key factor deciding whether granulomas 
become fibrotic or not (18, 66, 88, 241, 248, 254). Epithelial cells are also known to secrete 
many pro-inflammatory mediators, such as PGE2, which could influence the behavior of 
fibroblasts and myofibroblasts in this environment (66, 88, 188, 322, 357). The presence of 
epithelial cells would provide a more dynamics simulation environment, more similar to the 
actually tissue environment of the lung.  
One reason that epithelial cells have not already been introduced into GranSim is because 
the model focuses on granuloma formation, not changes in the overall lung architecture during 
infection. This focus has been sufficient for studying many elements of the immune response. 
The mechanical nature of fibrosis, however, beckons for a more complex tissue environment, 
which can be remodeled as a mark of severe fibrotic disease (401). With the addition of 
epithelial cells and some elements of tissue structure, GranSim can be adapted to study fibrosis 
in the context of Mtb induced granulomas, and other non-infectious causes of pulmonary 
fibrosis. The presence of epithelial cells in the simulation space of GranSim would provide a 
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more realistic lung environment that could be used to study a wide variety of pulmonary diseases 
such as cystic fibrosis. 
With this additional architectural aspect of the tissue surrounding granulomas, GranSim 
will be primed for extensive computational histology studies. Simulation snapshots can be 
processed using CellProfiler and other histology software. What would normally be descriptive 
and qualitative information could be converted into quantitative data with the high throughput 
nature of our simulation studies. Histological samples are very limited in vivo, but can be 
generated in mass using tandem simulations. These studies will not only shed light on the role of 
fibrosis during Mtb infection, but will also contribute to the development of novel computational 

















Supplementary Information for Chapter 3 
 
A.1 Multi-Scale Model Rules 
Here we describe the overall structure of our multi-scale hybrid agent-based model of a 
fibroblast/epithelial cell co-culture system. There are two key models that are linked to create the 
multi-scale model: a cellular scale model and a molecular scale model. Here we include a 
detailed description of the stochastic processes occurring in the cellular scale model that reads 
out at a tissue scale. The discrete molecular scale processes are described in full detail in a 
previous study (344). A schematic capturing how these models were derived independently and 
are linked is included in the main text (Figure 3.2) along with a description of how the model 
linking is done (see Methods). All values and definitions of parameter that are used in the models 
are listed in the Supplementary Tables S1, S2, S3, S4. 
 
A.2 Overall Structure of the Cellular Scale ABM 
 Agent based models are designed focusing on four components as follows: an 
environment (simulated tissue culture plate), agents (fibroblasts, myofibroblasts, and epithelial 
cells), rules that govern agent behavior, and a time-step that dictates how frequently events in the 





A.2.1 Environment  
The three-dimensional environment in this model represents one tenth of a well in a 96 
well tissue culture plate. At the bottom of the model environment is a square surface measuring 
1.78mm x 1.78mm. This surface represents the plastic at the bottom of a dish.  The plate is 
divided into a 6561 compartment grid (81 compartments by 81 compartments). Each 
compartment is a 22µm x 22μm x 22μm cube. Cellular agents are adherent to the “plastic” and 
are therefore restricted to the grid compartments directly above the in silico plastic bottom 
surface in what will be defined as the cellular layer.  Because cells are adhesion dependent, cells 
can only move in two dimensions within the cellular layer. We assume that each grid 
compartment can contain only one agent at a time based on their size. Their movement is guided 
by the ABM rules defined below. Above this layer is a three-dimensional layer that represents 
the volume of the plate (81 compartments by 81 compartments by 281 compartments). The full 
3D model contains 282 layers each with 6561 compartments. All layers above the cellular layer 
represent in silico media in the well of a tissue culture plate.  
 Some mediators are restricted to the two-dimensional (2D) bottom surface layer while 
others can diffuse throughout the three dimensional compartments. Extra-cellular matrix (ECM) 
proteins are secreted directly only the surface of the virtual dish where they are cross-linked into 
a matrix. These proteins accumulate on this layer and do not diffuse. Latent TGF-β1 (as secreted 
by fibroblasts and myofibroblasts) is secreted into the extracellular matrix where it adheres until 
the protein is activated. Proteins that do not diffuse are stored as continuous values in the 
compartment where they are secreted. Activated TGF-β1 and PGE2 are soluble mediators which 
can diffuse in three dimensions throughout the entire volume of the model, including the cellular 
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layer and all media layers above it.  These mediators are also stored as continuous values that 
occupy space anywhere within the model.  
We built an 81 x 81 x 282 3D grid. We assume there are no flux boundary conditions for 
all boundaries of the model grid for all agent movement and molecular diffusion steps. 5000 
epithelial cells and 500 fibroblasts are randomly placed on the grid, each within its own 
compartment in the cellular layer. This is consistent with in vitro studies typically plating a 10:1 
ratio of epithelial cell to fibroblasts (187).    
 
A.2.2 Agents 
There are two distinct types of cellular agents in the model, fibroblasts (representing 
pulmonary fibroblasts) and epithelial cells (representing alveolar epithelial cells). We assume 
that fibroblasts can differentiate into myofibroblasts, a process that is driven by αSMA synthesis 
(see Methods in main text). We also assume they do not de-differentiate back into a fibroblast, 
but rather remain a myofibroblast for the duration of a simulation. Once differentiated, we 
assume that myofibroblasts can no longer move or proliferate. Myofibroblasts are also 
susceptible to undergoing apoptosis in a probabilistic fashion.   
 
A.2.3 Cellular Scale ABM Rules 
ABM rules define cellular interactions as well as other processes in the model including 
cell movement, proliferation, death, and mediator secretion according to known biological 
behaviors in vitro. Additional rules in the model define molecule diffusion and degradation based 
on known rates identified in the literature (see Parameters below).   
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A.2.3.1 Cell Movement  
We assume that fibroblasts are the only cellular agents with the ability to move. They can 
move in 8 possible directions within the cellular layer. Fibroblasts examine their Moore 
neighborhood (the nine grid compartments surrounding the cell including the compartment 
occupied by the cell) and determine whether there is an unoccupied compartment. If an 
unoccupied compartment is found, then the cell has a probability of moving into that 
compartment (Table A.2). A fibroblast can move no more than once during a single model time 
step.   
 
A.2.3.2 Cell death, proliferation and differentiation  
 
A.2.3.2.1 Cell death due to age 
Two agent types, myofibroblasts and epithelial cells, can die of old age. When a cell 
reaches its maximum allowable age there is a probability that the cell will die. Dead cells will be 
removed from the grid (Table A.1, A.3).  
 
A.2.3.2.2 Epithelial cell apoptosis due to TGF-β1 concentration  
Epithelial cells are sensitive to high concentrations of TGF-β1. At birth each epithelial 
cell is assigned a maximum TGF-β1 threshold from a uniform distribution. This threshold 
captures the idea that that each epithelial cell has a slightly different sensitivity to TGF-β1 (67). 
At each model time step, epithelial cells checks the cumulative amount of TGF-β1 that it has 
bound. If the cumulative bound TGF-β1 reaches or exceeds the cells maximum threshold, then 
the cell dies and is removed from the grid. C. Fibroblast proliferation. Four rules govern when a 
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fibroblast can proliferate. (1) It must be 24 hours since the cell last divided  (433). (2) The cell 
must have bound enough TGF-β1 to meet the TGF-β1 proliferation threshold (Table A.1). (3) 
The cell must not have bound more than the maximum amount of PGE2 permissive of 
proliferation (Table A.1). (4) There must be an empty compartment in the fibroblast’s Moore 
neighborhood for a daughter cell to enter (434, 435). If these four conditions are met, then the 
fibroblast has a non-zero probability of proliferating (Table A.1). D. Fibroblast to myofibroblast 
differentiation. We assume that fibroblast to myofibroblast differentiation is determined by the 
amount of αSMA synthesized by a fibroblast and is described in detail in the “Multi-scale Model 
Calibration” section of the main text.  
 
A.2.3.3 Mediator Secretion  
We assume that fibroblasts are able to secrete both TGF-β1 and PGE2 at rates listed in 
Table A.1, respectively. We also assume that epithelial cells secrete only PGE2 at rates listed in 
Table A.4. Finally, we assume that myofibroblasts secrete ECM proteins with rates listed in 
Table A.3.  
 
A.2.3.4 Diffusion and degradation 
Continuous molecular diffusion is calculated in three dimensions using the Fast Fourier 
Transform method (436). To integrate this numerical method into the framework of an ABM we 
use the methods described in detail by Cilfone et al. (218). Active TGF-β1 and αSMA model 
have degradation rate constants (Table A.1). Latent TGF-β1 is stabile throughout the duration of 
the simulations in this paper. 
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A.2.3.4.1 Time step 
Interactions between agents are updated for each ABM time step (Δt = 1 hour) and are 
described above. Molecular scale processes, specifically TGF-β1 receptor ligand signaling in 
fibroblasts and secretion of mediators by all agent types, generally occur more quickly than 
cellular scale processes. For example, fibroblast proliferation takes about  24 hours (70, 103)  
where TGF-β1 receptor synthesis is around 4 minutes (207). These molecular processes are 
therefore updated on a more frequent molecular time step (Δt = 10 seconds), and thus each 
molecular process is updated 360 times per ABM time step. Diffusion of soluble molecules is 
updated at the diffusion time step (Δt = 60 seconds).  
 
A.2.3.4.2 Simulation  
Our combined model is implemented in C++ and runs on Linux/MacOS/Windows. 
Documentation and pseudo code are available in the online Supplement. A Runge-Kutta 4 
method is used to solve the ODEs. Each time step of the ABM simulation is further divided into 
60 pieces (step size of 60s) to reduce error. Fast Fourier Transform and forward Euler methods 
are used to solve the chemical diffusion equation (218) The molecular sub-model takes less than 
0.1 second of real time each iteration of the molecular dynamics model (437). Each simulation 









A.3 Multi-Scale Model Parameters 
 
Table A.1: Extracellular mediator Parameters and model simulation times 
Paramete
r Definition Value Source 
∆𝑡!"# Time over which the ABM is updated 1 h N/A 
∆𝑡!"##$%"&' Time over which diffusion is solved 60 s N/A 
∆𝑡!"##$!!" Time over which diffusion smoother is solved  0.1 s N/A 
𝑁!"##$!!" 
Number of times diffusion smoother is solver in one 
diffusion time step 10 N/A 
∆𝑡!"#$%&#'( 
Time over which TGF-β1 receptor ligand molecular 
model is solved 10 s N/A 
𝐷!"#$! Diffusivity of active TGF-β1 2.7x10-7 cm2/s DMW 
𝐷!"#! Diffusivity of PGE2 5.23x10
-6 cm2/s DMW 
𝛿!"#$! Active TGF-β1 degradation rate constant 
[0.001 , 0.1] 
pM/min (326) 
𝛿!"#! PGE2 degradation rate constant 
[0.001 , 0.1] 
pM/min Est. 
N/A = not applicable  DMW = derived from molecular weight              Est. = 
estimated by uncertainty and sensitivity analysis 
 
 
Table A.2: Fibroblast Parameters 
Parameter Definition Value Source 
𝑡!"#$%&'"()%#* Minimum time between proliferation events 24 h DNS 














Slope of the linear regression dictating fibroblast 
differentiation 0.5 Est. 
𝑃!"#$ Probability of fibroblast movement [1x10-2, 1] N/A 




Table A.3: Myofibroblast Parameters 
Parameter Definition Value Source 
𝑉!"# Rate of ECM synthesis [1, 100] units Est. 
𝑚𝑖𝑛!"# Minimum lifespan of myofibroblasts 1440 h (438) 
𝑃!"#$! Probability of death [0, 1] N/A 
𝑚𝑎𝑥!"# Maximum amount of ECM in a single compartment 100 units N/A 




Table A.4: Epithelial Cell Parameters 
Parameter Definition Value Source 
𝑉!"#$! Rate of PGE2 synthesis by epithelial cells 
[1x10-20, 1x10-18] 
pM/s  
𝑘!"# Rate of TGF-β1 binding by epithelial cells 
[0.0009, 0.09] 
pM/s Est. 
𝑘 Magnitude of PGE2 protection from TGF-β1 induced apoptosis  [0.0001, 100/0]  Est. 
𝐶 Non-zero constant 7x10-14 Est. 
























































Table A.5G: Significant PRCC Values for Cell Number at Day 7 (p<0.01)
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Figure A.1: Snapshot of the three-dimensional agent based model environment 
representing a virtual dish for the co-culture. Green spheres indicate epithelial cells 
while red spheres indicate fibroblasts. The blue lines indicated the edges of the 
boundaries of the ABM where media is present. Representative sections of top and 
bottom of the simulation environment are shown. The full simulation environment 
include 282 layers representing 6.17mm.The white lines indicate the edges of the 
boundaries of the cellular layer within the model (plastic bottom of well).  Time lapse 





Figure A.2: Data reproduced from Hetzel et al. 2005 showing TGF-β1 induce 
fibroblast proliferation (70). Normal human lung fibroblasts were cultured in either 
serum free media (SFM), SFM + 1.0ng/ml TGF-β1, SFM + 2.5ng/ml TGF-β1, or SFM + 





























Supplementary Information for Chapter 4 
 
Table B.1. Parameters and ranges used to generate baseline containment 
simulations  
Parameter name Value or range Units 
Mtb parameters 
Growth rate intracellular Mtb 1.003 cells 
Growth rate extracellular Mtb 1.001 cells 
Death rate of extracellular 
Mtb in caseum 1.5 cells 
Core model parameters 
Diffusion time step 60 seconds 
Molecular time step 6 seconds 
Diffusion smoother time step 1.2 seconds 
Number of smoother steps 0 n/a 
Number of host cells causing 
caseation 10 n/a 
Time to heal caseation [1642, 2462] days 
Threshold for TNFα induced 
apoptosis [1393, 2089] molecules 
Rate of TNFα induced 
apoptosis [1.17e-6, 1.76e-6] 1/seconds 
Minimum number of 
molecules allowing 
chemotaxis 
[0.514, 0.77] molecules 
Maximum number of 
molecules allowing 
chemotaxis 
[374, 562] molecules 
Diffusivity of TNFα 5.2e-8 cm2/s 
Diffusivity of IL10 5.2e-8 cm2/s 
Diffusivity of active TGF-β1 5.2e-8 cm2/s 
Diffusivity of chemokines 5.2e-8 cm2/s 
Degradation rate of TNFα 0.00158 molecules/molecular time step 
Degradation rate of IL10 0.00048 molecules/molecular time step 
Degradation rate of inactive 
TGF-β1 [9.28e-6, 1.39e-5] 
molecules/molecular time 
step 
Degradation rate of active 




Fraction of grid 
compartments with a 
macrophage 
[0.024, 0.036] n/a 
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Number of time steps before 
a resting macrophage can 
move 
2 n/a 
Number of time steps before 
an activated macrophage can 
move 
16 n/a 
Number of time steps before 
an infected macrophage can 
move 
[112, 168] n/a 
Synthesis rate of TNFα 
(𝑀𝑎𝑐𝑇𝑁𝐹𝛼!"#$!) 
1.5 molecules/diffusion time step 
Synthesis rate of CCL2 6 molecules/diffusion time step 
Synthesis rate of CCL5 6 molecules/diffusion time step 
Synthesis rate of CCL9 12 molecules/diffusion time step 
Synthesis rate of IL10 by an 
activated macrophage 0.3 
molecules/diffusion time 
step 
Synthesis rate of IL10 by and 
infected macrophage 0.02 
molecules/diffusion time 
step 
Synthesis rate of Inactive 
TGF-β1 by macrophages [1.4e-4, 2.12e-4] 
molecules/diffusion time 
step 
Number of bacteria a resting 
macrophage can phagocytose 1 n/a 
Probability of resting 
macrophage killing bacteria 
(𝑀𝑎𝑐𝐾𝑖𝑙𝑙!"#$%&'$) 
[0.23, 0.35] n/a 
Threshold for intracellular 
bacteria causing chronically 
infected macrophages 
[8,12] bacteria 
Threshold for intracellular 
bacteria causing macrophage 
to burst 
[13, 20] bacteria 
Number of bacteria an 
activated macrophage can 
phagocytose 
[4, 6] n/a 
Fraction of inactive TGF-β1 
activated by a mac 
(𝐴𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛!"#$%&!") 
[7e-5, 1e-4] n/a 
Amount of TGF-β1 that 
inhibits macrophages 
(𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"#) 
[0.01, 1] molecules 
Fraction of active TGF-β1 in 
a compartment bound by a 
mac 
[1.1e-5, 1.7e-5] n/a 
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Probability of an activated 
macrophage healing a 
caseated compartment in its 
Moore neighborhood 
[0.0128, 0.0129] n/a 
T cell parameters 
Probability of a T cell 
moving to the same 
compartment as a 
macrophage 
[0.05, 0.08] n/a 
Probability of a T cell 
moving to the same 
compartment as a T cell 
0.08 n/a 
Synthesis rate of TNFα by 




probability of inducing 
Fas/FasL mediated apoptosis 
[0.0152, 0.0228] n/a 
Probability of IFNγ-
producing T-cell to secrete 
TNFα 
[0.048, 0.072] n/a 
Probability of IFNγ-
producing T-cell to secrete 
TNFα 
[0.288, 0.432] n/a 
Synthesis rate of TNFα by 
cytotoxic T-cell 0.015 
molecules/diffusion time 
step 
Probability of a cytotoxic T-
cell killing a macrophage [0.012, 0.18] n/a 
Probability of a cytotoxic T-
cell killing a macrophage and 
all associated Mtb 
[0.61, 0.91] n/a 
Probability of cytotoxic T-
cell to secrete TNFα [0.056, 0.084] n/a 
Synthesis rate of IL10 by 
regulatory T-cell 0.739 
molecules/diffusion time 
step 
Synthesis rate of TGF-β1 by 
regulatory T cell [0.0067, 0.0101] 
molecules/diffusion time 
step 
Probability a regulatory T 
cell will deactivate an 
activated macrophage 
[0.011, 0.016] n/a 
Amount of TGF-β1 that 
inhibits T cells 
(𝑇𝐺𝐹𝛽1𝑚𝑎𝑥!"#$$) 
[0.01, 0.1] molecules 
Recruitment Parameters 
Maximum macrophage 
recruitment probability [0.112, 0.168] n/a 
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Maximum IFNγ-producing  
T cell recruitment probability [0.112, 0.168] n/a 
Maximum cytotoxic T cell 
recruitment probability [0.079, 0.12] n/a 
Maximum regulatory T cell 
recruitment probability [0.0232, 0.0348] n/a 








































Table B.2: Significant PRCC values for TGF-β1 parameters introduced to this 
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Table B.3: Significant PRCC values for TGF-β1 parameters introduced to this 










































# Total Macs       0.09  
# Resting Macs       0.08  
# Infected Macs  0.08     0.10  
# Chronically 
Infected Macs         
# Activated 
Macs  0.07     0.08  
# Dead Macs    -0.09     
# Total IFNg+  
T cells       0.08  
# Active IFNg+ 
T cells       0.08  
# Down 
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IFNg+ T cells         
# Dead IFNg+  
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# Total 
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Figure B.1: Simulated decreased secretion of TGFβ by macrophages results in 
increasing percentage of effector cytotoxic T-cells at day 200. 300 granulomas were 
simulated for 200 days with differing rates of latent TGFβ secretion by macrophages. The 
rate of secretion by macrophages is plotted against percent of total cytotoxic T-cells that 
are effector cytotoxic T-cells at day 200.Effector cytotoxic T-cell activity shows 
sensitivity to different rates of TGF-β1 secretion. 
 
 Cytotoxic T-cell effector activity, and therefore bacterial killing efficiency, is 
inhibited by TGF-β1 signaling. In the absence of TGF-β1, effector cytotoxic T-cells in 
the granuloma are increased in number. Since macrophages are a major contributor to 
TGF-β1 levels in the granuloma, we compare how TGF-β1 secretion rates by 
macrophages affects the percent of effector cytotoxic T cells that are in granulomas 
(Figure. B.1). We predict there is a negative correlation between the secretion rate of 
TGF-β1 and the percent of effector cytotoxic T cells in the granuloma (Figure. B.1). In 
order to see a meaningful increase in the effector functions of cytotoxic T cells in our 
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simulations, the TGF-β1 secretion rate by macrophages required a decrease by several 
orders of magnitude (Figure. B.1).  
 
 
Figure B.2: Gating strategy for flow cytometry studies. Granulomas do not contain 
enough cells for gating controls, and so positive and negative gates were determined by 
gating on erythrocyte-lysed whole blood (not shown) and these gates were then applied to 
granuloma samples. Isolated granuloma cells were gated on viable cells to exclude small, 
low complexity objects that confound analysis and then macrophages and T cells were 
identified by surface marker expression. Epithelioid macrophages and T cells were 
identified as CD11c+CD163- and CD3+CD11c- cells, respectively. T cells underwent a 
second round of gating against granzyme B to differentiate cytotoxic (granzyme B+) and 
noncytotoxic (granzyme B-) T cells. Subsequent analysis was done by gating each 
population’s primary surface marker (CD11c or CD3) against IL10R or TGFBR2 
expression, and comparing the MFI of positive and negative populations.   
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